Cellular therapy of Diabetes Mellitus by CHEN KIN FOONG






CHEN KIN FOONG 





A THESIS SUBMITTED  
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF BIOCHEMISTRY 





This work was begun following my move to a foreign land, Singapore - a beautiful 
garden city. First conceptualised in the Laboratory of Applied Human Genetics, Division of 
Medical Sciences (DMS), National Cancer Centre (NCC), this work has received fruitful 
collaborations from several Departments and Centres in Singapore. I am therefore deeply 
indebted to a great number of people for their love, support, guidance, encouragement, advice, 
kindness, and friendship, without whom, I would not have the opportunity to write this page. 
   I am most grateful to my supervisor, Professor Kon Oi Lian for taking me on board to 
her research team, and for her support, guidance and encouragement, as well as her patience and 
understanding during moments of personal difficulties. I thank her for delivering her knowledge 
selflessly and relentlessly, and spending invaluable time to read and edit this thesis, which is 
unarguably anything but a pleasant task. I appreciate the opportunities to work with other 
researchers outside of NCC, thanks to her leadership and networking. I would also like to thank 
Professor Peter Hwang, for rendering his help with manuscript preparations and for taking good 
care of Professor Kon.  
 I am also appreciative to my collaborators and their colleagues for their commitment, 
dedication, guidance, encouragement and friendship: Irene Kee, Song In-Chin, Jason Villano, 
Heng, Selamat, Inria, Asliyah, Jin Yi, Zheng Lin, Robert Ng and  Professor Pierce Chow 
(Department of Experimental Surgery, Singapore General Hospital), Drs Tan Soo Yong and Lai 
Siang Hui (Pathology Department, Singapore General Hospital), Dr. Wong Jen San (Department 
of Surgery, Singapore General Hospital), Dr. Lee Shu Yen (Singapore National Eye Centre), Dr 
Thng Choon Hua (Department of Oncologic Imaging, NCC), Dr. Caroline Lee (DMS, NCC), 
and Dr Kong Wai Ming and Lawrence Tham (Bioinformatics Group, Nanyang Polytechnic, 
Singapore). 
I would also like to express my gratitude to Dr. Li Huihua and Hee Siew Wan (Clinical 
Trials Office, NCC) for statistical guidance, Dr. Lim Sai Kiang (Institute of Medical Biology, 
A*Star, Singapore) for the gift of Gt(Rosa)26 transgenic mice, Professor Sir Roy Calne 
(University of Cambridge) for his advice and encouragement, and Drs. Wang Nai-Dy and Tan Ee 
iii 
 
Hong (Department of Physiology, National University of Singapore) for their useful guidance 
and discussions on the isolation and preparation of primary murine hepatocytes.  
 I would also like to thank the followings for their able and laudable technical assistance: 
Magdalene Koh and Elsie Kok (Pathology Department, Tan Tock Seng Hospital, Singapore), 
Alden Tan (Temasek Polytechnic, Singapore), Lucas Lu and Patricia Netto (Electron 
Microscopy Unit, National University of Singapore) and Joseph Lim (Singapore National Eye 
Centre). 
 I feel especially blessed to have spent my research years with these NCC inhabitants: 
Adrian Khoo, Audrey-Anne Ooi, Angie Tan, Beng Hooi, Bernice Wong, Bhuvana, Cheryl Lee, 
Cheryl Chew, Dr Chew Joon Lin, Christine Gao, Daniel Lie, Doris Ma, Gerald Chua, Dr Ha Tam 
Cam, Hui Min, Jai, Jacey, Jeanie Wu, Dr. Jelissa Cheng, Jenn Hui, Jerome Yap, Jian Wei, Justin 
Tan, Kathy Koo, Kho KW, Dr. Khoo Tan, Kian Chuan, Leong SH, Dr Lim Shen Kiat, Long YC, 
Ma Yatanar, Magdalene Lim, Mark Tan, Dr Marissa Teo, Mustaffa, Patrick Yuen, Dr. Paula 
Lam, Dr. Peter Wang, Rebecca Tan, Serene Lok, Siao Wei, Siok Yuen, Stephen Ma, Sze Sing, 
Sze Yin, Tejal, Ting Ting, Tsui Tsui, Vanaja, Vanessa Choo, Wai Har, Wai Keong, William 
Chin, Dr. Yap Swee Peng, Yih Shin, and many other colleagues in the division of Medical 
Sciences as well as in other departments, with whom I have had gained many assistance, 
friendship, happy memories and heartening days, especially when I first came to Singapore.  
           I am also grateful to my former teachers for providing me with the best education and 
helped shape who I am today: 陈月芳老师，戴君影校长，吴雅蕾老师 and Teacher 
Tan Lai Choo (primary school); Puan Zarina, Mr. Goh, Cikgu Tan, Puan Fatimah (secondary 
school); Drs. Nooraini, Zaherah, Tengku Haziyamin and Abu Bakar (UTM). 
 I am also very grateful to all my friends, and the comrades of the Soka Gakkai 
Association. I thank them for their love, listening ears, support, advice, encouragement, care, 
companionship and friendship. 
        Last but not least, I am heavily indebted to my family, for showering me with love, 
sheltering me with warmth, forgiving me whenever I was wrong and supporting me 
unconditionally.        
iv 
 
TABLE OF CONTENTS 
TITLE PAGE                    i 
ACKNOWLEDGEMENTS                                                                                               ii 
TABLE OF CONTENTS                                                                                              iv 
SUMMARY                                                                                                                      xi 
LIST OF TABLES                xiii 
LIST OF FIGURES                                       xiv 
LIST OF ABBREVIATIONS             xvii 
 
CHAPTER 1 
Introduction and Literature Review 
1.1. Cellular Therapy                   1 
1.1.1. Allogeneic/syngeneic transplantation                3 
1.1.2. Autologous transplantation                 4 
1.1.3. Xenotransplantation                    5 
1.1.4. References                      6 
1.2. Gene Therapy                    8 
1.2.1. Viral gene delivery                                                                                             10 
1.2.2. Non-viral gene delivery                            11 
1.2.3. References                    14 
1.3. Diabetes Mellitus                      18 
1.3.1. Classification of diabetes mellitus                   19 
1.3.2. What causes diabetes mellitus?                      20 
1.3.3. New perspectives on the pathogenesis of diabetes mellitus                      23 
1.3.4. Prevalence and impact of diabetes mellitus             29 
1.3.5. References                                30 
1.4. Diabetes Complications                           37 
v 
 
1.4.1. Diabetic retinopathy               38 
1.4.2. Diabetic nephropathy               38 
1.4.3. Diabetic neuropathies                                                39 
1.4.4. Diabetic macrovasculopathies                                       41 
1.4.5. Pathobiology of diabetes complications            41 
1.4.6. References                47 
1.5. Current Diabetes Treatment                                                           52 
1.5.1. Lifestyle modifications                        52 
1.5.2. Pharmacological interventions                           54 
1.5.3. Whole pancreas transplantation                                   60 
1.5.4. Islet transplantation                                  61 
1.5.5. References                        62 
1.6. Current Experimental Approaches for Restoring Insulin Secretion In Vivo              65 
1.6.1. Immunotherapy to protect and prevent loss of endogenous β-cells         65 
1.6.2. In vivo regeneration/expansion of β-cell mass                      68 
1.6.3. Developing transplantable β- or β-like cells                           70 
1.6.4. References                                                            82 
1.7. Objectives and Scope of the Study                                                                                    89 
 
CHAPTER 2 
Results and Discussion 
1.1. Primary Murine Hepatocytes 
2.1.1. Electroporation of primary murine hepatocytes           92 
2.1.2. Electroporation optimised for insulin transgene           92 
2.1.3. Processing and secretion of mature human insulin by hepatocytes                      93 
2.1.4. Static induction of human insulin by glucose and zinc in vitro                            94 
2.1.5. Kinetics of glucose- and zinc-induced insulin secretion                             95 
2.1.6. Transcriptional response of transgene in vitro                         97 
2.1.7. Diabetes induction in C57BL/6J mice                                                                  98 
2.1.8. Implantation of transfected primary hepatocytes into diabetic C57BL/6J mice   98 
vi 
 
2.1.9. Glucose-induced insulin secretion in vivo                     102 
2.1.10. Immunohistochemistry                               103 
2.1.11. Figures                         105 
2.1.12. References                                117 
2.2. Primary Porcine Hepatocytes 
2.2.1. Electroporation of primary porcine hepatocytes         121 
2.2.2. Regulated insulin production in vitro                                                                  122 
2.2.3. Irreversible ablation of endogenous β-cells in streptozotocin-diabetic swine     122 
2.2.4. In vivo metabolic effects after implantation of p3MTchINS-modified  
autologous hepatocytes            123 
2.2.5. Engraftment of insulin-secreting hepatocytes                             126 
2.2.6. Treatment attenuated target organ injury                                      127 
2.2.7. Figures                                                                     131 
2.2.8. References                                                                     150 
2.3. Primary Porcine Bone Marrow-derived Mesenchymal Stromal Cells (BMMSCs) 
2.3.1. Selection of  BMMSC-specific glucose-responsive promoter                            153 
2.3.2. Isolation and culture of porcine BMMSCs                                                          154 
2.3.3. Characterisation of porcine BMMSCs                                                                 155 
2.3.4. Electroporation of human and porcine BMMSCs                                               155 
2.3.5. No evidence of genomic integration of electroporated circular plasmid DNA   156 
2.3.6. Human EGR1 promoter is glucose-responsive in human and porcine  
BMMSCs                                                                 157 
2.3.7. Stably-modified porcine BMMSCs secreted less human insulin than circular 
plasmid-electroporated porcine BMMSCs                                                          160 
2.3.8. Xenogeneic implantation of pTopo3EGR1chINS-modified primary porcine 
BMMSCs into NOD-SCID mice                                                                         161 
2.3.9. Bioactivity of secreted transgenic human insulin                                                168 
2.3.10. Figures                                                                                           169 






3.1. General discussion                                                                            196 
3.2. References                                                                                                      207 
CHAPTER 4 
Materials and Methods 
4.1. Materials 
4.1.1. Chemicals and reagents                                                             213 
4.1.2. Plasmids              213 
4.1.3. Animals                         214 
4.2. Isolation and culture of primary adult somatic cells 
4.2.1. Primary murine hepatocytes                                    214 
4.2.2. Primary porcine hepatocytes                           215 
4.2.3. Primary porcine bone marrow-derived mesenchymal stromal cells  
  (BMMSCs)              215 
4.3. Plasmid construction 
4.3.1. Assembly of pEGR1-SEAP                         216 
4.3.2. Assembly of p3EGR1chINS                                  216 
4.3.3. Assembly of pTopo3EGR1chINS                          216 
4.3.4. Assembly of p3EGR1(A)chINS, p3EGR1(B)chINS  
and p3EGR1(C)chINS                        217 
4.4. Gene transfer in primary adult somatic cells 
4.4.1. Primary murine hepatocytes              217 
4.4.2. Primary porcine hepatocytes                          217 
4.4.3. Primary human and porcine BMMSCs                 218 
4.5. Generation of stable insulin-expressing porcine BMMSCs                   218 
4.6. In vitro characterisation of plasmid-modified primary adult somatic cells 
4.6.1. Primary murine hepatocytes 
4.6.1.1. Time course of transcriptional induction of transgene expression          219 
4.6.1.2. Static induction of human insulin secretion by glucose and zinc            220 
viii 
 
4.6.1.3. Kinetics of glucose- and zinc-induced human insulin secretion             220 
4.6.2.    Primary porcine hepatocytes 
4.6.2.1. Static induction of human insulin transcription and secretion                220  
in vitro 
4.6.3. Primary porcine BMMSCs 
4.6.3.1. Porcine BMMSCs immunophenotyped by  (FACS)            221 
4.6.3.2. Temporal response of human EGR1 promoter to extracellular  
glucose concentrations                                                  222 
4.6.3.3. Glucose-, insulin- and dexamethasone-inducibility of  
human EGR1 promoter in porcine BMMSCs                                 222 
4.6.3.4. Kinetics of glucose-induced human insulin secretion from  
plasmid-modified  porcine BMMSCs                                    223 
4.7. Implantation of plasmid-modified primary adult somatic cells 
4.7.1. Syngeneic implantation of primary murine hepatocytes                               224 
4.7.2. Autologous implantation of primary porcine hepatocytes                        224 
4.7.3. Xenogeneic implantation of primary porcine BMMSCs                     225 
4.8. Molecular biology techniques 
4.8.1. Plasmid isolation                                          225 
4.8.2. Cellular RNA isolation                                                       226 
4.8.3. Tissue RNA isolation                                   226 
4.8.4. Polymerase chain reaction (PCR)                         226 
4.8.5. Semi-quantitative PCR 
4.8.5.1. Detection of intracellular p3MTchINS                                                   227 
4.8.5.2. Determining genomic integration of electroporated transgene              227 
4.8.6. Real time Reverse Transcription (RT)-PCR                                 227 
4.8.7. DNA sequencing                          228 
4.8.8. Transcriptome profiling of porcine tissues 
4.8.8.1. Study design                                                                                           228 
4.8.8.2. Target preparation and hybridisation                                                     228 
4.8.8.3. Data analysis                                                                                          228 
4.8.9. Transcriptome profiling of human BMMSCs 
ix 
 
4.8.9.1. Study design                                               229 
4.8.9.2. Target preparation and hybridisation                                               229 
4.8.9.3. Data analysis                       229 
4.9. Cell biology techniques 
4.9.1. Microscopy 
4.9.1.1. Light and fluorescence microscopy                       230 
4.9.1.2. Scanning electron microscopy                       230 
4.9.1.3. Transmission electron microscopy                                  230  
4.9.2. Histology 
4.9.2.1. Mouse liver                                    231 
4.9.2.2. Pig liver, pancreas and kidney                              231 
4.10. Techniques involving animals 
4.10.1. General anaesthesia                        232 
4.10.2. Partial hepatectomy                                          232 
4.10.3. Induction of diabetes with streptozotocin 
4.10.3.1. C57BL/6J and NOD-SCID mice                                232 
4.10.3.2. Yorkshire-Landrace pigs                                        232 
4.10.4. Serial monitoring of metabolic and biochemical indices 
4.10.4.1. C57BL/6J mice                                    233 
4.10.4.2. NOD-SCID mice                       233 
4.10.4.3. Yorkshire-Landrace pigs                      233 
4.10.5. Intraperitoneal glucose tolerance test                          233 
4.10.6. Temporal response of glucose-induced insulin secretion in vivo                   234 
4.10.7. Intravenous glucose tolerance test                               234 
4.11. Statistical and survival analyses                                                                                   234 
4.12. References                                         235 
Appendices 
1. Plasmid maps                                    237 
2. Primary murine hepatocytes cultured on different matrices.                                       239 
3. TEM image of a p3MTchINS-transfected primary murine hepatocyte.                 240 
4. Mammalian cells transfected with pEGFP in NC electroporation buffer.      241 
x 
 
5. Details and data for biochemical tests performed in pigs.                 242 



























Current approaches to gene- and cell-based therapies have significant limitations e.g. 
donor scarcity, requirement for immunosuppression, potential tumorigenicity, unphysiological 
protein expression and poor scalability, all of which impede clinical applications. Taking 
diabetes mellitus as a paradigm, we sought to surmount these barriers by ex vivo electrotransfer 
of nonviral insulin expression vectors in primary adult somatic cells to serve as quasi-
physiological sources of insulin in mice and pigs. 
We first demonstrated proof-of-concept in a mouse model. Primary murine hepatocytes 
transfected with a human proinsulin cDNA plasmid construct, p3MTchINS, controlled by 
glucose and zinc regulatory elements showed increased insulin transgene transcription and 
secretion within 10-20 minutes of exposure to high glucose or zinc concentration in static and 
kinetic perifusion assays, and to glucose challenge in vivo. Human proinsulin was efficiently 
processed to mature insulin, the release of which did not occur from secretory granules. 
Implantation of p3MTchINS-electroporated syngeneic hepatocytes in one of 3 sites of C57BL/6J 
diabetic mice i.e. unresected liver, regenerating liver or mesentery corrected streptozotocin 
(STZ)-induced diabetes and glucose intolerance, and improved survival. Overall, intrahepatic 
implantation in regenerating liver produced the best outcome. Engrafted hepatocytes were 
identified mainly around central veins of liver having normal architecture. 
We next demonstrated scalability in a large preclinical autologous model. An 
electroporation buffer that achieved higher gene-transfer efficiency and cell viability was 
developed. In a single 3-hour procedure, hepatocytes isolated from a surgically-resected liver 
wedge were electroporated with p3MTchINS and re-implanted intraparenchymally under 
ultrasonic guidance into the liver of each of 10 STZ-induced diabetic Yorkshire-Landrace pigs. 
Extracellular glucose concentrations appropriately altered human insulin mRNA expression and 
C-peptide secretion within minutes in vitro and in vivo. Treated swine showed durable correction 
of hyperglycaemia, glucose intolerance, dyslipidaemia and other metabolic abnormalities, which 
correlated significantly with the number of hepatocytes implanted. Importantly, we observed no 
hypoglycaemia even under fasting conditions. Direct intrahepatic implantation of hepatocytes 
did not alter biochemical indices of liver function or induce abnormal hepatic lobular 
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architecture. About 70% of implanted hepatocytes functionally engrafted, appeared 
histologically normal, retained vector DNA and expressed human insulin for ≥47 weeks. Early 
correction of porcine diabetes also ameliorated diabetes-associated transcriptome changes and 
structural abnormalities in the eye, kidney, liver and aorta. 
As surgical procurement of hepatocytes may not be readily accepted clinically, we turned 
to primary bone marrow-derived mesenchymal stromal cells (BMMSCs) as alternative insulin-
secreting bioimplants. Isolated porcine BMMSCs were characterised by bivariate fluorescence-
activated-cell-sorting analysis. A transcriptomically-identified glucose-sensitive promoter, 
EGR1, drove quasi-physiological glucose- but not insulin- and dexamethasone-induced transgene 
secretion in modified BMMSCs during static and kinetic induction assays. Efficient gene transfer 
was achieved with NC solution and genomic integration of the circular plasmid was 
undetectable. Porcine BMMSCs transfected with the circular plasmid construct or stably 
integrated with the insulin transgene were intrahepatically- or intraperitoneally-xenotransplanted 
in STZ-diabetic and non-diabetic NOD-SCID mice. Hyperglycaemia and glucose tolerance were 
improved in a dose-responsive manner without inducing hypoglycaemia.  
In conclusion, this simple, safe and effective approach to cellular therapy may have wider 
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Introduction and Literature Review 
 
1.8. Cellular Therapy 
Attempts to transplant cells for therapeutic purposes have been explored since at least the 
seventeenth century, even before cells could be seen by the father of microscopy, Anton van 
Leeuwenhoek (1632-1723). The first therapeutic attempt of blood transfusion in human patients, 
which marks the beginning of the chapter of life-saving cellular therapy, took place in Paris in 
1667 by Jean-Baptiste Denis (1635-1704), and was published in the Philosophical Transactions 
of The Royal Society1 .  
It was however not until the middle of the 20th century that cellular therapy became the 
subject of intense investigation especially in the field of bone marrow (BM) transplantation for 
cancer therapy. In the mid-1950s, Barnes and Loutit, Main and Prehn, and van Bekkum et al. 
presented firm evidence that intravenous infusions of allogeneic BM protected mice from 
supralethal irradiation2. These findings suggested that oncologists might be able to increase the 
intensity of cytotoxic drug therapy and thereby improve cure rates of haematological 
malignancies because patients could be rescued from lethal BM aplasia with infusions of BM-
derived haematopoietic stem cells from healthy donors.  
However, initial attempts at translating BM-derived cellular therapy to clinical practice 
met with failure and created serious doubts about the feasibility of crossing the “allogeneic 
barrier”2. It was soon realised that clinical failures occurred mainly because the transplantation 
procedures used in patients had been established from experiments in inbred mice that do not 
require histocompatibility matching. Dirk van Bekkum attributed these failures to the overhasty 
application of animal data to human subjects while there was still a substantial lack of essential 
basic knowledge to bridge the gap between mice and humans2.  
The idea that BM transplantation could be a valuable tool in clinical practice was 
nevertheless revived when research continued and important progress was made in studies 
involving preclinical animals such as primates, pigs and dogs. In fact, it was in these animal 
models that two important discoveries were made that set the stage for today’s achievements and 
2 
 
favourable outcomes in clinical transplantation. These were the recognition that 
histocompatibility matching of donor and recipient pairs was particularly crucial in reducing the 
risks of graft rejection and graft-versus-host disease (GVHD)3,4,5, and the formulation of optimal 
post-transplant immunosuppression6,7 to maintain graft function. From the concerted efforts of 
cell biologists, biochemists, immunologists, surgeons, haematologists and oncologists have 
emerged experimental and clinical transplantation protocols utilising stem and progenitor cells, 
haematopoietic cells and differentiated cells (such as epithelial cells and neurons) to treat 
genetic, metabolic/endocrine, haematological, autoimmune, vascular and neurological disorders.  
Recent interest in cellular therapy for metabolic diseases was born of remarkable progress 
in cell transplantation for haematological malignancies and the generally unsatisfactory 
metabolic correction achieved by costly pharmacological agents that have been used to treat such 
diseases. Moreover, organ or cell transplantation is the only treatment modality for several rare 
metabolic disorders (orphan diseases) for which the development of useful and affordable drugs 
is financially unappealing to the pharmaceutical industry.  
Several cell types are typically used in the clinical transplantations of three major classes 
of metabolic/endocrine disorders. These are haematopoietic stem cells for the treatment of 
inherited lysosomal and peroxisomal storage disorders8, endocrine cells such as pancreatic islets, 
parathyroid, thyroid and adrenal cells for cell-mediated hormonal replacement therapy9 and 
hepatocytes to treat liver-directed inborn errors of metabolism10. The latter is also used to bridge 
patients with liver failure, or as an alternative, to whole organ transplantation11. Clinical results 
with cellular transplantations in these disorders have been encouraging, with most, if not all, of 
the recent attempts having achieved short-term correction or amelioration. However, the prospect 
for long-term correction with current transplantation protocols is less certain due mainly to 
immune-mediated loss of allograft function.  
The development of cellular therapy for metabolic disorders is not accorded the same 
attention as malignant diseases because of the perception that metabolic disorders are much less 
threatening to human health and moreover are already well supplied with pharmacological and 
other interventions. However, a recent systematic review of numerous studies that addressed the 
impact of chronic diseases on the quality of life indicated a paradox - individuals with 
endocrinologic/metabolic diseases e.g. diabetes mellitus, have had poorer quality of life 
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associated with worse physical/functional well-being compared with individuals suffering from 
other diseases e.g. cancer (Figure 1.1.1)12. Furthermore, these patients, especially type 1 
diabetics, are likely to suffer lower quality of life for an extended period due to the early onset 











Figure 1.1.1 The position of the disease clusters with respect to physical (PCS) and mental 
(MCS) functioning. A higher rank score indicates better functioning. (Figure source: ref.12) 
 
1.1.1 Allogeneic/syngeneic transplantation  
Allogeneic cellular transplantation is the transfer of cells that are antigenically distinct 
and genetically different from one member of a species to another individual of the same species. 
In the history of HSC transplantation (HSCT), the early studies of BM allografting were 
pioneered by E. Donnall Thomas, who was jointly awarded the Nobel Prize in Physiology or 
Medicine in 1990 with Joseph E. Murray for organ and cell transplantation2. 
Although this early work did not meet with great clinical success, it did stimulate 
continuous research in allogeneic transplantation that later proved to be clinically efficacious in 
haematological malignancies, thanks to the discovery of the human major histocompatibility 
complex and immunosuppressive agents. Analyses of the early clinical data revealed that 




malignancies – GVHD – in which lymphocytes contained in the donor graft recognise the host’s 
tumour cells as foreign and kill them. This discovery forms the basis of HSCT in current therapy 
of leukaemias and lymphomas.  
Clinical allogeneic cellular transplantation for other diseases that do not require the 
GVHD effect is, however, controversial owing to the need for long-term immunosuppression to 
prevent graft rejection. Various potent immunosuppression regimens may be able to tame the 
immunological reaction but their desirability in clinical use is debatable. Firstly, strong 
immunosuppression increases the risk of potentially fatal opportunistic infections acquired from 
the environment and/or from the donor.  Secondly, immunosuppressed patients have a higher 
risk of developing cancers and lympoproliferative disorders. Thirdly, despite 
immunosuppression, chronic rejection cannot always be prevented and may result in eventual 
loss of graft function.  
Syngeneic cellulartransplantation involves the transfer of cells between individuals who 
have identical genotypes, such as inbred mice and twins. All early murine experiments in the 
history of BM transplantation were syngeneic in nature and therefore did not replicate the 
majority of typical clinical situations. Realising that genetic factors were at play, Thomas’ first 
success of BM grafting was performed in two patients after total body irradiation using 
syngeneic donors (twin siblings)13. Leukaemia however recurred in both patients due perhaps to 
the lack of the graft-versus-tumour effect. Nonetheless, this was the first demonstrated success of 
cell engraftment between genetically identical human subjects. 
1.1.2. Autologous transplantation 
Autologous cellular transplantation refers to the removal, manipulation and re-infusion of 
a subject’s own cells for therapeutic purposes. The first experimental autologous transplantation 
was performed in a dog also by Thomas and colleagues. They showed that infusions of 
autologous canine BM cells after total body irradiation induced prompt reconstitution of BM and 
lymphoid tissue14. Although autologous BM transplantation in early clinical studies was deemed 
safe owing to the absence of life-threatening immune responses, it was also ineffective in 
eradicating haematopoietic-borne malignancies. Nonetheless, progress in the field and careful 
comparisons of treatment outcomes and the benefit-to-risk ratio of allogeneic and autologous 
HSCT have shown the latter to be a safer option. In some of the cases reported thus far, 
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autologous HSCT yielded clear evidence of clinical benefits and its development is progressing 
steadily. 
Given the advances in cell transplantation for diseases other than the classical 
haematological malignancies, autologous transplantation may now be regarded as the Holy Grail 
of cellular therapy because it entails minimal or no biological hazard, is highly favourable for the 
efficient engraftment and persistence of immunologically compatible cells, does not depend on 
donor availability and obviates pharmacological immunosuppression. Thus long-term function of 
autologous cellular grafts ought to be feasible. However, mobilisation of autologous cells is not 
as simple as procuring an allogeneic source for transplantation. For example, autologous cellular 
therapy often involves ex vivo genetic manipulation of the cells and extended culture in vitro, if 
intended for correction of a metabolic deficiency, and immune-conditioning or modulation of the 
cells before re-implantation, if intended for cancer treatment. 
1.1.3 Xenotransplantation 
Xenotransplantation is cross-species transplantation, the rationale for which has included 
the short supply of human donor organs and cells for transplantation. Dr. Keith Reemtsma (1925-
2002) was the first surgeon who showed that nonhuman organs could be transplanted into 
humans and function for significant periods. A total of six patients described in two reports of 
xenotransplantation however succumbed to overwhelming infection and died 8 days to10 months 
after receiving chimpanzee xenografts15.   
Although non-human primates are phylogenetically closer than other species to humans, 
pigs are the preferred species for clinical xenotransplantation because of some limitations in non-
human primates, for instance difficulties in breeding, ethical issues and organ size disparities16. 
In addition to their similarities to humans in organ size, anatomy, physiology and 
pathophysiology, pigs can be bred easily and at low cost. Pig’s islets are particularly attractive 
source of cells for the treatment of diabetes mellitus because pigs maintain their blood glucose at 
levels comparable to humans and porcine insulin is highly similar and biologically effective in 
humans17.  
Notwithstanding the considerable effort and money that has been invested in developing 
xenotransplantation for the past few decades, none of the experimental approaches such as 
encapsulation techniques to shield xenografts from immune-mediated destruction, has been 
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adopted in clinical practice18. At least three major difficulties and concerns dim its prospective 
application in transplantation medicine: (i) immunological rejection of transplanted xenogeneic 
cells by antibody-mediated (hyperacute and acute humoral rejections) and cell-mediated (T-cell-
mediated and innate-immune-cell-mediated rejection) responses18; (ii) the potential for cross-
species pathogen transmission and increased susceptibility to xenozoonoses due to the 
immunosuppressed post-transplantation state19, and (iii) physiological considerations such as the 
accelerated growth and shorter lifespan of the donor species that could be disadvantageous and 
whether xenoproteins will function satisfactorily in humans since pigs and humans have been 
separated in evolution for many millions of years20. 
Despite the challenging hurdles in organ xenografts, cellular xenotransplantation may be 
an easier prospect in clinical practice. The most profound biological barrier may be overcome if 
xenogeneic cells are carefully screened and purified before transplantation. However, patients 
would still need to take full doses of immunosuppressive drugs indefinitely to prevent immune-
mediated rejection of the transplanted cells. 
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1.2 Gene Therapy 
 Gene therapy (GT) can be defined as an approach to treat, cure or prevent a disease by 
replacing or repairing defective genes, introducing new genes, or changing the expression of a 
gene by means of gene addition, skipping of a mutated exon, suppression of a cryptic splice site 
or inhibition of the expression of a mutated gene1. 
 The concepts of GT arose following the fundamental discovery and description of the 
function of deoxyribonucleic acid (DNA) by Watson and Crick in 1953.  In the early 1960s, 
studies were conducted in cell lines to test whether foreign DNA could be introduced 
permanently, stably, functionally and heritably into mammalian cells to provide new genetic 
functions. However, because of the extreme inefficiency of the gene transfer methods then 
available, none of the systems convincingly verified the notion2. By the late 1960s, the 
discoveries that papovaviruses, SV40 and polyoma, in the course of transforming a cell from the 
normal to the neoplastic phenotype, integrated their genetic information into the genomes of 
target cells, affirmed the idea that efficient genetic transformation could be achieved. In the early 
1970s, the era of recombinant DNA technology arrived and promptly provided the two tools 
most needed for GT – efficient methods of gene transfer and specific genes in cloned form3.  
 The first disease-related gene to be cloned and characterised was the gene for human β-
globin4. It was soon demonstrated that the globin gene, other cloned genes and even total cellular 
DNA could be introduced into mammalian cells functionally using the calcium phosphate 
transfection method5. Even though the transfection efficiency was still deemed too low for 
clinical application, Martin Cline and colleagues reported in 1979 that human globin gene-
modified murine BM cells could partially repopulate the marrow of irradiated recipient mice6. 
They eventually proceeded in 1980 with a clinical experiment in which BM cells from 
thalassemia patients in Italy and Israel were transfected ex vivo with a similar technique, and the 
modified cells re-infused into the patients. This first clinical trial of GT however attracted severe 
criticisms on scientific, administrative and ethical grounds because Cline had not received any 
permission for the human studies3. It thus became apparent that human GT would be more 
complex technically and ethically than had been envisioned. In response to the outcry of the 
scientific and public communities, the Recombinant DNA Advisory Committee of the United 
States National Institutes of Health was formed in 1974 to regulate the application of molecular 
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genetics tools to human use. The committee later established the principles and guidelines for 
human GT, which generally limits its application to somatic cells and proscribes the use of 
germline cells due to strong ethical arguments that deal with potential clinical risks, changing the 
gene pool, and the inherent social dangers7.   
 By the mid-1980s, techniques that permitted clinically meaningful gene transfer were 
developed. The simplest early approach, termed classical GT, was aimed at correcting enzyme 
defects that caused metabolic diseases. Many single-gene disorders, for example, Lesch-Nyhan 
syndrome (hypoxanthine phosphoribosyltransferase deficiency), severe combined 
immunodeficiency disease (adenosine deaminase deficiency), cystic fibrosis (cystic fibrosis 
transmembrane conductance regulator deficiency), α1-antitrypsin deficiency, familial 
hypercholesterolaemia (LDL receptor deficiency), Gaucher disease (acid β-glucosidase 
deficiency) and coagulation disorders caused by deficiencies of clotting factors IX, VIII or others 
were among the early targets for experimental and clinical attempts that marked the beginning of 
human GT. These early attempts, while helped to conceptualise the field, nonetheless dampened 
the initial enthusiasm that perceived gene therapy as a revolutionary technology with the promise 
to cure almost any disease as clinical trial after clinical trial failed to show efficacy8.  
In 1999, a patient’s death during a clinical safety trial for ornithine transcarbamylase 
deficiency, which was attributable to the administration of an adenoviral vector, led to the 
realisation that failure to understand the biology of gene vector interactions with the human 
immune system could have fatal consequences9. This incident was a serious setback to the field, 
not least because it shook public trust in GT trials. The year 2000 then brought the first ever GT 
success in which three children were cured of a fatal immunodeficiency, X-linked SCID-X1 
syndrome. The initial elation and relief however turned into anxiety and alarm after 2 of the 11 
patients treated with the same retroviral protocol developed a leukaemia-like disease. It was later 
determined that malignantly transformed T-cells had arisen from transduced cells in which the 
retrovirus genome had inserted near, or within, the LIM domain only 2 (LMO2) oncogene, 
pathologically activating LMO2 expression10. Together, these unfortunate incidents in two 
different GT clinical trials undoubtedly heightened the inconvenient truth of using viral vectors 
and led to major changes in the procedures for public review, approval and regulation of clinical 
translation of GT worldwide 11.  
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Despite tightened regulations governing GT clinical trials, the Journal of Gene Medicine 
Clinical Trial Database or Wiley Database12 (the best available compendium of information on 
GT trials globally) reported a total of 1472 trials from 1989-2008 (updated as of September 
2008). Of these, 41.5% of trials were approved in 2004-2008. Only 304 are phase II or phase III 
efficacy trials, while 1168 trials are phase I studies to assess the safety of specific GT 
approaches. Much effort has been directed toward developing better non-viral vectors and 
improving safety of viral vectors13, partly due to heightened safety concerns with viral vectors. In 
addition, there has been a distinct trend for approved clinical trials to move from treating simple 
single-gene diseases with metabolic consequences to complex diseases that are more life-
threatening and consequently have a potentially higher benefit-to-risk ratio, such as cancers and 
HIV infection14. As of September 2008, the Wiley Database reported a total of 1072 (72.8%) 
trials in cancer and infectious diseases with less than one-fifth (19.4%) of approved trials 
directed at cardiovascular, monogenic, neurological and ocular diseases combined. This 
changing landscape of clinical trials could result in more failures and thus have serious 
consequences in the development of the field because complex disorders such as cancer may not 
be good candidates for demonstrating clear measurable benefit and efficacy of a GT approach15. 
Amidst all criticisms, it is only fair to acknowledge that the concepts of GT have 
progressed from being entirely theoretical to technical feasibility and even clinical 
implementation, accompanied by a modicum of acceptance of the general approach.  As always, 
investigators ought to be rethinking and redefining their approach to create a safe, efficacious 
and, sometimes, life saving therapy: determining which genes are likely the most effective, 
improving gene expression, creating and engineering vectors that permit appropriate duration 
and regulation of transgene expression, discovering and optimising new vectors, standardising 
production of affordable vectors for clinical application, improving the methods and routes of 
vector administration, enhancing the organ, tissue and cellular specificity and efficiency of gene 
delivery, and reducing clinical toxicity and attending to environmental safety. Of all the 
aforementioned challenges, it is generally accepted that one of the major impediments to the 
successful application of human GT is the lack of efficient non-hazardous gene delivery systems, 
of which there are two major types: viral and non-viral. 
1.2.1. Viral gene delivery 
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 From the earliest forms of life, natural barriers evolved to maintain the integrity of 
genetic information, which appears to be the prerequisite to sustain and propagate organisms. As 
obligate intracellular parasites that have evolved over millions of years, viruses are able to gain 
access into and exploit the cellular machinery of host cells in order to facilitate their replication. 
In effect, viruses have evolved to perform precisely the functions required for GT. Ideal virus-
based vectors harness the natural infection pathway but do not express viral genes essential for 
replication that are liable to cause host toxicity. This is achieved by deleting most, if not all, of 
the coding regions from the viral genome while leaving intact those sequences that are required 
for packaging, transferring and incorporation of the transgene into the host chromosome16. 
 With the advent of recombinant DNA, Shimotohno and colleagues first reported 
techniques that permitted the packaging of a therapeutic gene into a retrovirus capable of 
infecting human cells with high efficiency17.  Today, many different viruses are under 
development as GT vectors. Most are derived from and can be categorised into five main classes, 
i.e. adenoviruses, adeno-associated viruses (AAVs), oncoretroviruses, lentiviruses and herpes 
simplex-1 viruses (HSV-1s). Each class of vector has different properties and characteristics that 
make it suitable for some applications and unsuitable for others18.  
 Transducing a gene of interest into mammalian cells using engineered viruses initially 
seemed like a royal road to GT. However, as research progressed and failures were encountered 
especially in clinical trials, the challenges of using viral vectors showed their shortcomings as 
gene transfer vectors. First, viruses have limited gene delivery capacity. Packaging large genes is 
limited to certain viruses such as HSV-1, and is generally laborious and inefficient. Second, 
while long-term transgene expression could be desirable for many diseases, the use of viral 
vectors has resulted in early removal of the vector, rapid decrease in transgene expression or 
destruction of the transduced cells - outcomes that are facilitated by host immune responses to 
viral infections. Third, improperly disabled viruses can trigger exaggerated inflammatory 
immune responses that led to disseminated intravascular coagulation, acute respiratory distress 
and multi-organ failure19, which was determined to be the cause of death of Jesse Gelsinger, the 
first reported fatality from GT9. Subsequent studies in monkeys indicated that adenoviral capsid 
proteins (the viral vector used in the ornithine transcarbamylase trial), rather than the genetic 
cargo, might elicit an early inflammatory cytokine cascade20. Fourth, viruses such as the 
commonly used retrovirus, lentivirus and adeno-associated virus could insert the transgene into 
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the host genome causing insertional mutagenesis, and inactivation of tumour suppressor genes or 
inappropriate oncogene expression (if transgene insertion occured at potentially oncogenic sites) 
– all of which could induce malignancy. The latter was apparently the cause of T-cell 
leukemogenesis in 4/9 and 1/10 young children treated with recombinant retrovirus during two 
recent SCID-X1 trials in France21 and UK22, respectively. Fifth, the frequent lack of specificity 
of targeting transgene delivery to intended tissues and cells is yet another challenge with the use 
of viral vectors. This characteristic promiscuity is more of a liability than a benefit as the 
systemic delivery of viruses generally leads to unwanted vector uptake by many different cell 
types in multiple organs, including the reproductive organs. Even local delivery of viruses can 
result in escape and dissemination to other tissues. Finally, the costs of developing and producing 
viral vectors under standard good manufacturing practice conditions are high and could be 
prohibitive14.  
Despite all the challenges and disadvantages, some clinical successes have been reported 
and these positive outcomes encourage further development of viral vectors. Some recent 
advances include identification and development of new virus species (e.g. Epstein-Barr virus, 
foamy viruses, measles, vaccinia and coronaviruses) as gene transfer vectors, use of polyethylene 
glycol “stealth” coatings to disguise viral vectors and thus minimises host immune responses, 
and moving to less demanding clinical applications of GT such as oncology13.  At present, viral 
vectors are still the best available and most widely-studied vehicles for gene transfer into most 
tissues. As of September 2008, the Journal of Gene Medicine Clinical Trial Database reported a 
clear preference for viral vectors as the vehicle of choice in clinical trials (viral vectors: 1038 or 
70.5%; naked plasmid and non-viral vectors: 434 or 29.5% of all trials). 
1.2.2. Non-viral gene delivery   
Non-viral gene delivery systems transfer therapeutic gene into cells without the 
mediation of infectious recombinant virus particles. Thus, they do not possess the disadvantages 
and toxicity risks of viral vectors. In general, non-viral delivery systems are much less toxic and 
immunogenic, and thus are regarded as safe. Furthermore, they offer significant advantages of 
simplicity of use and ease of large scale production23. However, their exploitation in gene 
therapy has been limited by their inefficiency of cellular transfection.  
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 A non-viral system is composed of (i) a delivery method (such as synthetic 
macromolecules or mechanical devices) and (ii) nucleic acids (typically plasmid DNA encoding 
therapeutic gene(s)). Due largely to the serious adverse effects of viral vectors, there is now 
resurgent interest in developing improved non-viral gene delivery techniques. These may 
typically be categorised into two broad groups: (i) delivery mediated by chemical carriers; and 
(ii) naked DNA delivery by physical methods.  
Chemically-mediated gene delivery was first reported by Felgner in 1987 using 
liposomes24. In the 1990s, a large number of cationic lipids, such as quaternary ammonium 
detergents, cationic derivatives of cholesterol and diacylglycerol, and lipid derivatives of 
polyamines, were reported. However, after more than a decade of research and development with 
unsatisfactory gene delivery results, these carriers are now mostly abandoned for in vivo use and 
replaced with novel chemical gene carriers such as modified peptides, biodegradable polymers 
and cationic copolymers that can be categorised into several groups25: (1) those forming 
condensed complexes with DNA to protect DNA from nucleases and other blood components; 
(2) those designed to target delivery to specific cell types; (3) those designed to increase delivery 
of DNA to the cytosol or nucleus; (4) those designed to dissociate from their complex with DNA 
in the cytosol and (5) those designed to release DNA in the target tissue to achieve continuous or 
controlled expression. Chemical carriers, developed to incorporate several of the foregoing 
characteristics were reported to achieve higher gene transfer efficiency in vitro25. Nonetheless, 
these chemical carriers still fall short in in vivo gene transfer, and also evoke systemic toxicity. 
For example, rapid induction of proinflammatory cytokines such as TNF-α, IL-6 and IL-12 was 
associated with systemic injection of cationic liposomes26.  
The simplest mechanical technique for gene delivery is direct injection of naked plasmid 
DNA into tissues, systemic or regional injection into blood vessels. Use of carrier-free naked 
DNA is arguably the safest gene delivery method to date. However, owing to the rapid 
degradation of DNA by serum nucleases and clearance by the mononuclear phagocyte system, 
the transfection efficiency and consequently, expression levels are generally far below 
requirements for clinically meaningful effects25. To address this difficulty, various physical 
methods emerged in the late 1990s to enhance naked DNA delivery. Physical methods such as 
electroporation, hydrodynamic pressure, ballistic pressure (gene gun), application of magnetic 
fields and ultrasonography have been demonstrated to enhance the transfer of plasmid DNA into 
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cells both in vitro and in vivo by bringing DNA to the proximity of cell membranes, and 
temporarily and reversibly disrupting cell and nuclear membranes to facilitate DNA ingress into 
nuclei27.  
The application of controlled electric fields to induce transient cell permeabilisation, 
known as electroporation, can be performed both in vitro and in vivo for virtually all cell types, 
provided electroporation conditions have been optimised. Electroporation can achieve high 
transfection efficiency both in vitro and in vivo if high cell mortality and irreversible tissue 
damage, respectively, are avoided28.  
Gene guns shoot gold- or tungsten-coated DNA into tissues or cells to allow direct 
penetration through the cell membrane into the cytoplasm and even nucleus, bypassing the 
endosomal compartment29. However, shallow depth of tissue penetration limits their utility for in 
vivo applications25.  
Ultrasound-mediated gene transfer in vascular tissues can be further enhanced by using 
microbubbles, or ultrasound contrast agents that lower the threshold for cavitation by ultrasound 
energy30. At present, however, only a limited range of cell types such as vascular and muscle 
cells are reported to be efficiently though transiently transfected with this method. 
In summary, many novel non-viral gene delivery systems have emerged in the aftermath 
of highly publicised adverse reactions (immunotoxicity, fatality and leukaemogenesis) to adeno- 
and retroviral vectors. While viral vectors have shown limited clinical efficacy in some trials, 
this is less true of non-viral vectors. Moreover, the ability to scale up experimental methods that 
work in small animals (mainly murine species) to larger pre-clinical animal models has not been 
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1.3 Diabetes Mellitus  
Diabetes has a long historical background of no less than 2000 years. Ancient Hindu 
writings described this disease as a deadly one, which caused intense thirst, excessive body 
wasting and large urine output that attracted ants and flies. In the first century AD, Arataeus of 
Cappadocia named the disease “diabetes”, from a Greek word meaning “to siphon” or “to go 
through”, which reflected the early understanding of the disease - excessive fluid loss. Several 
centuries later, the Latin word for honey, “mellitus”, was appended to diabetes to mean “sweet 
fluid”1. 
Diabetes mellitus (DM) is now regarded as a clinically and genetically heterogeneous 
group of metabolic syndromes that have abnormally high blood glucose and glucose intolerance 
as their hallmark characteristics2. The hyperglycaemia is caused by deficiency in insulin 
secretion and/or resistance of the body’s cells to insulin action. In addition, there are often 
associated disturbances in fat and protein metabolism. DM is diagnosed on the basis of World 
Health Organisation recommendations, which incorporates both fasting (no caloric intake for at 
least 8 h) and 2 h after glucose load (75 g) criteria (Table 1.3)3.  
 
Table 1.3  Diagnostic criteria of diabetes mellitus and other categories of hyperglycaemia. 
(Adapted from ref.3)  
 Glucose concentration in venous plasma (mmol/L) 
 
Diabetes mellitus Fasting ≥7.0 or 2 h post-glucose load ≥11.1 
Impaired glucose tolerance Fasting (if measured) <7.0 and 2 h post-glucose load* ≥7.8 and <11.1 
Impaired fasting glucose Fasting ≥6.1 and <7.0 and 2 h post-glucose load* (if measured) <7.8 
 





1.3.1. Classification of diabetes mellitus 
Classically, two main forms of diabetes have been recognised since the 1800s, both of 
which are now known to be characterised by acute or progressive β-cell failure4. Type 1 diabetes 
(T1D), still most prevalent in its childhood onset, is mainly a chronic T-cell-mediated 
autoimmune disease characterised by selective destruction of the islet β-cells. A small proportion 
of idiopathic cases that resemble T1D are, however, not caused by aberrant T-cells, but by other 
pathogenetic mechanisms such as exposure to environmental toxins, β-cell lytic virus infections 
and rare genetic syndromes4. TID is a state of absolute insulin deficiency and leaves its patients 
with no useful treatment other than exogenous insulin administration. Despite decades of 
intensive research, the exact aetiology and pathogenesis of T1D remain elusive, and there is no 
assured means of preventing it5. 
Type 2 diabetes (T2D), accounting for ~90% of all diagnosed diabetes, is a multi-faceted 
metabolic disorder characterised by insulin resistance (impaired insulin effectiveness on its target 
tissues) and abnormal insulin secretion3. Increased secretory demand caused by insulin resistance 
and the intrinsic β-cell secretory defects may explain the eventual relative loss of β-cell mass in 
the course of T2D6. T2D patients do not depend on exogenous insulin for survival, but may 
require it for optimal glycaemic control when endogenous insulin secretion from β-cells is 
insufficient and/or other treatment modalities eventually fail7.  
Following the development of radioimmunoassays that distinguish diabetes based on 
plasma C-peptide and insulin levels, and the need for a good classification system to facilitate 
orderly epidemiologic and clinical research, the older terms of “juvenile-onset”, “maturity-onset” 
and “adult-onset” diabetes were replaced with “insulin-dependent” and “non-insulin dependent” 
diabetes on the recommendation of the National Diabetes Data Group of the United States 
National Institutes of Health in 1979. A year later, the World Health Organisation Expert 
Committee on Diabetes endorsed the recommendation. In 1996, an expert committee of the 
American Diabetes Association (ADA) considered the research developments in DM of the 
preceding two decades and proposed further changes to the National Diabetes Data Group/World 
Health Organization classification scheme in which the terms “type 1 diabetes” and “type 2 
diabetes” were introduced and accepted by the latter in 19974. This new classification 
acknowledges the fact that, while T2D patients may not require insulin initially, many will 
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progress to a stage when insulin is essential for optimal metabolic control8. It also distinguishes 
two forms of diabetes in terms of genetic and environmental aetiologic factors, pathogenesis, and 
clinical presentations; each with different recommended treatment algorithms. The classification 
system also includes less common additional categories i.e. “other specific types of DM”, and 
gestational DM. The former encompasses diabetes attributed to other established or partially 
known aetiologies such as pancreatic diseases, genetic defects in insulin action, drug or 
chemical-induced pancreatic injuries and endocrinopathies, while the latter recognises 
hyperglycaemia occurring during pregnancy, which may result in various complications for the 
mother and foetus 4. 
Despite the formal classification, recent insights from diabetes research suggest that the 
difference between both major forms of diabetes is not always obvious and that their pathogenic 
processes may not be mutually exclusive. It is now recognised that both T1D and T2D are multi-
factorial diseases with several predisposing genetic and environmental factors, some of which 
are common to both9. Moreover, due to the complexity of the disease and failure to identify truly 
distinctive differences between T1D and T2D, several more forms of diabetes have been 
proposed, including type 1a, type 1b, type 1.5, latent autoimmune diabetes in adults (LADA), 
maturity-onset diabetes of the young (MODY) 1-6, double diabetes, hybrid diabetes and latent 
autoimmune diabetes in youth (LADY)10. This realisation has evoked calls to review the present 
classification of diabetes on the basis that it offers no rational basis, in light of recent research, to 
perpetuate a mistaken dichotomy of two distinct forms of diabetes that is likely to be a hindrance 
to advancing further understanding of the disease and its treatment11. 
1.3.2. What causes diabetes mellitus? 
Diabetes is now accepted, in major part, as a disorder of β-cell insufficiency (failure of β-
cell compensation, premature β-cell apoptosis, autoimmune-mediated β-cell destruction) as high 
blood glucose levels occur only when β-cells fail to secrete enough insulin demanded by the 
body12. Insufficiency progresses to the eventual loss of the β-cell mass, resulting in 
relative/absolute insulin deficiency and progressive hyperglycaemia13. Beta-cell mass is 
regulated by at least four independent mechanisms, namely β-cell replication (proliferation of 
existing β-cells), β-cell size, β-cell neogenesis (the emergence of new β-cells from pancreatic 
ductal epithelial and progenitor cells) and β-cell apoptosis. The total rates of the first three 
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mechanisms minus the rate of β-cell apoptosis contributes to the growth rate of β-cell mass. The 
exact mechanisms for progressively diminishing β-cell mass characteristic of T2D have not been 
clearly elucidated but is generally regarded as the result of increased β-cell apoptosis14.  
The mechanisms for β-cell apoptosis may not be the same in T1D and T2D even though 
both are linked to mitochondrial death signals15. Loss of β-cell mass in T1D is attributed to 
autoimmunity targeted at various proteins expressed by the β-cell. Existing autoantibodies16 that 
serve as biomarkers for T1D are glutamate decarboxylase (GADA), protein tyrosine phosphatase 
IA2 (IA2A), antibodies to insulin (IAA), islet cytoplasmic autoantibodies (ICA) and the recently 
identified antibodies to zinc transporter ZnT8 (Slc30A8)17. Typically, more than one 
autoantibody is present to initiate progression of T1D, and combined measurement of ZnT8A, 
GADA, IA2A and IAA raised detection rates of 98% at disease onset of all T1D17.  
In addition, risk genotypes of T1D and T2D are different. Of particular note are specific 
HLA alleles and haplotypes residing predominantly in the HLA loci DR and DQ that are 
strongly associated with T1D. Nonetheless, these genotypes are not fully penetrant and only 
about 50% of the carriers are susceptible to the disease5. Other genetic loci that harbour insulin-
dependent diabetes mellitus susceptibility genes (termed IDDM genes), such as insulin-VNTR 
(IDDM2) and CTLA-4 (IDDM12), contribute roughly 15% of genetic susceptibility18.  
Environmental factors (also known as exogenous diabetogenic triggers) may also initiate 
β-cell destruction by perturbing immune functions and thus initiate autoimmunity19. Suggested 
environmental triggers include food antigens (e.g. cow’s milk, gluten and cereals), toxins (e.g. 
nitrosamines) and viruses (e.g. coxsackie, enteroviruses and congenital rubella)18. While some of 
the putative triggers have been implicated in a small number of studies, their roles remain 
debatable and non-definitive.  
In the process leading to β-cell death, invasion of activated T-cells triggered by the 
aforementioned genetic and environmental factors elicit humoral (B-cell) responses that produce 
antibodies to β-cell autoantigens and inflammatory cytokines20. Together these molecules 
activate β-cell genes controlled by the transcription factors nuclear factor- κB (NF-κB) and 
signal transducer and activator of transcription-1 (STAT-1). NF-κB activation leads to 
production of nitric oxide and chemokines, and depletion of endoplasmic reticulum (ER) 
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calcium15. These events cause ER stress, trigger release of mitochondrial death signals, and 
eventually result in apoptosis21.  
The pathogenesis of T2D has a strong genetic background. Beta-cell dysfunction is 
thought to begin early, perhaps at birth in individuals who inherit one or more susceptible genes. 
This hypothesis is supported by candidate-gene studies and the recent genome-wide association 
studies that have identified at least eleven significant single-nucleotide polymorphisms, each 
located close to a gene that has been implicated in β-cell development, physiology and/or 
function22.  
Several causative mechanisms for the decline in β-cell function in T2D have been 
proposed. These include chronic exposure to elevated levels of glucose (glucotoxicity) and free 
fatty acids (FFAs) (lipotoxicity)6, islet amyloid formation23 and inflammation24. Mitochondrial 
dysfunction that leads to insulin resistance has also been implicated in the decline of β-cell 
function25.  
While it is still debatable precisely how gluco- and lipotoxicity induce apoptosis, it is 
well established that exposure of β-cells to high glucose first causes glucose hypersensitisation 
and later apoptosis, via undefined mechanisms, possibly involving oxidative phosphorylation15. 
On the other hand, lipotoxicity leads to apoptosis and, to a lesser extent, β-cell necrosis26. 
Apoptosis is caused by ER stress initiated by a high intracellular FFA load that exceeds β-cells’ 
esterification capacity, resulting in delayed processing and export of newly synthesised proteins, 
and impaired ER calcium handling27. Incidentally, similar defective mechanisms in the ER have 
also been implicated in obesity-induced insulin resistance in target tissues such as skeletal 
muscle, liver and adipose tissues, thus placing ER stress as a common molecular pathway in the 
pathogenesis of T2D, i.e. insulin resistance and loss of β-cell mass28.  
Accumulation of islet amyloid derived from amyloid polypeptide, a protein co-expressed 
and co-secreted with insulin by β-cells has been implicated as a cause of β-cell cytotoxicity. 
While it is recognised that amyloid polypeptide has the propensity to form membrane-permeant 
toxic oligomers, it remains unclear exactly why these oligomers form and what their exact role is 
in inducing β-cell death23.  
 Unlike T1D, β-cell demise in T2D is independent of NF-κB and nitric oxide production. 
Several studies have shown that β-cell death is caused neither by cytokines secreted by 
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infiltrating mononuclear cells nor by β-cells as in T1D15. The presence of scavenger 
macrophages is the consequence of β-cell death rather than its cause15. In addition, an intriguing 
model has been proposed to explain the progression from normal insulin secretion to failed 
compensation and eventually to β-cell death in T2D. This model builds on the observation that 
an increase in β-cell mass and function, and consequently insulin hypersecretion often causes 
reactive post-prandial hypoglycaemia that precedes the onset of T2D in both mice and humans. 
This observation evokes the notion of β-cell hyperfunction leading to β-cell failure from 
“overwork” or “exhaustion” as proposed several decades ago29.  
1.3.3. New perspectives on the pathogenesis of diabetes mellitus 
Currently, several lines of evidence have emerged pointing to chronic inflammation as 
another pathogenic process that is common to T1D and T2D. From this perspective, diabetes is 
viewed as a heterogenous group of inflammatory disorders set against different genetic 
backgrounds. Central to this concept is the demonstration that similar inflammatory markers 
cause β-cell death in T1D as disrupt insulin action and mediate insulin resistance in T2D30.  This 
discovery is supported by clinical observations of convergent inflammatory biomarkers in T1D 
and T2D patients31. Specifically, many children and young adolescents develop a diabetes-like 
syndrome with a combination of metabolic and inflammatory markers typical of both T1D and 
T2D32. 
A wealth of evidence has established a closely conserved evolutionary link between 
metabolic and immune systems. In addition to having similar architectural structures of their 
functional units conserved from Drosophila melanogaster to all mammals, overlapping pathways 
regulate both metabolic and immune functions through common regulatory molecules and 
signalling systems33. In particular, discoveries that nutrients can act through pathogen-sensing 
systems such as Toll-like receptors resulting in inflammatory responses34 and identification of 
multiple molecules having important roles in both systems (e.g. tumour necrosis factor- α (TNF-
α), leptin, adiponectin, resistin, visfatin, c-Jun amino-terminal kinase (JNK), inhibitor of NF-κB 
kinase, protein kinase C (PKC) isoforms, and peroxisomal proliferating-activated receptors) led 
to the identification of signalling pathways that integrate stress and systemic inflammatory 
responses with insulin signalling inhibition and insulin resistance33. The earliest clue for the role 
of inflammation in the pathogenesis of T2D was provided by the discovery of Hirosumi and 
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Hotamisligil that TNF-α, a proinflammatory molecule, induces insulin resistance by activating 
signalling cascades involving JNK-mitogen-activated protein kinase (MAPK)35. Following their 
report, insulin-receptor signalling was found to interact with inflammatory signalling at the level 
of insulin-receptor substrates (IRSs) through activation of serine kinases36 and to be inhibited via 
activation of JNK by cytokine signalling, lipid products, reactive oxygen species (ROS) or 
through inositol-requiring enzyme 1 (IRE-1) during ER stress33. For many years, the source of 
proinflammatory cytokines capable of inducing insulin resistance was thought to be adipocytes. 
However, recent studies have shown migratory macrophages to be the major source of cytokines 
in obesity-induced T2D37.   
In humans, the first indirect evidence that linked T2D to inflammation was reported in 
1876 by Ebstein, who observed that high doses of salicylate, now known to prevent NF-κB 
activation (a mediator of inflammation), improved glucosuria in diabetic patients38.Many recent 
studies corroborate this early observation. First, data from a nested case-control, population-
based prospective study suggested that subclinical inflammation has a role in the pathogenesis of 
T2D. Specifically, this study showed that a combined increase in plasma interleukin (IL)-1β and 
IL-6, rather than IL-6 alone, is a better predictor of T2D risk39. Second, polymorphisms in the 
promoters of interferon-γ, TNF-α and IL-6, and in the coding region of peroxisome proliferator-
activated receptors-γ30, have been strongly correlated with the incidence of T2D. Third, plasma 
innate immunity-related acute-phase proteins such as C-reactive protein (CRP), haptoglobin, 
fibrinogen, TNF-α, plasminogen activator inhibitor and serum amyloid A are all strongly and 
independently correlated with T2D in numerous epidemiologic studies24,40,41. Lastly, a large 
number of association studies have shown that chronic elevation of circulating inflammatory 
markers is significantly correlated with T2D-associated atherosclerosis42. 
T1D, on the other hand, has long been regarded as a chronic inflammatory disease of the 
islets43. Autoimmune insulitis directed against the aforementioned self-antigens involves 
infiltration by CD4+ and CD8+ T-cells, antigen-presenting cells (macrophages, dendritic cells and 
B-lymphocytes), cytotoxic T-cells and natural killer cells that generate molecules such as 
cytokines, ROS and nitric oxide radicals. Three main cytokines act in synergy to induce β-cell 
damage and apoptosis in humans: IL-1β, TNF-α, and interferon-γ41.  IL-1β is secreted by 
activated macrophages, and intriguingly by the β-cell itself under certain conditions. TNF-α is 
solely secreted by macrophages while interferon-γ is produced by T-helper cells15. An 
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association between T1D and the presence of systemic inflammation is however debatable. 
While elevated levels of CRP have been reported in islet autoantibody-positive T1D patients, 
other studies failed to confirm the association41. More large population-based prospective studies 
are needed to clarify and resolve this controversy.       
Recent advances in DM research have yielded interesting and intriguing findings that 
advocate the concept that diabetes is a single, albeit complex, disease. In particular, there is a 
hypothesis that the natural history of diabetes in individual patients, regardless of its type, is 
influenced largely by the tempo of its progression10. For most people, the β-cell reserve present 
at birth is sufficient to sustain them through life without diabetes. For others, however, 
accelerated loss of β-cells owing to multiple genetic and environmental factors results in 
diabetes. Following this argument, the “accelerator hypothesis” postulates that insulin resistance 
accelerates β-cell death either directly or indirectly by provoking an immune reaction in 
genetically susceptible individuals44, and could be tested in a future randomised controlled trial 
in which insulin resistance is reduced in children at risk for T1D. 
 While a genetic component in both forms of diabetes is undeniable given the familial 
clustering, high prevalence in certain ethnic groups, and the fact that concordance in 
monozygotic twins has been consistently shown to be greater than that in dizygotic twins in 
many large cohort studies45, the recent increased prevalence of diabetes especially among 
children and young adults must largely be attributed to changes in non-genetic risk factors 
because a generation is too short for a change in gene pool of this magnitude. Therefore, lifestyle 
and environmental aspects must certainly accelerate the disease in those genetically predisposed. 
Indeed, several lines of evidence support a critical role of environmental factors in the 
development of T1D19. First, less than 10% of carriers of HLA-diabetes susceptible genes 
progress to clinical manifestation. Second, pairwise concordance rate below 40% was observed 
in monozygotic twins. Third, there is a more than 10-fold difference in incidence among 
Caucasians living in the same continent (Europe). Lastly, disease incidence has been reported to 
increase in populations who moved from a low-incidence to a high-incidence region. All these 
point to varying degrees of interaction between genetic susceptibility and environmental factors, 




 In parallel with accumulating evidence that models DM as an immune-mediated 
metabolic disorder with underlying gene-environmental interactions, a related hypothesis has 
recently gained support. This new perspective on the aetiology and pathogenesis of diabetes 
suggests an interplay among three main elements: intestinal microbiota (exogenous factor), 
intestinal mucosal barrier (genetic factor) and intestinal inflammatory responses (immunological 
factor)46. Evidence from mouse and human studies has been marshalled to support a synergism 
among these three factors that could result in various clinical symptoms of diabetes.  
In the case of T1D, aberrant intestinal microbiota composition, an abnormally highly 
permeable intestinal barrier and altered intestinal immune responsiveness were all noted in both 
animal and population-based clinical studies. First, compositions of the intestinal microflora 
between healthy and allergic infants in countries with a high and low prevalence of allergies 
have been documented to be different, and these differences often precede clinical 
manifestations46. The gut microflora has long been recognised to play an active role in numerous 
physiological processes related to metabolism and the immune system of the host, including 
growth, angiogenesis, defence against pathogens, mediating both innate and adaptive immunities 
through signaling molecules and metabolites, development of the intestinal microvilli, 
fermentation of indigestible dietary fibre, and anaerobic metabolism of peptides and proteins that 
contribute to metabolic energy for the host47. Taken together, it is therefore reasonable to 
envisage that alteration of its composition could well alter the above processes. Indeed, 
significant correlations were established in several experimental studies designed to examine the 
effect of interventions that altered the inherent gut microbiota on modulation of gut immunity 
and the pathogenesis of T1D. For instance, administration of certain antibiotics (e.g. 
doxycycline) and/or probiotics decreased the incidence of T1D in diabetes-prone BB rats48 and 
non-obese diabetic (NOD) mice49, possibly by inducing expression of anti-inflammatory 
cytokines. In addition, selective increases of bifidobacteria in the gut improved glucose tolerance 
and modulated inflammatory tone in mice fed a high-fat-diet, possibly through regulation of 
endotoxemia50. Moreover, dietary factors are known to modulate the intestinal microbiota, 
especially during infancy when the bacterial community first develops51. Hence, it is tempting to 
speculate that dietary interventions may be able to modulate immune and inflammatory 
responses and general physiological activities in the intestine. 
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Second, multiple studies have reported intestinal alterations in non-coeliac, T1D patients 
and in individuals at risk of T1D. Specifically, humans at risk of T1D as well as other 
autoimmune diseases were noted to possess a more permeable or “leaky” intestinal barrier, 
identified by sugar permeability tests and histomorphological analyses52. A study aimed at 
identifying the contributing mechanism to increased intestinal permeability showed that 
upregulation of an intestinal tight junction modulator, zonulin, induced loss of small intestinal 
barrier function and caused T1D in diabetes-prone BB rats. Further, blockade of the zonulin 
receptor reduced the cumulative incidence of T1D by 70%53. In humans, high serum levels of 
zonulin that correlated with increased intestinal permeability have been observed in T1D 
patients54. Taken together, these findings indicate that an abnormally permeable intestine in T1D 
would allow for greater exposure of the intestinal immune system to exogenous antigens.  
Third, perturbing the homeostasis between gut antigens and host immunity has been 
implicated in gut inflammation55. In a recent study to determine if T1D pathogenesis relates to 
intestinal immunity, markers of immune activation not due to a typical autoimmune disorder i.e. 
coeliac disease were investigated in small intestinal biopsies taken from children with T1D. The 
results implicated altered activation of both innate and adaptive immune cells in the intestinal 
mucosa of these patients46. On the other hand, altered responses to food and microorganism-
derived antigens are also consistently associated with increased intestinal permeability and the 
development of aberrant inflammatory responses. In particular, some studies have suggested that 
early exposure to certain food antigens increases the risk of autoimmunity and subsequent 
induction of intestinal inflammation in the presence of abnormally high intestinal permeability46. 
Nonetheless, determining which is the triggering factor and which is the manifested consequence 
remains a moot point. 
Similarly to T1D, commensal microbiota could also be linked to the pathogenesis of 
T2D, directly or indirectly. Although not strongly or historically associated with antigen (food, 
microbial and/or viral) exposure as in T1D, T2D is regarded as a chronic inflammatory disease 
often induced by obesity and dependent on macrophage activation. Karin et al proposed that a 
key aspect of the pathogenesis of chronic inflammatory disorders, including cancer, is an 
aberrant epithelial barrier that results in activation of resident inflammatory cells by microbial 
invaders or endogenous ligands37. Either as a consequence of this or from a genetic 
predisposition (or both), failure of intestinal immune homeostasis results, leading to chronic 
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systemic inflammation. Intriguingly, although intended for T2D, this model supports the 
mechanisms postulated by the new perspective on T1D pathogenesis discussed previously.   
Several recent lines of evidence involving intestinal microbiota echo the proposed 
microbial participation in the pathogenesis of T1D and T2D. First, obesity affects the community 
and diversity of murine gut microbiota56. Following this discovery, these investigators went on to 
identify an obesity-associated gut microbiome that has an increased capacity to harvest energy 
from the diet. One fascinating feature of this microbiome was that it is transmissible as 
colonisation of germ-free mice with an “obese microbiota” resulted in a significant increase in 
total body fat compared to colonisation with a “lean microbiota”57. Another study that supports 
the role of the gut microbiota, published a year later, reported protection against obesity in germ-
free mice colonised with a “lean microbiota” fed a calorie-dense diet compared to pair-fed mice 
colonised with a normal gut microbiota that became obese58.  Almost concurrently, high-fat diet 
induced augmentation of systemic bacterial lipopolysaccharide (endotoxaemia), an early event 
triggering inflammation, obesity and insulin resistance59. Intriguingly, the increase in plasma 
lipopolysaccharide was determined to be the consequence of an increased proportion of 
lipopolysaccharide-containing microbiota in the gut. This further supports possible involvement 
of intestinal microflora in the pathogenesis of diabetes.  
Interestingly, the acquisition of certain microbiota is influenced by both host and 
environmental factors. The latter include, among others, maternal genital microbiota, mode of 
delivery, obstetric techniques, sanitary conditions, geographic location, and mode of feeding. 
The involvement of these factors indicates an early, perpetual colonisation by certain microbial 
communities that may possibly be life-long. On the other hand, Hoskins was among the first to 
suggest that one’s genotype can influence the composition of the intestinal microbiota. 
Specifically, he demonstrated in a seminal work that the composition of blood group antigen-
specific glycosidases harboured by the faecal bacteria mirrored the specific blood type of the 
host60. More recently, the involvement of genetic determinants was confirmed by a study 
demonstrating that the faecal microbiota of monozygotic twins were significantly more similar 
than those of dizygotic twins61. Additionally, one intriguing discovery was that bacterial fatty 
acid profiles were significantly different between inbred strains of mice congenic for the major 
histocompatibility complex, indicating that genes in this region play a role in shaping the 
composition of the gut microbiota60.    
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Clearly, mounting evidence has evolved to suggest a relationship between intestinal 
microbiota, host genotype and environmental factors in the pathogenesis of T1D and T2D. 
However, while gene-environmental interactions have been implicated, direct evidence for the 
involvement of specific intestinal microbiota in diabetes initiation and/or progression is still 
lacking. A complete working out of this and other questions will undoubtedly result in novel 
interventions to prevent and treat diabetes. 
1.3.4. Prevalence and impact of diabetes mellitus 
 Today, the efforts of numerous researchers worldwide are directed at developing a cure 
for diabetes, a disease of epidemic proportion in the 21st century. The total number of people 
with diabetes in the world in 2000 was estimated at 171 million, giving a prevalence of 2.8%. 
This figure is however projected to rise to 366 million with a prevalence of 4.4% by 2030, an 
increase of more than 200%62. This rising tide results from an apparently inexorable increase in 
the world’s population, urbanisation, prevalence of obesity, sedentary and obesogenic lifestyles 
and paradoxically, increased life expectancy. In fact, this figure could be an underestimation in 
light of increasing prevalence of diabetes risk factors, especially obesity.  
In general, global diabetes prevalence is similar in men and women, although it is slightly 
higher in younger men. Nonetheless, there will be more women with diabetes than men, owing to 
their greater longevity. The total number of diabetics is different among the age groups. More 
than half of all diabetics are in the 45-64 year age group62. A significant rise in childhood obesity 
leading to diabetes has been observed worldwide, with T2D now occuring more commonly than 
T1D63. Moreover, children diagnosed with T1D also expressed markers typical of T2D. Along 
with the increase in prevalence, the estimated lifetime risk of developing diabetes for children 
born in 2000 is 32.8% for males and 38.5% for females. These diabetics are projected to have 
significant reductions in life expectancy. For example, men will lose 11.6 life-years (or 18.6 
quality-adjusted life-years) while women will lose 14.3 life-years (or 22.0 quality-adjusted life-
years)64. 
Despite having similar risk factors and disease syndromes, different prevalence rates 
occur in different populations and countries. For instance, developing countries in Asia, Africa 
and South America will expect a larger increase compared to developed countries in the 
Europe62. Moreover, the age-adjusted prevalence of diabetes is lower among people of European 
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descent (~5%) than among aboriginal populations (~40%)65. There appears a plausible 
explanation for this.  According to the “thrifty gene hypothesis”, humans are maladapted to 
developed world conditions of abundant food and decreased requirement for manual labour (a 
diabetogenic environment), having descended from hunter-gatherer ancestors. However, since 
the industrial revolution began in Europe, Europeans have been exposed to this diabetogenic 
environment longer than most other populations and therefore may be better adapted to and 
protected against its metabolic consequences. This hypothesis is supported by epidemiological 
observations linking low birth weight with the risk of obesity and diabetes where the “survival of 
the fittest gene” in an environment of intrauterine malnutrition is considered the thrifty gene 
operator66. Interestingly, this could also be applied to domesticated animals to explain the 
increased diabetes incidence among “home-guarding” dogs and “rodent-catching” cats , whereas 
diabetes is extremely rare in pigs and cows as they are selectively bred for their efficiency to 
accumulate and store energy for human consumption65. 
Diabetes is a very expensive disease to treat and manage because it demands life-long 
intensive medical care that imposes heavy financial burdens to patients and their families, as well 
as to national health service budgets. In the US, direct and indirect medical expenditures 
attributable to diabetes (the former include diabetes care, treatment of diabetes complications and 
excess prevalence of general medical conditions; the latter includes lost workdays, restricted 
activity days, mortality and permanent disability) in 2002 amounted to US$132 billion. 
Moreover, after adjusting for demographic differences, diabetics incur about 2.4-fold higher 
medical costs than non-diabetics. These figures may not reflect the true burden of diabetes 
because other intangible components such as pain and suffering, care provided by unpaid 
caregivers, psychological burden and additional health care spending in high cost services were 
likely omitted67.   
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1.4 Diabetes Complications 
The most debilitating consequence of all forms of diabetes is the development and 
progression of complex co-morbidities known as vascular and neural complications - the major 
cause of mortality, morbidity and expenditures in diabetic patients. Microvascular complications, 
manifest as aberrant angiogenesis and basement membrane thickening in the retina, kidney and 
peripheral nerves, are the cause of diabetic retinopathy, nephropathy, peripheral and autonomic 
neuropathies, respectively. These diabetes-associated conditions are the leading cause of 
blindness, renal failure, limb amputation and varied manifestations of neural dysfunction (e.g. 
impotence, gastropareisis)1. Diabetic macrovasculopathy, on the other hand, affects large arteries 
that supply the heart, brain and lower extremities, causing atherosclerotic coronary artery 
disease, occlusive peripheral arterial disease and cerebrovascular disease. Macrovascular 
complications manifest clinically as myocardial infarction and stroke, and collude with 
peripheral neuropathy to cause lower limb gangrene2. Cardiovascular disease is the most 
prevalent of all diabetic vascular complications. It is manifested in approximately 25% of all 
diabetics and accounts for ~44% and ~52% of deaths in T1D and T2D, respectively3. Established 
risk factors for diabetes-related complications are poor glycaemic control, early onset and long 
history of diabetes, genetic predisposition, hypertension, hyperlipidaemia, smoking, obesity, and 
sedentary lifestyle4.   
Besides vascular complications, there are other less common acute and chronic 
complications unrelated to diabetic vasculopathy5. Acute complications are metabolic in nature 
i.e. diabetic ketoacidosis, hyperglycaemic hyperosmolar state, and malignant hyperthermia-like 
syndrome with rhabdomyolysis. Most have a high risk of mortality and are thus medical 
emergencies. Chronic complications, on the other hand, may cause considerable morbidity and 
even mortality several years after the diagnosis of diabetes. These include glycogenic 
hepatopathy, non-alcoholic steatohepatitis, cataracts, neuropsychiatric disorders, pregnancy-
related disorders (enhanced maternal risk, increased fetal and neonatal pathological findings, 
long-term effects on the offspring, increased perinatal mortality and congenital anomaly), 
polycystic ovary syndrome, necrobiosis lipoidica, gastropathy (gastric dysmotility) and various 
gastrointestinal complications6. Interestingly, DM is also known to increase the risk of various 
maglinancies7. While there is a clear association, the cause-effect relationship is however 
uncertain.        
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1.4.1 Diabetic retinopathy 
Diabetic retinopathy is the most common cause of blindness in the world among adults 
aged 20-74 years. In the Wisconsin Epidemiologic Study of Diabetic Retinopathy, 3.6% of 
patients with T1D and 1.6% of patients with T2D were blind. In addition, 86% and 33% of 
blindness in young T1D patients and older T2D patients, respectively, was caused by diabetic 
retinopathy8. Oedema, ischaemia- and hypoxia-induced neovascularisation in the retina cause 
diabetic retinopathy. Morphological changes in the early, non-proliferative phase of diabetic 
retinopathy include thickening of the basement membrane of the retinal capillaries and loss of 
intramural capillary pericytes (contractile cells of the microvasculature that are important for 
regulating blood flow and permeability), which result in microaneurysm and exudate formation.  
Formation of microaneurysms leads eventually to the proliferative phase of retinopathy, 
characterised by excessive vascular permeability of the retinal capillaries and vascular occlusion 
with subsequent development of macular oedema and fibrovascular proliferation. Both latter 
complications may cause vitreous hemorrhage and detachment of the retina - common causes of 
vision loss9.  
Data from large cohort studies, such as the Wisconsin Epideomiologic Study of Diabetic 
Retinopathy, have shown increased prevalence and severity of diabetic retinopathy among poorly 
controlled diabetics, especially in insulin-requiring patients.  For instance, in the cohort of T2D 
patients with less than 5 years of known DM, 40% of insulin-taking patients compared to 24% of 
non-insulin taking counterparts had retinopathy of similar severity10. Interestingly and almost 
counter-intuitively, both the Diabetes Control and Complications Trial and the United Kingdom 
Prospective Diabetes Study demonstrated that intensive insulin treatment is associated with a 
decreased risk of either the development or progression of diabetic retinopathy in T1D and T2D 
patients, respectively11,12. Taken together, these studies indicate that while intensive and effective 
insulin treatment that achieves target HbA1c levels  reduces the incidence and severity of diabetic 
retinopathy, non-stringent insulin treatment aimed at reducing post-prandial glucose levels is 
simply not sufficient to halt the initiation or progression of retinal injury. 
1.4.2. Diabetic nephropathy 
Diabetes has also become the most common cause of end-stage renal disease (ESRD). 
Overall, 20-30% of diabetic patients develop laboratory evidence of nephropathy. Significantly 
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more patients with T1D (30-40%) progress to ESRD compared to T2D patients (5-10%). 
Approximately 25-50% of ESRD patients will ultimately require dialysis or kidney 
transplantation13. However, diabetic patients with ESRD fare less well in these two procedures 
than non-diabetic ESRD patients14. Development of diabetic nephropathy is characterised by 
basement membrane thickening of glomerular and tubular capillaries, expansion of mesangial 
extracellular matrix, renal hyperplasia and hypertrophy before the onset of measurable renal 
dysfunction i.e. glomerular hyperfiltration (glomerular filtration rate >135 ml/minute/1.73 m2), 
persistent microalbuminuria (urinary albumin excretion rate of 20-200 μg/min) and proteinuria 
(total urinary protein excretion > 0.5 g/24 hours)15. Besides that, changes within the 
tubulointerstitium, for instance proximal tubular cell atrophy and tubulointerstitial fibrosis, are 
also important features of diabetic nephropathy16. 
Similar to diabetic retinopathy, all prospective epidemiological and clinical studies have 
established a relationship between glycaemic control and risk of diabetic nephropathy. 
Intriguingly, there are diabetic patients who do not develop any renal impairment as assessed by 
proteinuria despite years of poor glycaemic control. This would suggest that hyperglycaemia is a 
necessary but insufficient condition for causing renal injury and that other contributing or 
predisposing factors are required for development of clinical nephropathy17.  In this regard, 
genetic determinants are thought to play important role in an individual’s susceptibility to 
nephropathy18.  
A large number of nephrology studies in the past 30 years have yielded a unified theory 
of diabetic renal disease progression. Briefly, following persistent glomerular capillary injury, 
local hypertension develops and leads to proteinuria and downstream cytokine effects initiated 
by local production of angiotensin II. Many nephritogenic macrophages and T-lymphocytes are 
attracted and engage in the inflammatory process, giving rise to interstitial nephritis. Some 
tubular epithelial units respond to the inflammation, dissociate from the basement membrane and 
adjacent sister cells and undergo epithelial-mesenchymal transitions forming fibroblasts, which 
migrate, proliferate and produce excess collagen. This cascade eventually causes renal fibrosis 
and loss of function, characteristic of ESRD19.    
1.4.3. Diabetic neuropathies 
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Diabetic neuropathies (DN) comprise of a variety of syndromes affecting somatic and 
autonomic nerves20.  These complex conditions are the most common form of diabetes-
associated neurological and microvascular complications. The frequency of diabetic neuropathy 
is determined by the diagnostic methods employed, whether by clinical examination alone or 
supplemented with electrophysiological measurements21. The population-based Rochester 
Diabetic Neuropathy Study has established that the prevalence of neuropathy was 54% in T1D 
and 45% in T2D. In general, the prevalence was about 10% at the time of diagnosis, rising to 
more than 50% among patients with more than a 5-year history of diabetes22. 
Common features of diabetic neuropathy, which often involve small myelinated and 
unmyelinated somatosensory fibers, include axonal degeneration in nerve fibers, primary 
demyelination due to Schwann cell insufficiency, secondary segmental demyelination related to 
impairment of the axonal control of myelination, proliferation of Schwann cells, atrophy of 
denervated bands of Schwann cells, onion-bulb formations, and basal lamina hypertrophy20.  
The current classification of diabetic neuropathies was first proposed by Thomas based 
on presumed aetiology, topographical and pathological features. It has since been modified to 
include “prediabetic neuropathy” or impaired glucose tolerance neuropathy23. Generally, DN fall 
into two major categories: focal and generalised14.   
The most common focal neuropathy is the distal symmetrical length-dependent diabetic 
polyneuropathy that involves degeneration of all types of long nerve fibers, whether myelinated 
or unmyelinated24.  Early signs of length-dependent progression of nerve dropout include 
numbness, tingling sensations and lightning pains in the toes or feet, which then spread 
proximally, even to the fingers and eventually to the abdomen and chest. The symptoms are 
primarily sensory and symmetrical early in the process, reflecting the more delicate nature of 
sensory versus motor nerves. Established length-dependent diabetic neuropathy is irreversible 
despite post hoc improvement in metabolic control. However, good glycaemic control is 
associated with a lower risk of further deterioration. Despite numerous large scale studies, it has 
not been possible to ascribe the occurrence of neuropathic pain, the major burden of the 
manifestation of length-dependent diabetic neuropathy, to any specific morphological feature, 
suggesting that different mechanisms are at play in the genesis of pain. Indeed, the identification 
of mutations in the gene coding for a sodium channel in patients with familial insensitivity to 
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pain indicates that the response to neuropathic pain stimuli could be attributable to genetic make-
up24. 
The most common generalised neuropathy is sensorimotor polyneuropathy, which affects 
peripheral and autonomic neurons. It is manifested in multiple organ systems, commonly the 
cardiovascular, gastrointestinal, urogenital, and respiratory systems25. The symptoms of 
sensorimotor polyneuropathy are therefore protean and include cardiac dysfunction, 
hypoglycaemia unawareness, orthostatic dizziness, erectile dysfunction, abdominal pain, 
constipation and diarrhoea. Peripheral neuropathy, in conjunction with peripheral vascular 
disease, is a set up for impaired wound healing, gangrene, diabetic foot ulcers and limb 
amputation26. 
1.4.4. Diabetic macrovasculopathies 
In contrast to microvasculopathy, the risk of macrovasculopathy was previously not 
considered to be reduced by glycaemic control. Instead, diabetic macrovascular disease 
correlates with general risk factors for atherosclerosis i.e. dyslipidaemia, hypertension, 
hyperhomocysteinaemia, age, smoking, obesity and physical inactivity27. These notions are 
consistent with the observation that atherosclerotic vascular disease has a much higher 
prevalence in T2D than T1D28. However, several large prospective studies in the last decade 
have shown that hyperglycaemia is clearly involved in predicting atherosclerotic vascular 
disease29. More recently, the incidence of myocardial infarction and coronary artery disease 
mortality were reported by three studies to correlate with postprandial but not fasting glycaemic 
profile30. It is now generally acknowledged that all the risk factors of atherosclerosis combined 
with hyperglycaemia create a state of constant low-grade inflammation and endothelial 
dysfunction that progressively damages the vascular wall.   
1.4.5. Pathobiology of diabetes complications 
The presence of a common pathogenic mechanism causing micro- and macrovascular 
complications was suggested several decades ago because both develop in T1D and T2D patients 
even though the disease aetiologies are somewhat different. Hyperglycaemia was shown to be an 
independent vascular risk factor in the 1970s31. Indeed, glucose induces the expression of genes 
related to atherogenesis and angiogenesis regulation in vitro32. Moreover, evidence from several 
prospective clinical studies conducted in the 1990s, for example Diabetes Control and 
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Complication Trial11, United Kingdom Prospective Diabetes Study12, European Prospective 
Investigation of Cancer and Nutrition (EPIC-Norfolk)33 and Diabetes Mellitus, Insulin Glucose 
Infusion in Acute Myocardial Infarction (DIGAMI) study34 have established a strong 
relationship between glycaemia and diabetic microvasculopathy in both T1D and T2D, and an 
association between post-prandial hyperglycaemia and cardiovascular diseases. Collective data 
from these studies coherently demonstrated that intensive glycaemic control in TID and T2D 
does delay the progression of retinopathy, nephropathy, neuropathy and atherosclerosis.  
Since then, a large corpus of data from in vitro and in vivo studies has attempted to 
elucidate the pathogenic mechanisms in glucose-induced diabetic vasculopathy. In the last 
decade, four proposed mechanisms have prevailed: increased advanced glycation end-product 
(AGE) formation (Figure 1.4.5.1), activation of PKC isoforms (Figure 1.4.5.2), stimulation of the 
aldose reductase and the polyol pathway (Figure 1.4.5.3), and increased flux through the 
hexosamine pathway (Figure 1.4.5.4)35. Increased reactive oxygen species (ROS) formation 
implicated in these mechanisms (illustrated for example in Figures 1.4.5.1 and 1.4.5.3) may, in 
turn, induce vascular inflammation and alter the expression of growth factor and cytokine genes, 
and thus play a key role in the activation of macrophages, platelets and endothelial cells36. 
Several controlled clinical trials initiated in the late 1990s were premised on the 
relevance of these four mechanisms to the pathogenesis of diabetes complications. However, 
these trials (e.g. CHAOS, HOPE, GISSI-Prevenzione, SPACE, and the Heart Protection Study) 
produced mixed results and a confused picture37. Further analyses of the results revealed at least 
three additional factors that may have contributed to discrepant outcomes. First, the phenomenon 
of hyperglycaemic memory, which refers to the persistence or progression of hyperglycaemia-
induced vascular alterations even during periods of normoglycaemia, appears highly recalcitrant. 
Second, at least some patients were probably unknowingly under-treated as trial subjects were 
not monitored with reliable biomarkers of oxidative stress. Third, genetic susceptibility to both 
micro- and macrovascular complications could play a more significant role than was appreciated. 
The rather anxious research community was, however, relieved when Nishikawa and 
Brownlee proposed a common element linking and unifying all four mechanisms, namely that 
hyperglycaemia-induced overproduction of superoxide by the mitochondrial electron-transport 
chain activates all four pathogenic pathways by inhibiting the key glycolytic enzyme, 
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glyceraldehyde-3 phosphate dehydrogenase (Figure 1.4.5.5). Their finding explains how 
oxidative stress results in ROS-induced diabetic vascular damage38.  
 Meanwhile, endothelial activation and subsequent dysfunction is regarded as one 
of the most important changes in the pathogenesis of diabetic vascular complications39. 
Endothelial cells, from their unique position between blood and tissues, are among the first cell 
type to encounter humoral changes. The endothelial layer normally forms a permeability barrier, 
prevents thrombus formation on the luminal surface of the vascular wall, regulates vascular tone 
and controls blood flow and pressure40. However, in response to chronic ambient 
hyperglycaemia, endothelial cells become activated, undergo morphological and transcriptional 
changes that affect their physiological functions and interactions with other cell types27. For 
instance, activated endothelial cells express a variety of pro-thrombotic and pro-inflammatory 
molecules, growth factors and adhesive proteins that facilitate the attachment and transmigration 
of leukocytes through the vessel wall. In addition, these molecules also activate other interacting 
cells such as retinal pericytes, renal mesangial cells, smooth muscle cells, platelets, macrophages 
and adjacent epithelial cells, with eventual loss of normal tissue and organ functions27. One 
unifying mechanism that links hyperglycaemia to endothelial dysfunction is the downstream 
activation of poly(ADP-ribose) polymerase by each of the four pathways implicated in 
hyperglycaemia-induced overproduction of mitochondrial superoxide41,42. 
While experiments targeting pathways implicated in diabetes complications using novel 
therapeutic interventions (e.g.  poly(ADP-ribose) polymerase inhibitors, and catalytic 
antioxidants such as superoxide dismutase (SOD)/catalase mimetics) have been mostly 
encouraging, it is uncertain if these approaches will prove to be translatable to clinical 
application. 
 In addition to playing a role in the pathogenesis of T1D and T2D, a wealth of data shows 
that inflammation is also a major mechanism responsible for vascular damage in diabetes. 
Indeed, inflammatory markers (e.g. fibrinogen and CRP)43, mediators (e.g. vascular cell adhesion 
molecule-1, intracellular adhesion molecule-1, TNF-α, interferon-γ, IL-1β, vascular endothelial 
growth factor and monocyte chemoattractant protein-1), and immune cells (e.g. macrophages, T-
cells and mast cells) are involved in every phase of atherogenesis, from the early stages of fatty 













Figure 1.4.5.1 Mechanisms by which intracellular production of advanced glycation end-
product (AGE) precursors damages vascular cells. Covalent modification of intracellular 
proteins by dicarbonyl AGE precursors alters several cellular functions. Modification of 
extracellular matrix proteins causes abnormal interactions with other matrix proteins and with 
integrins. Modification of plasma proteins by AGE precursors creates ligands that bind to AGE 
receptors, inducing changes in gene expression in endothelial cells, mesangial cells and 








Figure 1.4.5.2 Consequences of hyperglycaemia-induced activation of PKC. Hyperglycaemia 
increases diacylglycerol (DAG) content, which activates PKC, primarily the β- and δ-isoforms. 
Activation of PKC has a number of pathogenic consequences by affecting expression of 
endothelial nitric oxide synthetase (eNOS), endothelin-1 (ET-1), vascular endothelial growth 
factor, transforming growth factor-β (TGF-β) and plasminogen activator inhibitor-1 (PAI-1), 












Figure 1.4.5.3 Aldose reductase and the polyol pathway. Aldose reductase reduces aldehydes 
generated by reactive oxygen species (ROS) to inactive alcohols, and glucose to sorbitol, using 
NADPH as a co-factor. In cells where aldose reductase activity is sufficient to deplete reduced 
glutathione (GSH), oxidative stress is augmented. Sorbitol dehydrogenase (SDH) oxidises 










Figure 1.4.5.4 The hexosamine pathway. The glycolytic intermediate fructose-6-phosphate 
(Fruc-6-P) is converted to glucosamine-6-phosphate by the enzyme glutamine: fructose-6-
phosphate amidotransferase (GFAT). Intracellular glycosylation by the addition of N-
acetylglucosamine (GlcNAc) to serine and threonine is catalysed by the enzyme O-GlcNAc 
transferase (OGT). Increased donation of GlcNAc moieties to serine and threonine residues of 
transcription factors such as Sp1, often at phosphorylation sites, increases the production of 















Figure 1.4.5.5 Potential mechanism by which hyperglycaemia-induced mitochondrial 
superoxide overproduction activates four pathways of hyperglycaemic damage. Excess 
superoxide partially inhibits the glycolytic enzyme glyceraldehyde-3 phosphate dehydrogenase 
(GAPDH), thereby diverting upstream metabolites from glycolysis into pathways of glucose 
overutilization. This results in increased flux of dihydroxyacetone phosphate (DHAP) to DAG, 
an activator of PKC, and of triose phosphates to methylglyoxal, the main intracellular AGE 
precursor. Increased flux of fructose-6-phosphate to UDP-N-acetylglucosamine increases 
modification of proteins by O-linked N-acetylglucosamine (GlcNAc) and increased glucose flux 
through the polyol pathway consumes NADPH and depletes GSH. (Figure source: ref. 35) 
 
There is also much data showing that increased inflammatory markers and 
proinflammatory cytokines (e.g. CRP, NF-κB, IL-6, TNF- α, prostaglandin E2, and IL-1β) in T1D 
patients is strongly and independently associated with hyperglycaemia-induced microvascular 
complications45,46,47. Moreover, increased filtration of monocytes and macrophages were also 
observed in diabetic renal glomeruli and retina, apparently due to the activation of 12/15-
lipoxygenase inflammatory pathway by growth factors, adhesion molecules and transcription 
factors (e.g. vascular endothelial growth factor, TGF-β, platelet-derived growth factor, monocyte 
chemoattractant protein-1and NF-κB) produced by resident epithelial cells and the vascular 
endothelium48. 
Recent progress in understanding the mechanism responsible for the development of 
diabetes complications has also suggested important involvement of pattern recognising 




signalling and responses of both innate and adaptive immune systems through two possible 
pathways, i.e. binding to modified self-structures (self-antigens modified by glycation such as 
AGE) and sensing of metabolic stress (oxidative stress induced by hyperglycaemia)49. 
Interestingly, as TLRs and ScRs are also involved in the sensing of microbial molecules44 and as 
macrophages produce methylglyoxal (a precursor of AGE) during bacterial infections50, it is 
therefore tempting to speculate that the new perspective on the role of intestinal microbiota in the 
pathogenesis of diabetes may also be applicable in the pathogenesis of diabetic vasculopathy. 
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1.5. Current Diabetes Treatments 
 A wealth of biochemical and metabolic data generated over several decades on the acute 
and chronic consequences of diabetes, has led to large scale clinical trials that established the 
unequivocal benefit of intensive blood glucose management in reducing the risk of development 
and progression of various vascular and neurological complications1. Since then, pharmaceutical 
companies stepped in to produce a range of drugs with different modes of action and various 
insulin preparations that have different pharmacokinetic profiles, to help achieve tight control of 
blood glucose and glycated haemoglobin (HbA1c) levels in diabetics. The wide-ranging 
modalities available often heighten uncertainty among patients and their care-givers regarding 
the most appropriate treatment choices. 
Acknowledging the situation, the American Diabetes Association (ADA) and European 
Association for the Study of Diabetes (EASD) publish a continuing series of consensus position 
statements and approaches on the management of hyperglycaemia to guide the choice of 
appropriate treatment modalities. Of note, each ADA and EASD consensus recommendation is 
graded on the quality of its evidential support2,3. We will only list and discuss currently available 
grades A and B treatment recommendations. Grade A recommendation is supported by clear 
evidence from well-conducted, generalisable, randomised controlled trials that are adequately 
powered, including evidence from well-conducted multicentre trials and meta-analyses that 
incorporate quality ratings. Grade B recommendation is supported by evidence from well-
conducted cohort and case-controlled studies (including prospective and meta-analysis of cohort 
studies).  
Therapies recommended by the ADA and EASD include lifestyle modifications, 
pharmacological interventions, and whole pancreas and islet transplantations. These therapies 
have merits in achieving the following goals in diabetes treatment: (1) eliminate symptoms of 
hyperglycaemia, (2) prevent diabetic ketoacidosis, (3) arrest the severe catabolic state and regain 
lean body mass, (4) reduce frequent infections, (5) decrease foetal and maternal morbidity in 
pregnancy, and (6) prevent or delay micro- and macrovascular complications. 
1.5.1. Lifestyle modifications 
            Lifestyle changes including exercise, diet, smoking cessation and minimised 
alcohol intake have been widely recognised as the most effective intervention for the prevention 
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of diabetes4. Principally promoting weight loss and improving insulin sensitivity, lifestyle 
modifications target key pathophysiologic mechanisms that drive diabetes progression. Indeed, 
no fewer than nine sufficiently powered clinical trials of at least one year’s duration have 
demonstrated the effectiveness of lifestyle interventions in improving metabolic abnormalities 
such as obesity, dyslipidaemia, and procoagulant and proinflammatory activities5.  
In conjunction with accumulating evidence obtained from several clinical studies and the 
recent US Surgeon General’s Report on Physical Activity and Health that underscores the 
importance of physical activities in health promotion and disease prevention, the ADA 
recommended that diabetic patients be advised to perform at least 150 min/week of moderate 
intensity aerobic physical activity (50-70% of maximum heart rate) and also be encouraged to 
perform resistance training three times a week in the absence of contraindications2, 
acknowledging that resistance exercise improves insulin sensitivity to a similar degree as aerobic 
exercise. Regular exercise is documented to improve insulin sensitivity and blood glucose 
control, reduce cardiovascular risk factors, induce weight loss, and promote overall well-being6.  
Despite the possible benefits of regular exercise, the ADA issued a cautionary statement 
that physical activities should be carried out as a well-adjusted and planned therapeutic regimen 
with the assistance of a diabetes care team that includes an individual knowledgeable in exercise 
physiology. An excessive release of counter-regulatory hormones during exercise may aggravate 
already high blood glucose levels and ketogenesis in inadequately treated T1D patients, causing 
acute complications such as diabetic ketoacidosis. In contrast, hypoglycaemia may ensue in T2D 
patients from the combination of hyperinsulinaemia with increased mobilisation of glucose and 
other substrates induced by physical exertion. In addition, diabetic patients with underlying 
vascular and neurologic complications may succumb to various hazards if the exercise 
programme is not tailor-made to suit individual needs. Exercise guidelines for diabetic patients 
with or without complications have been published in The Health Professional’s Guide to 
Diabetes and Exercise7. 
Medical nutrition therapy (MNT) plays a pivotal role in managing diabetes and 
preventing, or at least delaying, the development rate of diabetes complications. In general, ADA 
advocates individualised MNT to avoid excess energy intake while balancing nutritional 
availability. MNT is best provided by a trained dietician2. Major nutrition recommendations in 
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controlling diabetes include weight loss, monitoring carbohydrate intake (daily dietary allowance 
is 130g/day) and saturated fat limited to <7% of total calories. Sugar, alcohol and non-nutritive 
sweeteners are safe when consumed within the daily intake levels established by the Federation 
of Drug Association, USA. Conversely, routine supplementation of vitamins, minerals and 
antioxidants, and high-protein diets for weight loss are not recommended as there is no clear 
evidence of benefit8. 
In summary, lifestyle interventions have been proven effective in improving glucose 
homeostasis, particularly in overweight T2D patients2,3. However these measures are impractical 
for T1D patients and may not produce desired effect in T2D patients unless a normal body mass 
index and a regular regimen of physical activity are established9. 
1.5.2. Pharmacological interventions 
While establishing that tight control of blood glucose with insulin is integral for better 
outcomes in T1D management, the treatment protocol of Diabetes Control and Complication 
Trial in 1993 was also associated with significant morbidity, i.e. marked increase in 
hypoglycaemia (62 episodes per 100 patient-years)1. This raised doubts that the advantages of 
tight glycaemic control may be outweighed by adverse side effects.   
Despite the shortcoming, the only efficacious treatment for T1D after several decades of 
research remains intensive insulin therapy i.e. three or more insulin injections per day or 
continuous subcutaneous insulin infusion (CSII) with the aim of reducing the risk of long-term 
diabetes complications. In its most recent statement, the ADA recommended three components 
in the therapy of T1D: 1) use of 3-4 injections per day of basal and prandial insulin or CSII 
therapy, 2) matching prandial insulin to carbohydrate intake, premeal blood glucose and 
anticipated activity, and 3) use of insulin analogues, especially in patients in whom 
hypoglycaemia is a problem2.  
Diabetics can choose an insulin regimen from a variety of formulations that have 
different pharmacokinetics and duration of insulin activity. A number of rapid-acting and long-
acting insulin analogues have been developed to help address the issue of hypoglycaemia. These 
recombinant insulin analogues have modified amino acid sequences that impart different 
pharmacokinetic profiles suitable for use in different clinical contexts, and, when properly used, 
significantly reduce hypoglycaemia risk10. Insulin preparations in clinical use include rapid-
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acting (e.g. insulin lispro and aspart), short-acting (e.g. regular), intermediate-acting (e.g. lente 
and NPH), long-acting (e.g. ultralente and glargine), and mixed insulin preparations with 
predetermined proportions of different pharmacokinetic types (e.g. 70% NPH/30% regular and 
75% NPL/25% insulin lispro). Regardless of the precise regimen, assiduous blood glucose 
monitoring ought to accompany insulin therapy11.  
In the event of failed glycaemic control even with three or four daily insulin injections, or 
when therapy becomes ineffective due to inflexible daily schedules, CSII may be employed. 
However, CSII should only be recommended to patients who are strongly motivated to improve 
glucose control and willing to work with their health care providers. Moreover, while CSII may 
also cause hypoglycaemia as with other insulin regimens, it also carries the risk of more frequent 
ketotic episodes of rapid onset whenever insulin delivery is interrupted e.g. pump failure. 
Besides, infections and inflammation at the needle site are not rare12.    
Bolus subcutaneous injections of insulin have been the basis of insulin administration for 
most patients. While it does improve hyperglycaemia, especially with the availability of 
pharmacokinetically versatile insulin analogues, the natural pattern of glucose-induced and basal 
insulin secretion will never be replicated with bolus regimens. Moreover, many diabetics shun 
the prospect (and expense) of intensive insulin injections accompanied by frequent self-
monitoring of blood glucose, while those who do embark on intensive treatment may not 
persevere. In view of the difficulties faced by patients and health services in sustaining intensive 
insulin therapy by injection, alternative routes of insulin delivery have been investigated, such as 
peroral (enteric-gastrointestinal), sublingual, rectal, ocular, intravaginal, transdermal, intranasal 
and pulmonary routes (reviewed in reference 13). However, most of these routes of delivery 
offer no clear therapeutic advantage due mainly to slow absorption and low bioavailability, and 
are therefore not recommended for clinical application. 
Recent advances and clinical experience however suggested a possible role for inhaled 
insulin in the control of post-prandial glucose excursions in both T1D and T2D patients. In fact, 
several insulin inhalers targeting the pulmonary route, for example Nektar/Exubera™ (Nektar 
Therapeutics Inc., Pfizer Inc., and Aventis Pharma) and Aerodose® Inhaler (Aerogen Inc., USA) 
have received approval from the Federation of Drug Association, USA and have been marketed. 
However, inhaled insulin is immunogenic and its bioavailability, typically 5-6% relative to 
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subcutaneous insulin, is unpredictable due to local biodegradation and pathophysiological 
variables e.g. the breathing pattern, exercise, the presence of airflow obstruction and interstitial 
lung diseases. This unfavourable feature has also contributed to high cost. Moreover, long-term 
safety and information on the continued efficacy have not been established13. 
In contrast to T1D, standard treatment for T2D has always included a range of orally 
active pharmacological agents besides exogenous insulin; the latter being indicated only when 
adequate glycaemic control cannot be achieved with diet, exercise and multiple oral medications. 
In fact, as T2D is characterised by progressive loss of β-cell function, treatment is frequently 
escalated with increasing duration of disease. Figure 1.5.2.1 summarises the ADA and EASD 














Figure 1.5.2.1 Algorithm for the metabolic management of type 2 diabetes. Reinforce lifestyle 
interventions at every visit and check A1C every 3 months until A1C is <7% and then at least 
every 6 months. The interventions should be changed if A1C is 7%. aSulfonylureas other than 
glybenclamide (glyburide) or chlorpropamide. bInsufficient clinical use to be confident 
regarding safety. (Figure source: ref. 3) 
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Currently approved oral agents ameliorate hyperglycaemia through different mechanisms 
(Figure 1.5.2.2)14. Sulphonylureas and the glitinides are insulin secretagogues that act on β-cells.  
Biguanides and thiazolidinediones decrease peripheral resistance by sensitizing target tissues to 
insulin action; biguanides have the additional effect of reducing hepatic gluconeogenesis.  
Alpha-glucosidase inhibitors modify the rate of carbohydrate absorption from the gut, incretin 
mimetics and inhibitors of dipeptidyl peptidase-4 enhance glucose-stimulated insulin secretion 















Figure 1.5.2.2 Pharmacological treatment of hyperglycaemia according to site of action. GLP1 
= glucagon-like peptide. DPP-IV = dipeptidyl peptidase IV. (Figure source: ref. 14) 
 
Sulfonylureas and non-sulfonyurea (meglitinide and phenylalanine derivatives) insulin 
secretagogues stimulate insulin secretion by binding to the SUR-1 subunit that regulates the 
adenosine triphosphate (ATP)-dependent potassium channel (KATP) in the plasma membrane of 
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β-cells. Binding induces closure of the KATP channel and subsequent membrane depolarisation 
that causes opening of the voltage-dependent L-type calcium channels. These events lead to a 
rise in intracellular calcium concentration, which stimulates the migration of secretory vesicles 
laden with insulin granules and exocytosis of pre-formed insulin15. This process of physiological 
insulin secretion makes the effectiveness of all insulin secretagogues dependent on a substantial 
reserve of functioning β-cells. Although sulphonylureas have been used since the early 1950s, 
concerns regarding side effects such as hypoglycaemia, weight gain and nonspecific action on 
other tissues expressing SUR-1 subunit, and the inherent mechanism that targets only β-cell, 
have limited their clinical use. 
Two classes of oral agents targeting insulin-responsive tissues and organs i.e. biguanides 
and thiazolidinediones are currently prescribed to reduce insulin resistance and hepatic 
gluconeogenesis (biguanides only)15. Metformin, the only approved and widely used biguanide, 
alleviates hyperglycaemia directly by inhibiting gluconeogenesis and decreasing glycogenolysis; 
and indirectly by reducing plasma free fatty acids through slowing the rate of lipid oxidation. In 
addition, metformin also reduces peripheral insulin resistance and increases glucose disposal in 
skeletal muscle by stimulating the activity and expression of glucose transporter-4, increasing the 
number of insulin receptors and enhancing the binding affinity of insulin for its receptor. All of 
these actions are, however, insulin-mediated16. Clinical studies have also demonstrated beneficial 
effects of metformin on various aspects of the metabolic disease syndrome. For instance, it 
induces body weight loss, decreases serum triglycerides and LDL cholesterol, and improves 
fibrinolysis. Unlike insulin secretagogues, metformin rarely causes hypoglycaemia. Its major 
side effects are gastrointestinal symptoms (nausea and diarrhoea) that are usually not severe and 
transient.  Its generally favourable pharmacological profile makes metformin the drug of choice 
for most patients with T2D. Indeed, metformin is the only oral anti-hyperglycaemic agent that 
has shown clear therapeutic benefit without adverse effects in large and methodologically 
rigorous trials e.g. the Diabetes Prevention Program17. Nonetheless, metformin is contraindicated 
for diabetics with renal insufficiency3.  
Thiazolidinediones, on the other hand, increase insulin-mediated glucose uptake in 
muscle and adipogenesis in the adipose tissue by binding to peroxisome proliferator-activated 
receptors-γ, a member of the nuclear receptor superfamily of ligand-activated transcription 
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factors. Binding of thiazolidinediones result in altered expression of peroxisome proliferator-
activated receptors-γ-regulated genes such as lipoprotein lipase, fatty-acid binding proteins and 
phosphoenol pyruvate kinase that are involved in the regulation of lipid metabolism, insulin 
action, and adipose tissue differentiation16. Three thiazolidinediones approved for clinical use, 
troglitazone, rosiglitazone, and pioglitazone improve insulin resistance syndromes (reduction in 
serum triglycerides and FFAs, improvement in insulin sensitivity, dyslipidaemia and endothelial 
dysfunction, and decline in fibrinolysis). However, troglitazone (the first thiazolidinedione to 
receive approval) caused rare idiosyncratic liver toxicity that progressed to hepatic failure and 
death of some patients and was withdrawn from clinical use in 20002. Rosiglitazone was recently 
found to be associated with significantly increased risks of myocardial infarction and congestive 
heart failure18, the latter also being increased by the use of pioglitazone19. The ADA and EASD 
have since issued a precautionary note on the use of thiazolidinediones3.             
 Alpha-glucosidase inhibitors are classical competitive inhibitors that bind to α-
glucosidase enzymes such as glucoamylase, maltase, sucrose and dextrinase at the brush border 
of enterocytes to inhibit cleavage of oligosaccharides to monosaccharides, thus delaying and 
limiting the absorption of these sugars through the intestinal mucosa. The primary clinical effect 
of these drugs is to reduce the availability of simple sugars, thus decreasing post-meal glycaemic 
excursions. Two α-glucosidase inhibitors are currently approved for diabetes treatment i.e. 
acarbose and miglitol20. The noticeable side effects of α-glucosidase inhibitors are limited to the 
gastrointestinal tract from fermentation of excessive amounts of complex carbohydrates in the 
colon. Although this class of drug does not cause hypoglycaemia since they have no effect on 
monosaccharides, they are for the same reason less efficacious at restoring normoglycaemia. 
A novel drug class that mimics the actions of glucagon-like peptide-1 (GLP-1) has 
recently been approved as an addition to the armamentarium. GLP-1 is a gut-derived incretin 
hormone that stimulates glucose-dependent insulin secretion, suppresses elevated glucagon 
production, inhibits gastric emptying, and increases satiety. Two strategies to increase GLP-1 
activity in vivo include administering degradation-resistant GLP-1 receptor agonists such as 
incretin mimetics and retarding inactivation of endogenous GLP-1 by dipeptidyl peptidase-4 
inhibitors21. Treatment with three agents currently available i.e. exenatide, pramlintide and 
sitagliptin, caused reductions in both fasting and postprandial glycaemia, increased weight loss, 
60 
 
and were associated with only mild and transient side effects in clinical trials. However, the 
ADA and EASD do not recommend this new drug class because of their modest glucose-
lowering effectiveness, limited clinical data, frequent gastrointestinal disturbances and high 
cost2,3. 
Combination therapy using two or more of the aforementioned drug classes is used 
commonly because monotherapy rarely achieves optimal glycaemic control. Indeed, combining 
agents with different modes of action and pharmacokinetic characteristics is synergistic and in 
some cases, permits the use of submaximal doses that help to reduce side effects. In fact several 
clinical studies have shown that combined regimens of insulin and an oral agent are equivalent 
to, if not better than, treatment with insulin alone16. Typical combination therapy regimens 
include supplementing an oral agent with insulin, or combining two oral agents that have major 
differences in their effects such as metformin and a sulphonylurea2.  
1.5.3. Whole pancreas transplantation 
Whole pancreas transplantation has been demonstrated to be the most efficacious 
diabetes treatment since the mid-1980s. Successful pancreas transplant recipients often have an 
improved quality of life, primarily by obviating the need for frequent blood glucose 
measurements and exogenous insulin injections, and dietary restrictions. However, it is only 
partially successful in treating diabetes-related complications because the procedure is usually 
performed in diabetics who already have some of the disabling complications22.  
While the main stumbling block that deprives many diabetics of the benefits of 
transplantation is none other than the shortage of donor pancreata23, there are also continuing 
discussions on the balance of risks and benefits of whole pancreas transplantation. This is 
because pancreas transplantation is a complex surgery that, in less specialised centres, may be 
attended by significant morbidity and even mortality. Moreover, patients are frequently 
hospitalised for extended periods and often readmitted due to problems such as intra-abdominal 
infection and vascular thrombosis. Surgical complications aside, pancreas-only transplants also 
demand lifelong immunosuppression which may itself be diabetogenic and also cause side 
effects that impair the quality of life. Nonetheless the success of transplantation medicine has 
raised important questions of ethics and the law that continue to be discussed and debated23.  
61 
 
The most common transplant performed for T1D patients with end-stage renal disease is 
simultaneous kidney/pancreas (SKP) transplants24. This is because the significant benefits that 
patients suffering from both disease burdens receive from the procedure justify the risks of 
surgery and potent immunosuppression25. In contrast, few patients received a pancreas transplant 
alone (PTA) because subjecting patients to a procedure with a higher risk:benefit ratio than SKP 
requires additional clinical justification. Thus the ADA has recommended that potential PTA 
recipients should have: (1) a history of frequent, acute, and severe metabolic complications that 
require medical attention; (2) clinical and psychological problems with insulin administration 
that are sufficiently serious as to be life-threatening; and (3) been consistently unable to prevent 
acute metabolic complications with insulin-based therapy complication22.  
1.5.4 Islet transplantation 
 Compared to whole pancreas transplantation, isolated islet transplantation might appear 
more appealing. In addition to not requiring major surgical procedures as the islets can be 
infused into the portal vein under local anaesthesia, it can be performed more than once without 
major discomfort to the patient.   
Clinical islet transplantation was first introduced by the Minnesota group in the early 
1990s with overall poor results25. It was not until 2000 that islet transplantation attracted wide 
attention again and become a promising treatment option for T1D when a group in Edmonton led 
by James Shapiro published early excellent results with a transplant protocol, later dubbed the 
“Edmonton protocol”, which included several modifications not attempted before26. First, an 
immunosuppressive regimen comprised of induction therapy with a humanised interleukin-2 
receptor antibody (daclizumab) and maintenance therapy with low dose rapamycin (sirolimus) 
and tacrolimus was used in place of glucocorticoids. Second, more islets (in total about 11,000 
islet equivalents (IE) per kilogram body weight) were transplanted in more than one session, 
usually from two cadaveric donors.  In their experience, normoglycaemia was restored only after 
the second or even a third transplant. Third, islets were transplanted immediately after isolation 
from whole pancreata and were not cultured in vitro. Fourth, prolonged cold storage of pancreata 
and the use of animal serum products during islet isolation were avoided24,25.  
 A total of seven patients transplanted with islets from two or three donors under the 
Edmonton protocol were reported to achieve normoglycaemia and near normal HbA1c without 
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requiring exogenous insulin26. Nonetheless, most of the recipients had glucose intolerance by 
formal testing, with stimulated plasma C-peptide levels that were approximately one-third of 
normal indicating incomplete metabolic reconstitution24. Moreover, progressive loss of function 
of the grafted islets was observed i.e. the percentage of recipients who remained insulin-
independent fell from 80% at one year to less than 10%, 5 years after transplantation27. The 
causes for loss of transplanted islet function are unclear but were probably multifactorial i.e. 
chronic rejection, recurrence of the autoimmune disease, and increased apoptosis of the islets 
coupled with failure of compensatory replication as immunosuppression may impede the 
differentiation of islet progenitors25,28. It is nonetheless worth noting that transplantation of 
autologous islets i.e. islets isolated from a surgically excised pancreas for various indications and 
then implanted into the patient’s liver (islet autografts), achieved significant and long-lasting 
therapeutic effect (>13 years), even when far fewer islets were used than in the Edmonton series 
of allogeneic islet transplantation. It is plausible to infer that the distinct difference in outcome 
between autologous and allogeneic transplants resides in processes that evoke allorejection or 
autoimmunity25.  
While islet transplantation demonstrated clear therapeutic efficacy without serious 
complications and was therefore a true advance in islet replacement therapy, only a miniscule 
number of all diabetics could benefit because replicating the success of the Edmonton protocol 
would be possible only in a few specialised centres. In fact, islet cell transplantation is still 
classified as an experimental procedure and may only be performed as a controlled research 
study22. It is also important to reconsider if the adverse effects of life-long immunosuppression 
outweigh the relatively short-term gains of islet transplantation. 
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1.6. Current Experimental Approaches for Restoring Insulin Secretion In Vivo 
The promising results afforded by current strategies in insulin replenishment encourage 
initiatives to explore alternative ways that would obviate the hazards and limitations associated 
with presently available treatment methods. These efforts could be broadly categorised into two 
major approaches: (1) protecting, regenerating or increasing endogenous β-cell mass; and (2) 
developing new, possibly inexhaustible sources of insulin-expressing cells. The latter strategy 
relies on generating β- or β-like cells via induced replication, differentiation, forced expression 
of transcription factors or direct in vivo reprogramming; and modifying non-β cells to function as 
surrogate sources of insulin secretion. 
1.6.1. Immunotherapy to protect and prevent loss of endogenous β-cells 
Autoimmunity causing T1D results from failure of abnormal “educator” T-cells to 
present all self proteins, including β-cell proteins, and thereby failure to eliminate potentially 
autoreactive T-cells. Immunotherapy for T1D has mostly been attempted at two main stages of 
the disease process1. The first is prior to clinical onset, which aims to prevent the onset of 
diabetes in individuals at risk. These disease-susceptible individuals may be identified by 
detection of serum antibodies specific to various autoantigens. The second is immediately after 
diagnosis of diabetes when a significant amount of β-cell mass is believed to still remain.  Three 
approaches, namely antibody- and antigen-based immunotherapies, and cell-based tolerogenic 
therapy targeting these interventional windows have been explored in experimental and clinical 
settings.  
Antibody-based immunotherapy 
 Monoclonal antibodies are used to target various immune components in T1D, such as 
soluble mediators (e.g. cytokines and chemokines) and immune cells (e.g. T-cells, B-cells and 
antigen-presenting cells). The most widely studied antibodies are anti-CD3 and those targeting 
CD4+ and CD8+ T-cells2. These monoclonal antibodies demonstrated significant therapeutic 
benefit in a subset of patients recruited in clinical trials. While able to target large numbers of 
effector cells, the protection offered by these antibodies was transient as long-term treatment 
elicited neutralising antibodies. In addition, both pathogenic and normal T- (and B-) cells were 
indiscriminately depleted, inducing a state of immunosuppression for a significant period of time 
even after the antibodies were withdrawn2. Moreover, some recipients acquired “flu-like” 
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symptoms due to cytokines that were released by antibody-bound T-cells. Besides, reactivation 
of latent Epstein-Barr viral infections were also reported in patients treated with anti-CD33. 
Antigen-based immunotherapy 
 Administration of a specific autoantigen in a tolerogenic regimen may induce protective 
immunity by generating antigen-specific regulatory T-cells (Tregs). Tregs act through three 
possible ways: (1) releasing inhibitory cytokines; (2) inducing anergy/deletion of autoreactive 
effector T-cells; and (3) converting autoreactive T-cells into non-pathogenic cells. Antigens that 
have been tested as tolerogens in the experimental NOD mouse model and subsequently in both 
prevention and intervention human trials include insulin, GAD65, heat shock protein 60 and their 
constituent peptides2. While demonstrating efficacy in experimental rodents, clinical trials (e.g. 
the Diabetes Prevention Trial-Type 1) with these tolerogens failed to prevent diabetes in human 
subjects. Subsequent analyses revealed that factors such as the dosage of the autoantigen, 
schedule of administration, timing of intervention and other poorly defined aspects of the 
autoimmune response in humans may explain the poor outcome4. Indeed, despite more than 30 
years of attempts to prevent, delay or reverse T1D, and over 200 agents capable of preventing or 
treating diabetes in the classical NOD mouse model, few have demonstrated clear benefit in 
humans. Possible reasons for the disappointing clinical trials include the fact that the NOD 
mouse is a complex model as it expresses markers of both T1D and T2D5 and that successful 
murine treatment protocols often could not be applied to human subjects6. Recognising the key 
factors mentioned above in determining the success of specific antigen-based immunotherapy, 
researchers have initiated several recent trials targeting new-onset T1D in children. But these 
new trials (e.g. T1D TrialNet, Finnish Diabetes Prediction and Prevention Project and Primary 
Oral/intranasal Insulin Trial) aimed at investigating tolerogens such as oral insulin, Q fever 
vaccine, methotrexate and antithymocyte globulin, have again shown little or no therapeutic 
efficacy7. These failures highlight the need to better understand the complex 
immunopathogenesis of human T1D.  Indeed, it is widely recognised that, in patients with T1D, 
the immune response is driven not only by one but many autoantigens. This level of complexity 
is aggravated by the unknown chronology for effective intervention and by the existence of 
multiple molecular subtypes of T1D, defined by the interplay between particular genotypes and 
multiple environmental exposures8.   
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 Due to the heterogeneous antigenic repertoire of T1D and the difficulty in establishing 
antigen-specific-based therapy, considerable efforts have been devoted to non-antigen-specific 
immunotherapy. This approach uses broad-spectrum immunosuppressive agents that deplete or 
inactivate pathogenic T-cells. Initial trials using cyclosporine, azathioprine, prednisone and anti-
thymocyte globulin led to short-term enhancement of β-cell function and reduction in insulin 
requirements. However, such agents have general immunosuppressive effects, leaving recipients 
vulnerable to opportunistic infections and other adverse effects such as nephrotoxicity. The 
concern for the short- and long-term safety, especially in the setting of paediatric T1D, limits the 
exploitation of these agents as therapeutic drugs7.     
Combinatorial (antibody- and antigen-based) immunotherapy 
 In view of the complexity of T1D and enormous challenges in identifying the precise 
pathogenic process in every susceptible individual, combining antibody- and antigen-based 
immunotherapies may be a more practical approach. Combinatorial approaches have the 
advantage of exploiting notable strengths of the respective interventions while limiting potential 
side effects. Indeed, several studies in NOD mice have shown the advantage of a combinatorial 
approach recently. For example, Bresson et al. showed that a sub-optimal dose of non-mitogenic 
anti-CD3 coupled with intranasal administration of proinsulin peptide was more effective in 
reversing diabetes than either approach alone9. However, as with any experimental approach, 
declaration of success must await proof of clinical efficacy.  
Cell-based tolerogenic therapy 
 Transfer of Tregs or tolerogenic dendritic cells has been shown in experimental models to 
re-establish self tolerance in autoimmune T1D10. Tolerogenic dendritic cells are known to play 
important roles in induction of T-cell immunity, i.e. silencing self-reactive T-cells by inducing 
peripheral T-cell tolerance, and maturation and proliferation of Tregs while inhibiting 
proliferation of T helper type 1 cells11. Clinical application of transplanting antigen-specific 
Tregs such as CD4+CD25+ Tregs and vaccination with tolerogenic dendritic cells are however 
beset by safety concerns and technical difficulties10. First, as these cells are comparatively rare, 
their ex vivo propagation for clinical use is necessary. However, these cells are relatively non-
proliferative in vitro and may loss their functions or undergo genetic modification after 
prolonged culture. Second, the isolation of Tregs is often contaminated with effector T-cells 
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which can exacerbate the pre-existing autoimmune condition if they are co-transplanted. Third, 
the in vivo durability of Tregs and retention of the desired functions of tolerogenic dendritic cells 
in vivo, especially after circulation to inflamed tissues, remains unknown in humans. Finally, the 
greatest risk of such therapy lies in the inability to eliminate the transferred Tregs should they 
become hazardous e.g. nonspecifically suppress immunity, become tumorigenic or evolve into 
effector T-cells. Over and above the technical limitations, autoimmune T1D requires chronic 
therapy which many in the field consider impractical with cell-based tolerogenic 
immunotherapy10. 
1.6.2. In vivo regeneration/expansion of β-cell mass 
 Beta-cell mass increases in response to several pathophysiological cues, including insulin 
resistance, pregnancy and after gastric bypass surgery12. Ablation of the hepatic insulin receptor 
in transgenic mice is accompanied by a ten-fold increase in β-cell mass13. Partial pancreatic duct 
ligation in adult rats stimulated doubling of the β-cell mass14. These early observations led to the 
notion that it may be possible to stimulate regeneration of endogenous β-cells to treat diabetes. 
The source of new β-cells is nevertheless controversial and has become the subject of intense 
study. Two major schools of thought exist: one proposes islet neogenesis (i.e. budding of new 
islets from adult stem/progenitor cells residing in the pancreas or in other tissues) while the other 
favours self-replication of pre-existing β-cells.  
Islet neogenesis from pancreatic stem/progenitor cells    
 Adult stem/progenitor cells are rare cells with low proliferation capacity that play central 
roles in maintenance, repair, and regeneration of their respective tissues. Various adult stem cells 
have been identified in tissues such as skin, gut, brain and kidney. Until recently, the existence of 
adult pancreatic stem/progenitor cells was controversial. Putative cells that could be clonally 
expanded and that expressed low levels of insulin were found in mouse pancreas. Uncertainty 
arose from failure to demonstrate conclusively a bona fide β-cell progenitor in postnatal 
pancreas, and more importantly, that such cells are capable of differentiating into fully functional 
islets. This controversy has recently been resolved in mice by Xu et al., who demonstrated 
convincingly that progenitor cells located in the ductal lining of the pancreas undergo 
neurogenin3-dependent (i.e. hyperplasia-induced) differentiation in response to pancreatic injury 
to give rise to all islet cell types, including β-cells15. These glucose-responsive β-cells 
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proliferated both in situ and when cultured in embryonic pancreas explants. Adult pancreatic 
stem/progenitor cells represent an attractive cell source for diabetes therapy. Their use would be 
ethically uncontroversial and could be autologous grafts thus avoiding rejection. However, as 
these slow proliferating cells are rare and thus almost impossible to procure in sufficient quantity 
from a patient’s own pancreas; in vitro expansion could pose a major hurdle in utilising these 
cells for clinical application. In contrast, in situ proliferation of these cells stimulated by 
chemical or surgery may be more realistic. Nevertheless, it is unclear whether this will happen in 
the background of autoimmune diabetes. Even if in situ expansion of endogenous β-cell mass 
occurs, will the rate of induced proliferation be sufficient to compensate for ongoing 
autoimmune destruction of β-cells? 
Replication of pre-existing β-cells 
  In contrast to the ambiguity of identifying pancreatic stem/progenitor cells, replication of 
mature β-cells has been confirmed much earlier by several reports. Dor et al. provided 
conclusive evidence by using genetic lineage tracing to show that pre-existing β-cells, rather than 
stem/progenitor cells, were the major source of new β-cells in adult mice both under normal 
physiological conditions and after 50-70% pancreatectomy16. A recent report by Teta et al. casts 
further doubt on the involvement of any progenitor cell type in the regeneration of β-cells in 
adult mice by employing an unbiased DNA analogue-based lineage-tracing technique that 
eschewed controversial candidate markers for putative stem/progenitor cells17.  
Thus, many diabetes researchers have refocused their attention on mature β-cells as the 
regenerative source. However, it is worth noting that several previous studies indicated that the 
mechanisms of β-cell mass regeneration are species-dependent18. In rodent models of T2D, β-
cell mass regeneration was shown to occur primarily via self-replication. A similar observation 
was reported in NOD mice19. In patients with T2D, however, β-cell neogenesis seems to be 
predominant while β-cell self-replication remains low or unchanged20. Hence, clarification is 
urgently needed before more disparate findings emerge to dampen the initial elation, as 
extrapolating from one species to another could be problematic. Interestingly, while 
demonstrating that surviving β-cells have a remarkable regenerative capacity in an injured 
pancreas and that normal β-cell mass can recover even in the setting of hyperglycaemia, Nir et 
70 
 
al. showed that β-cell proliferation was inhibited by immunosuppressant drugs, thus highlighting 
the double-edged sword of immunosuppression21. 
1.6.3. Developing transplantable β- or β-like cells 
Ex vivo expansion of β-cells 
 As β-cells have substantial capacity for self-replication, inducing β-cell expansion in 
culture has been investigated as a means to obtain sufficient β-cells for clinical transplantation. 
Beta-cell expansion in vitro was found to resemble the process of epithelial-mesenchymal 
transition (EMT) during which cells first dedifferentiate, expand in number and then 
redifferentiate back to a β-cell phenotype22. A variety of conditions were explored to facilitate 
EMT in β-cell cultures, including use of serum-free medium, matrix overlay with Matrigel, 
incubation with growth factors (e.g fibroblast growth factor, hepatocyte growth factor and 
epidermal growth factor), insulinotropic agents (e.g. nicotinamide and betacellulin), peptides (e.g 
glucagon like peptide-1 and exendin-4) or pharmacological agents (e.g. Ly294002, an inhibitor 
of PI3-kinase). These efforts however met with only limited success. Three common problems 
prevail: (1) human β-cells generally have a short life-span in culture, being terminally 
differentiated cells; (2) the replication rate of human β-cells is much lower than that of rodent β-
cells; and (3) β-cells lose their insulin synthesis capacity with time, probably due to senescence 
and failure to redifferentiate to a β-cell phenotype23. 
Extra-pancreatic stem/progenitor cells 
Adult stem cells such as bone marrow mesenchymal stem cells (BM-MSCs) have been 
shown to acquire ectodermal, mesodermal and endodermal phenotypes both in vitro and in 
vivo24. These findings challenged the concept that the differentiation potential of stem/progenitor 
cells is restricted to the organs in which they reside. Murine BM-MSCs have been reported to 
transdifferentiate into insulin-producing cells and to express multiple β-cell genes25. However, 
the insulin content of such cells was less than 1% that of normal β-cells26. In a provocative 
murine study, circulating BM-MSCs were reported to migrate to the pancreas and adopt a β-cell 
fate. This finding was contested vigorously by subsequent studies suggesting that, rather than 
serving as pancreatic progenitors, BM-MSCs function to facilitate new β-cell formation. For 
instance, Hess et al. showed that transplantation of BM-MSCs into STZ-induced diabetic mice 
restored euglycaemia by enhancing the replication of surviving β-cells27. This finding was 
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supported by three other groups who reported similar results using extra-pancreatic stem cells18. 
Nevertheless, it is unclear how these transplanted cells exert a permissive effect on β-cell 
replication.  
Stem/progenitor cells from human umbilical cord blood (UCB-MSCs) display 
characteristics and immunophenotype similar to BM-MSCs28. Although generation of insulin-
producing cells from UCB-MSCs has not been shown to date, several studies reported 
improvement in experimental diabetes after transplantation of these cells29.  
In contrast, monocytes from human peripheral blood were purportedly differentiated into 
insulin-producing cells. When xeno-transplanted into diabetic mice, reversal of hyperglycaemia 
was observed, albeit for a short duration due to immunorejection30. Adult stem/progenitor cells 
isolated from liver, intestine, brain, dermis and mouse salivary glands have been reported to 
differentiate into insulin-producing cells. However, more recent investigations have indicated 
that most of these alleged findings were probably the result of cell fusion events18. 
Embryonic stem cells 
Embryonic stem (ES) cells are pluripotent diploid cell lines derived from the inner cell 
mass of blastocysts31. They are capable of proliferating indefinitely in an undifferentiated state 
but can be induced to differentiate into cells of all three germ layers both in vitro and in vivo. 
Although ES cells hold promise as an inexhaustible source of new β-cells, especially as human 
ES cell lines have been successfully derived and made available to the scientific community, 
there are still many major hurdles to overcome before their application for clinical use32.  
Soria et al. first described the generation of insulin-secreting cells by spontaneously 
differentiating ES cells into a large variety of different cell types, followed by selection of 
insulin-expressing clones using a cell trapping strategy, in which the gene conferring resistance 
to neomycin was placed under the control of the insulin promoter33. However, this was extremely 
inefficient. Lumelsky et al. later showed that ES cells can be directed to differentiate into insulin-
secreting cells by adapting a strategy used to generate neural cells from ES cells34. Production of 
insulin-expressing cell aggregates was initiated by enriching for nestin-positive cells, which were 
then expanded in a serum-free medium in the presence of growth factors. However, other 
investigators using similar manipulations failed to reproduce the result. Critical analysis revealed 
that a majority of the differentiated cells exhibited a neuronal phenotype, which was known to 
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express low amounts of insulin35. Furthermore, nestin-positive cells were found to contribute to 
the extra- and intra-islet microvasculature rather than to islet cells36. Several other approaches to 
obtain enriched insulin-producing populations include selection by manipulating the culture 
conditions and forced expression of key transcription factors such as Paired box 4 and Pancreatic 
and Duodenal Homeobox 1 (Pdx1)23. Even though these studies failed to show a significant 
content of insulin or a physiological regulation of insulin secretion, two salient points in this field 
have been established: A fully differentiated β-cell should express insulin, C-peptide, Pdx1, islet 
amyloid polypeptide and v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), 
and pre-selection for a nestin-enriched population should be avoided37. In addition to the 
multiple challenges of deriving enough homogeneous insulin-secreting cells reproducibly for 
clinical application, another crucial limitation that has not been overcome is the tumorigenic 
propensity of these cells. Owing to their high developmental plasticity and signalling pathways 
that resemble those encountered in oncogenesis, it is well recognised that ES cells often give rise 
to teratomas and teratocarcinomas in vivo18. 
The lack of success in these early attempts has refocused attention on the fundamentals of 
normal embryonic development in order to better understand the events in endoderm 
formation23. This seems to have borne fruit as several potentially important protocols have been 
established recently. Kubo et al. described a protocol that enriched for definitive endoderm from 
mouse ES cells by first culturing the cells in a serum-containing medium, followed by serum-
depleted medium supplemented with activin A38. D’Amour et al. reported generation of 
functional human adult islets from cells isolated from the definitive endodermal germ layer by 
directing them through a series of intermediate steps that mirrored normal pancreas development 
in vitro39. Li et al. recently established a simpler yet reproducible protocol for generating 
renewable cell lines that produce ample insulin from mouse ES cells40 and primary mouse 
embryo culture41. Beginning with the formation of embryoid bodies, these workers first 
generated clones of lineage-restricted progenitor cell lines that express high levels of endoderm- 
and mesoderm-associated genes and reduced levels of ectoderm-associated genes42. This strategy 
enriched for clones that have a reduced tendency to form teratomas and are more inclined to 
differentiate into mesoderm- and endoderm-derived cells. Differentiation of these clones in 
serum-free culture conditions containing nicotinamide yielded homogeneous, secretory granule-
containing cells that released insulin and C-peptide in equimolar ratio, similar to primary β-cells. 
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Moreover, transplantation of these stably propagated and expanded cell lines restored 
euglycaemia in diabetic mice and no teratoma was observed for at least 3 months after 
transplantation into STZ-SCID mice. However, insulin secretion from these cells lacked 
physiological regulation and caused hypoglycaemia. This outcome emphasises another challenge 
in attempts to generate fully differentiated β-cell from ES cells in vitro40. Nonetheless, if a 
similar strategy succeeds in generating insulin-producing cells from human ES cells, an 
important advance in ES cell-based diabetes treatment would be achieved, as the method avoids 
laborious and error-prone long-term serial cultures. It is worth noting that human ES cells grow 
more slowly and have higher mortality rates in culture compared to murine ES cells30 and 
aneuploidy has been detected repeatedly in human ES cells after long-term culture43.  
Induced pluripotent cells (iPS) 
Unlike ES cells, autologous somatic cells that would not provoke immune rejection and 
are not ethically constrained in their derivation are attractive candidates for generation of insulin-
producing cells. First introduced by Takahashi and Yamanaka44, iPS are adult somatic cells that 
have been reprogrammed to reacquire a pluripotent state. In the initial description, 
reprogramming of these cells to pluripotency occured via retroviral-mediated ectopic expression 
of a defined and limited set of transcription factors, i.e. Oct4, Sox2, Klf4 and c-Myc, and by 
culturing the transduced cells under ES cell conditions. Several new combinations of 
transcription factors (i.e. Nanog, Lin28, hTert and SV40)45 were proposed but failed to increase 
the efficiency of induced pluripotency. Generally, it takes 2 months to produce iPS from biopsied 
human fibroblasts46. Other somatic cells were also amenable to such reprogramming, including 
human and mouse fibroblasts, human BM-MSC47, mouse hepatocytes and gastric epithelial 
cells48, and more recently human ectodermal keratinocytes49.  
Both human and mouse iPS have been reported to resemble ES cells morphologically and 
functionally as they share similar gene and surface antigen expression profiles, and 
developmental potential. Nonetheless, subtle differences have been observed between human iPS 
and ES cells50. As the detailed mechanism of reprogramming is unknown, the relevance of these 
differences remains speculative. Presently, only one report has demonstrated generation of 
insulin-secreting cells from iPS derived from human skin fibroblasts51. However, teratomas 




Direct reprogramming of adult somatic cells 
Dubbed as a cell alchemist, Melton and his colleagues recently demonstrated that mouse 
pancreatic exocrine cells, the most common cell type in the pancreas, can be directly 
reprogrammed to insulin-producing cells without first reverse engineering into iPS52. This was 
achieved by transient forced expression of only three genes, namely neurogenin3, Pdx1 and 
MafA. Induced β-cells were indistinguishable from normal β-cells in morphology and 
ultrastructure although gene expression profiles were not compared. These exocrine-turned-
endocrine cells secreted insulin and reduced hyperglycaemia of STZ-mice. However, 
normoglycaemia was not restored because adenovirus-mediated in vivo transduction of exocrine 
cells was quantitatively insufficient. Nonetheless, this was the first demonstration that one 
terminally differentiated cell type could be directly transdifferentiated into another cell type 
without involving dedifferentiation. 
 Induced ectopic expression of endocrine transcription factors 
Developments in gene inactivation and in vivo cell lineage tracing technologies have 
helped to identify a proposed pro-endocrine developmental cascade and its putative transcription 
factors and cofactors, although the precise hierarchical order still needs further clarification53. 
Thus even a specialised somatic cell could, in theory, be manipulated to express all the factors 
required to transdifferentiate into another cell type. As the liver and pancreas develop from 
adjacent regions of the embryonic endoderm, Horb and colleagues54 hypothesised that expression 
of the correct transcription factor(s) could trigger liver cells to undergo a phenotypic change into 
pancreatic cells. They later showed in amphibians that liver-directed forced expression of Pdx1, 
a key transcription factor essential for the development of the pancreas that is not expressed in 
the liver, converted liver cells to both endocrine and exocrine cells of the pancreas in vitro and in 
vivo. The pancreatic phenotype of transdifferentiated liver cells persisted even though transgenic 
Pdx1 expression was transient54.  
Ferber et al. developed this concept in mammals, demonstrating in STZ-mice that 
systemic infection of liver with adenovirus-rat Pdx1 resulted in hepatic expression of mouse 
insulin-II and trace amounts of insulin-I that ameliorated hyperglycaemia55. However, other islet 
proteins, including glucagon and somatostatin, were also secreted by transduced cells. This 
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phenomenon was confirmed by several other groups who additionally demonstrated 
simultaneous expression of pancreatic acinar cell markers. Indeed, secretion of pancreatic 
exocrine enzymes such as trypsin and amylase by transduced liver cells were incriminated as the 
cause of hepatoxicity, liver fibrosis and death. Notwithstanding this complication, further 
experiments involving more downstream transcription factors rekindled the hope of applying 
such an approach for diabetes treatment. Specifically, sequential expression of combinations of 
Pdx1, NeuroD1 and betacellulin enhanced insulin expression and formation of intracellular 
inclusions reminiscent of β-cell insulin granules without severe liver dysfunction56. In addition, 
several other transcription factors including neurogenin3, MafA, NK homeobox factors (Nkx) 
and Paired-box factors have been found to guide generation of insulin-producing cells57. Specific 
soluble factors such as nicotinamide, hepatocyte growth factor and activin-A are known to have 
synergistic effects in inducing insulin expression18. Taken together, this body of work 
demonstrated that the final phenotypic characteristics of the islet are at least partly the 
culmination of all transcription events activated by a hierarchy of pancreatic developmental cues. 
This is reminiscent of the events observed in the transdifferentiation of pancreatic cells to 
hepatocytes58.  
Due to safety concerns regarding in vivo viral transduction and controversies surrounding 
the use of foetal tissues, a similar strategy has been attempted ex vivo. Gut endoderm has been 
targeted in the basis of shared ontogeny of hepatocytes and pancreatic cells. While some were 
able to show moderate reduction of hyperglycaemia in diabetic mice, insulin secretion from 
transduced cells was low, transient and not glucose responsive. The latter was consistent with the 
observation that the transduced cells failed to express genes important for β-cell glucose sensing. 
Moreover, transduction ex vivo resulted in expression of non-β-cell genes (somatostatin, 
glucagon and pancreatic polypeptide) and exocrine markers (elastase and amylase)59. This 
indicates that experimental outcomes of in vitro manipulation are clearly different from those 
that occur in vivo. It also highlights the importance of identifying the precise combination and 
chronological relationships of transcriptional and environmental factors required for complete 
transdifferentiation.    
  An unanswered question in generating insulin-producing cells by transdifferentiation is 
that none of the published work thus far has been able to confirm unequivocally the true lineage 
and exact liver cell type that eventually adopts the insulin-producing phenotype23. Furthermore, 
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there is no evidence that the change from one differentiated cell type to an insulin-producing cell 
is radical as gene products characteristic of the original cells persist even when the cell acquires 
insulin expression57. Some critics have therefore proposed that the term ‘transdifferentiation’ 
should be used only after accurate determination of cellular ancestry.   
Insulin gene transfer into surrogate β-cells 
 In contrast to the complex and often empirical methods used to transform the cellular 
phenotype for insulin production, an alternate approach simply transfers a proinsulin cDNA 
expression cassette into non-β-cells. The native insulin gene encodes for proinsulin, which is an 
inactive protein consisting of two chains, namely A- and B-chain, connected by the 35-amino 
acid C-peptide. Processing of proinsulin in β-cells involves several proteolytic enzymes (i.e. 
endoproteases PC2 and PC3, and carboxypeptidase H) that selectively successively cleave the 
prohormone at multiple sites to remove the C-peptide. The A- and B-chains are then reconnected 
by disulphine bridges and folded to biologically active insulin. This post-translational processing 
of proinsulin was the cause of failed early attempts at creating surrogate β-cells from kidney, 
fibroblasts and Chinese hamster ovary cell lines since these cells do not possess the required 
proteolytic enzymes60. Until mid-1990s, researchers had been focusing on modifying cells that 
naturally possess the enzymatic machinery necessary for creating native insulin.  
Neuroendocrine cells are appealing candidates for transgenic insulin production. In 
addition to having the requisite enzymes for processing proinsulin to insulin, they are also 
naturally endowed with regulated secretory pathways for insulin secretion. However, attempts at 
using pituitary cells have been only partially successful because these cells are not 
physiologically glucose responsive. Pituitary cells, modified to express components of glucose 
sensing i.e. glucokinase (GK) and/or GLUT2, responded only to unphysiological glucose 
concentrations61. Nevertheless, this problem appears to have been overcome by altering the 
kinetics of glucose phosphorylation62. Optimism notwithstanding, the fact that these cells co-
express diabetogenic hormones such as adrenocorticotropic hormone is a disadvantage that 
makes them less appealing candidates for β-cell surrogacy. Entero-endocrine cells that possess 
secretory vesicles and prohormone convertases such as gastrin-secreting G-cells have also been 
modified to produce insulin under the regulation of the gastrin promoter. Transgenic insulin co-
localised with gastrin in secretory vesicles, and was co-secreted with gastrin following exposure 
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to peptone63. While this model allowed prandially peptone-regulated secretion of insulin, it was 
not glucose-regulatable and hence hypoglycaemia may ensue following a protein-rich but sugar-
deficient meal.  
Brilliant work by Groskreutz and colleagues in 199464 expanded the range of cell types 
capable of modification into surrogate β-cells. Using site-directed mutagenesis, both native 
endopeptidase cleavage sites on human proinsulin cDNA were altered to sequences recognised 
by furin, a ubiquitously expressed endoprotease found in the Golgi. Thereafter, several types of 
glucose responsive cells became amenable to modification for physiologically appropriate 
insulin expression. Muscle cells became the next attractive candidate particularly due to their 
large cell mass, easy accessibility and high transducibility. In addition, myoblasts can be induced 
to form myotubes that do not proliferate62. However, despite the authors’ claim of insulin 
production from the entire musculature following insulin gene transduction, hyperglycaemia was 
not normalised. Subsequent co-expression of insulin and GK in skeletal muscle, although shown 
to be more effective in transgenic mice, also failed to induce euglycaemia in STZ-mice. This was 
later considered to be caused by the generally low activity of the physiological promoter 
employed in this study as dual transduction of insulin and GK driven by strong viral promoter 
did normalise serum insulin and blood glucose levels65. 
Since muscle cells do not naturally exhibit glucose-regulated secretion, some researchers 
turned to K cells, glucose-responsive enteroendocrine cells. Intestinal K cells express GK and 
secrete glucose-dependent insulinotropic polypeptide in response to ingested glucose with 
kinetics very similar to physiological insulin secretion62. K cells however present several 
challenges en route to becoming clinically meaningful surrogate β-cells. As their numbers are 
small amidst a large sea of neighbouring gut cells, a gene delivery system that specifically targets 
these cells is lacking. They are also not easily accessible, difficult to isolate and modify ex vivo. 
Moreover, as these cells are short-lived, it seems almost impractical to modify them even if the 
aforementioned limitations are overcome. 
Other more readily available, large and easily expandable cell sources such as fibroblasts 
and fat cells have also been modified for insulin production. However, the high proliferative 
capacity of primary fibroblasts in vivo caused uncontrolled insulin hyperexpression that 
ultimately resulted in lethal hypoglycaemia in transplanted STZ-mice66. Ito et al. reported that 
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implantation of retrovirally-transduced adipocytes ameliorated hyperglycaemia in STZ-mice67. 
While the blood glucose lowering effect correlated with the number of modified adipocytes 
transplanted, there was no measure of glucose tolerance and glucose-stimulated insulin secretion. 
Moreover, insulin expression was not sustained, probably from silencing of the viral promoter. 
Most investigators have identified hepatocytes, the most abundant cell type in the liver, 
as ideally suited for adaptation for insulin production. Hepatocytes possess several advantages 
that are not shared by most other cell types. First, hepatocytes are naturally glucose-sensing cells 
as they express GK and the high Km glucose transporter, GLUT2, thus critically recapitulating 
the molecular components of the glucose sensing system of β-cells. Second, they are endowed 
with the requisite transcription factors and co-factors for glucose-responsive expression of 
several genes, especially those involved in metabolism. Third, the innate ability of hepatocytes to 
produce and secrete large amounts of proteins such as albumin and clotting factors makes them 
an excellent “factory” for insulin production. Fourth, the liver’s high regenerating capacity 
reduces the risk of treatment-induced target organ insufficiency. Theoretically, this feature also 
makes the liver a virtually inexhaustible cell source amenable for insulin gene modification. 
Finally, situated downstream of the portal circulation, the liver is the first organ that receives 
nutrient signals from the gut. Hence, modified hepatocytes are better poised for a quicker 
glucose-induced response. Indeed, hepatocytes are the initial targets for physiological insulin 
action. Endowed with these favourable features, it is hardly surprising that most of the more 
successful attempts at insulin gene therapy have employed hepatocytes.  
A major criticism of insulin gene therapy has been the uncoupling of 
transcription/translation from secretion of transgenic insulin in response to changing serum 
glucose concentrations. As this approach relies solely on transcriptional regulation, a relatively 
long lag time in insulin secretion and its cessation compared with the extremely rapid response 
of translational regulation and secretion of preformed insulin in β-cells is inevitable.  
Hypoglycaemia is a major concern arising from this limitation, especially following 
improvements in the efficiency of viral transduction that escalate insulin secretion from 
transduced cells. Therefore, overcoming treatment-induced hypoglycaemia has been an 
important objective of researchers working toward realising insulin gene therapy.  
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Several methods have been employed to improve insulin secretion kinetics. For instance, 
regulation by non-glucose signals and use of synthetic or non-mammalian promoters have been 
examined. In the former, the use of a rapamycin-inducible promoter demonstrated that a premeal 
dosing schedule with graded doses of rapamycin can be employed to control postprandial blood 
glucose excursions68. In the latter, tripartite ligand-dependent regulatory systems that employ (a) 
Gal4 DNA-binding domain; (b) ligand-binding domain of the oestrogen or progesterone receptor 
and (c) a mammalian transcription activation domain, drives insulin expression from Gal4-
responsive promoter following administration of RU486 (a progesterone antagonist) or 17β-
estrodiol69. While both approaches moderately improved the kinetics of insulin secretion, the 
requirement for drug consumption may limit further exploitation of such approaches. 
In a study providing proof of concept that secretory kinetics can be modulated post-
translationally, Rivera et al. modified insulin cDNA to contain multiple conditional adhesion 
domains (CAD) at the furin cleavage sites70. Expressed insulin was found to aggregate via the 
CAD and was retained within the ER. Following exposure to a CAD ligand, the CAD was 
enzymatically removed and insulin was secreted via the constitutive pathway. As this approach 
resembles translational regulation of insulin expression, possible elicitation of ER stress 
responses in such a model may limit its clinical use59. 
Lee et al. presented an alternative method of producing bioactive insulin in modified non-
β-cells by replacing the 35-amino acid residue C-peptide with a 7-amino acid peptide, thereby 
creating a functional single chain insulin analogue that eliminates the need for proteolytic 
processing71. There are two advantages of this model. Firstly, the construct can be used to induce 
mature insulin release from cells that lack prohormone convertases; secondly, it bypasses the 
proteolytic processing steps that could, in theory, result in a faster transit of insulin. While 
appearing innovative, this approach could have considerable drawbacks if applied to diabetic 
patients. Specifically, apart from the possible immunogenicity and lower bioactivity (20-40%) of 
single chain insulin, abolition of C-peptide production may have unintended and as yet little 
known consequences. C-peptide has been reported to have physiological functions distinct from 
those of insulin72. 
     Other intriguing studies have demonstrated the appearance of secretory vesicle-like 
granules following insulin gene transfer. Simpson et al. developed a stably-modified liver cell 
80 
 
line (HepG2ins/g) that showed glucose-responsive insulin expression from the cytomegalovirus 
(CMV) promoter73. After further modification to express GLUT2, this cell line secreted insulin 
in a physiological glucose-regulated manner74.  Immunoelectron microscopy revealed that 
HepG2ins/g cells stored insulin in granules that appeared similar to those in normal β-cells. Their 
collaborators, Tuch et al.75, went on to demonstrate β-cell-like regulation of insulin secretion 
from another hepatic cell line, HUH7, following similar gene transfer. Additionally, they showed 
the expression of several endocrine pancreatic-specific genes from the modified line, which led 
them to suggest that neoplastic liver cells could be induced to become β-cell like. Recently, the 
Simpson laboratory has shown that in vivo lentiviral delivery of a similar insulin construct to the 
liver induced hepatocyte transdifferentiation along a pancreatic lineage and long-term (i.e. up to 
500 days) insulin gene expression in STZ-Wistar rats76. Similar to two previous reports, hepatic 
insulin storage in granules was also detected. It is unclear how simple insulin gene transfer, 
either by electroporation or lentiviral transduction, could result in transdifferentiation of 
hepatocytes to β-like cells. As no other laboratory has yet reported similar findings, successful 
replication of this model by other laboratories is eagerly awaited and could warrant development 
for clinical trials.  
Most investigators currently rely on glucose-dependent transcriptional regulation of 
insulin secretion. Earlier experiments have utilised cell-specific promoters such as GLUT277 and 
albumin78, and insulin-suppressible promoters as a safety measure, including 
phosphoenolpyruvate kinase79, activated L-type pyruvate kinase80, insulin-like growth factor 
binding protein-181 and glucose-6-phosphatase82. While able to drive insulin expression and 
somewhat ameliorated hyperglycaemia in diabetic mice, insulin output from these promoters was 
low and self-limiting, even when coupled with viral enhancer sequences such as SV40, since 
insulin could negatively feed back to inhibit promoter activity62. Moreover, these promoters 
generally demonstrated unphysiological kinetics of insulin expression that could last for hours, 
and predictably caused hypoglycaemia in some models77,78. Other promoters, such as the insulin 
promoter itself, modulate considerably more rapid transgene expression. Using a 412 bp rat 
insulin I promoter fragment that retains glucose-responsive elements necessary for 
transcriptional regulation by glucose, Leibiger et al. were able to demonstrate rapid and short-
term effect of glucose on insulin gene transcription83. Specifically, by employing the nuclear run-
off technique and online monitoring of insulin gene promoter-driven green fluorescent protein 
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(GFP) expression in a single cell, they showed that stimulation of insulin-producing cells with 
just 10 mM glucose for 15 minutes increased preproinsulin mRNA levels and GFP expression. 
These results were indirectly supported by three other earlier studies83,84,85 and more 
convincingly by Efrat et al., who detected increased levels of nuclear preproinsulin mRNA in 
βTC-3 cells 10 minutes after glucose stimulation86. In addition, phosphoenolpyruvate kinase 
promoter has also been shown to induce insulin secretion (10-fold in 15 minutes)79. These 
findings do not support the view that glucose-dependent transcriptional control is necessarily a 
long-term effect occurring hours after glucose stimulation. 
In summary, induced insulin expression in surrogate β-cells by means of gene transfer 
has advanced significantly over recent years. Nonetheless, it should be noted all but one of these 
studies was performed in diabetic rodents i.e. small animal models. The only pre-clinical 
experiment conducted in a large animal model, i.e. pancreatectomised pigs did demonstrate the 
feasibility of controlling hyperglycaemia by transplanting a genetically-immortalised, insulin-
secreting human hepatocyte cell line87. It is noteworthy that as the rodent livers have much 
higher basal glucose output rates than human livers, relatively low levels of constitutive basal 
insulin secretion could improve glycaemic control in diabetic rodents, especially when insulin is 
being produced locally in the liver88. In contrast to viral transduction, non-viral cell transfection 
has not been explored as a safer option for gene delivery in generating insulin-producing 
surrogate β-cells, due possibly to lower transfection efficiency. Moreover, earlier proof-of-
concept demonstrations of insulin gene transfer always employed fast-growing cell lines despite 
the possible risks of in vivo tumorigenicity. Indeed, the high proliferative capacity of insulin-
gene modified cell lines was also implicated as one of the causes of hypoglycaemia66,77. Further, 
the effects of local transgenic insulin secretion on neighbouring cells have almost always been 
neglected. As insulin is mitogenic, it is clearly necessary to examine the consequence of ectopic 
insulin expression both on the insulin-producing cells themselves (autocrine effects) as well as 
on neighbouring cells and tissues (paracrine effects). Finally, diabetic patients do not suffer from 
diabetes per se, but rather from its consequence. It is therefore crucial to investigate to what 
extent an intended treatment may prevent the occurrence of the range of diabetes-related 
complications. This clinically important aspect has not so far been investigated following 
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1.7 Objectives and Scope of the Study 
This study aimed to develop clinically applicable cellular therapy for single protein 
deficiencies in general, and insulin-deficient diabetes mellitus as a specific proof-of-concept 
application. We reasoned that a safe, effective and clinically sound approach for treating 
metabolic diseases could be devised by simultaneously addressing key aspects, with particular 
emphasis on the choice of cell type and vector encoding the therapeutic protein of interest, vector 
delivery method and the scalability of the approach to a large pre-clinical animal model.  
The safety and therapeutic efficacy of an approach that combined these elements were 
investigated in inbred mice, and subsequently extended to outbred swine to determine scalability. 
We utilised two types of primary adult somatic cells, i.e. hepatocytes and bone marrow-derived 
mesenchymal stromal cells (BMMSCs).  Each of these cell types was modified with a nonviral 
insulin expressing vector in which the therapeutic transgene was expressed from a tissue-specific 
hybrid promoter. Gene transfer was achieved using electroporation.  
 Specific aims outlined below are divided into three phases; each describes isolation, 
modification, characterisation and transplantation of a primary cellular source i.e. primary 
hepatocytes obtained from mouse (syngeneic) or pig (autologous), or primary porcine BMMSCs 
(PBMMSCs) (xenogeneic) to achieve quasi-physiological insulin secretion in streptozotocin 
(STZ)-induced diabetic animals. The specific aims below appear in the chronological sequence 
of the study. 
1. Murine hepatocytes 
1.1. To isolate primary hepatocytes from mouse liver with high yield and viability 
1.2. To electroporate isolated primary murine hepatocytes with high efficiency and viability 
1.3. To document the characteristics of insulin transgene transcription and secretion of 
modified primary murine hepatocytes  
1.4. To induce STZ-diabetes in C57/BL6J mice preparatory to syngeneic cell therapy  
1.5. To determine the most suitable anatomic site and techniques for cell implantation in 
diabetic C57/BL6J mice 
1.6. To document the therapeutic efficacy and safety of implanting primary hepatocytes 
modified for insulin secretion in C57/BL6J mice. 
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1.7. To demonstrate engrafted insulin-expressing murine donor hepatocytes by 
histochemistry and immunohistochemistry.  
2. Porcine hepatocytes  
2.1. To isolate primary porcine hepatocytes from an excised liver wedge of Yorkshire-
Landrace pigs with high yield and viability 
2.2. To develop a low-cost electroporation solution that supports high transfection efficiency 
and viability in primary porcine hepatocytes 
2.3. To document the characteristics of insulin transgene transcription and secretion of 
modified primary porcine hepatocytes  
2.4. To induce STZ-diabetes in Yorkshire-Landrace pigs preparatory to autologous cellular 
therapy  
2.5. To document the therapeutic efficacy, durability and safety of implanting modified 
primary autologous hepatocytes in diabetic Yorkshire-Landrace pigs 
2.6. To identify and characterise engrafted insulin-expressing porcine hepatocytes 
2.7. To determine the extent to which restitution of insulin secretion protects diabetic pigs 
from diabetes-induced secondary complications in target tissues. 
3. Porcine bone marrow-derived mesenchymal stromal cells (PBMMSCs) 
3.1. To isolate and establish optimal culture conditions for primary PBMMSCs 
3.2. To identify glucose-responsive genes in cultured human BMMSCs (HBMMSCs) using 
whole genome transcript arrays 
3.3. To characterise the promoter of an identified glucose-responsive gene 
3.4. To construct insulin transgene vectors capable of quasi-physiological insulin expression 
and secretion by virtue of the glucose-responsive promoter identified from specific aims 
3.2 and 3.3. 
3.5. To electroporate cultured human and porcine BMMSCs with high efficiency and 
viability 
3.6. To document the characteristics of insulin transgene transcription and secretion of 
modified PBMMSCs  
3.7. To induce STZ-diabetes in NOD-SCID mice preparatory to xenogeneic cellular therapy  
3.8. To evaluate anatomic implantation sites and techniques in diabetic NOD-SCID mice 
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3.9. To document the therapeutic efficacy of implanting modified PBMMSCs in diabetic 
NOD-SCID mice 
































Results and Discussion 
 
2.1. Primary Murine Hepatocytes 
2.1.1. Electroporation of primary murine hepatocytes 
Primary hepatocytes were selected as the most appropriate adult somatic cells to serve as 
bioimplants for quasi-physiological secretion of human insulin. We first tested our approach in a 
small animal model to demonstrate proof-of-concept. Due to concerns of biosafety and 
immunogenicity of viral vectors when directly administered in vivo as in gene therapy, we chose 
to modify primary hepatocytes ex vivo using a non-viral method. However, primary cells are 
resistant to most conventional non-viral gene transfer techniques in vitro, i.e. calcium phosphate 
and liposomes. Therefore, we resorted to electropermeabilisation of hepatocytes. This technique 
uses short electrical pulses to transiently and reversibly increase the permeability of cell 
membranes, thus allowing ingress of DNA into cells1.     
We achieved efficient transgene delivery into primary murine hepatocytes by 
electroporation using the proprietary Amaxa NucleofectorTM system. In the absence of a protocol 
for electroporating primary hepatocytes, we initially used the manufacturer’s optimisation guide 
(of 12 preset programmes) and a reporter plasmid expressing green fluorescent protein, pEGFP. 
Three programmes T28, T20 and H22 resulted in highest transfection efficiencies of 30-35%, 25-
30% and 20-25%, respectively (Figure 1A). However, they had different effects on cell viability. 
H22 was associated with highest viability (85-95%), T20 with intermediate viability (60-70%) 
while viability after T28 electroporation was poorest (40-50%). 
2.1.2. Electroporation optimised for insulin transgene 
It is well-established that liver regeneration, carried out by the proliferation of all the 
remaining mature cellular populations composing the hepatectomised organ, takes place within 
24 hours after partial hepatectomy (PH). In fact, hepatocytes are the first to proliferate to 
reconstruct the lost hepatic tissue2.We hypothesised that hepatocytes undergoing mitosis may be 
more permissive for uptake and nuclear transfer of plasmid DNA. To test this notion, we isolated 
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hepatocytes from unresected liver and from livers 24 h and 48 h after ~30% PH. Primary 
hepatocytes obtained under each of these conditions were transfected with pEGFP using 
programmes T20, T28 and H22. Programme H22 on hepatocytes isolated 24 h after PH yielded 
transfection efficiencies that were doubled from 20-25% to 40-50% while maintaining good 
viability (80-90%). The same conditions were thus adopted for transfection of the insulin 
transgene. To evaluate hepatocellular damage induced by different electroporation programs, L-
alanine,2-oxoglutarate aminotransferase (ALT) activity was assayed in culture media withdrawn 
6 h after plating electroporated hepatocytes. Figure 1B shows human insulin concentrations in 48 
h conditioned media under different conditions of hepatocyte isolation (from unresected liver and 
regenerating liver 24 h and 48 h after PH) and electroporation (programmes T20, T28 and H22). 
Hepatocytes isolated from liver 24 h and 48 h after PH secreted significantly more insulin 
(198.4±6.6 and 186.0±34.4 pM, respectively; mean ± s.e.m.) than hepatocytes isolated from 
unresected liver (43.0±2.0 pM) (P<0.0001 and <0.002, respectively). However, within each 
group of hepatocytes, comparable insulin secretion was obtained with all 3 electroporation 
programmes tested. We noted that using programme H22 on hepatocytes isolated 24 h after PH 
caused least cellular injury as judged by significantly lower ALT activity in the conditioned 
media (H22: 2.8±0.08 U/L; T20: 3.63±0.15 U/L; T28: 3.75±0.11 U/L; mean ± s.e.m.; P<0.05 for 
the difference between H22 and T20, and between H22 and T28). These data supported our 
hypothesis that nuclear envelope dissolution during mitosis increased transfection efficiency and 
hence higher expression of the insulin transgene.  
2.1.3. Processing and secretion of mature human insulin by hepatocytes 
The non-viral vector used in this study i.e. p3MTchINS was an insulin expression 
plasmid that consisted of a 1.8 kb human proinsulin cDNA under the regulation of a bifunctional 
hybrid promoter, i.e. human metallothionein IIA (MT-IIA) promoter (3 kb) linked to three 
tandem copies of the carbohydrate response element (ChoRE) of the L-type pyruvate kinase 
promoter3 (see Appendix 1 for the plasmid map). The human proinsulin cDNA was modified by 
a colleague, Jaichandran Sivalingam, who introduced tetrabasic furin-cleavable sites4 and the 
HisB10Asp substitution that is known to enhance biopotency5. This variant was reported to have 
4- to 5-fold higher biological potency than native insulin, possibly due to higher avidity of 
receptor binding6 as well as more rapid secretion via the constitutive pathway7 . 
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To confirm proinsulin processing by hepatocytes and to investigate if processing was 
influenced by different cell attachment matrices, we electroporated primary mouse hepatocytes 
with p3MTChINS and cultured the cells on rat tail collagen I, mouse collagen IV or Matrigel® 
(106 cells per matrix-coated plate). Conditioned media were assayed for human insulin and 
proinsulin 24, 48 and 72 h after plating. Matrices did not influence cell attachment as judged by 
calculating the number of attached cells in ≥3 randomly selected microscopic fields of 200X 
original magnification (Appendix 2). Hepatocytes cultured on collagen I secreted significantly 
more processed human insulin (P<0.0001 cf. collagen IV and Matrigel®). The mature form of 
human insulin was the major secretory product on all matrices. Cleavage of modified proinsulin 
was likely to have occurred in the trans-Golgi network where furin is known to be localised8 and 
where transgenic insulin expressed in hepatocytes has been located9. Taking the sum of the 
molar concentrations of human insulin and proinsulin in the conditioned media to be 100%, the 
molar concentration of human proinsulin was 2.2±1.4% on collagen I, 3.2±1.9% on collagen IV 
and 8.7±2.3% on Matrigel® (mean ± s.e.m.; n=3) (Figure 1C). Proinsulin concentration relative 
to mature insulin was significantly higher in Matrigel® matrix compared to collagen I and IV 
(P=0.0091 and 0.0424, respectively). Matrigel® matrix is a solublised basement membrane 
preparation extracted from the Engelbreth-Holm-Swarm mouse sarcoma rich in extracellular 
matrix proteins10,11. It is capable of maintaining the differentiated phenotype of hepatocytes and 
thus their liver-specific function in vitro by promoting rounded, clustered morphology and 
polarisation12. In contrast, collagen I and IV are known to promote cellular proliferation and 
differentiation13. Our results suggest the possibility that primary murine hepatocytes were more 
competent at proinsulin processing when cultured on matrices that may have induced 
proliferation and/or differentiation. Isolated primary hepatocytes were hence plated on collagen I 
in all subsequent experiments. 
2.1.4. Static induction of human insulin by glucose and zinc in vitro 
The response of the bifunctional promoter was tested in primary hepatocytes 
electroporated with p3MTChINS.  Figure 2A shows that the threshold glucose concentration for 
stimulated insulin secretion was 2.5 mM (P=0.0039 cf. insulin secretion at 1 mM glucose), 
approximating the threshold response of β-cells of about 4 mM glucose. Insulin secretion 
showed no evidence of declining at the highest glucose concentration tested (25 mM). The 
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mechanism of glucose-responsive transcription via ChoRE is mediated by a carbohydrate 
response element binding protein (ChREBP) which is highly expressed in liver. Nuclear 
translocation and DNA-binding activity of ChREBP is positively regulated by dephosphorylation 
of specific serine and threonine residues in a high glucose environment thereby upregulating 
transcription, while protein kinase A-catalysed phosphorylation has the opposite effect. Changes 
in DNA-binding activity of ChREBP occur within 10 minutes in vivo14. 
The threshold zinc concentration for stimulated insulin secretion was between 10 and 15 
μM (P=0.065 and 0.0014, respectively cf. zinc-free medium) (Figure 2B). While zinc is not a 
physiological regulator of insulin synthesis by β-cells, it is a normal micronutrient. Given that 
physiological levels of circulating zinc vary little within the range of 10-20 μM15, p3MTchINS-
modified primary hepatocytes could therefore provide a steady interprandial output of insulin. 
This is clinically meaningful because about 50% of total daily insulin secretion in humans occurs 
in the basal state16. Like glucose stimulation, all higher zinc concentrations tested (20-60 μM) 
continued to further induce highly significant increases in insulin secretion (P< 0.001). Although 
blood zinc levels do not fluctuate greatly, zinc supplementation with meals was associated with 
2- to 3-fold increase in serum zinc concentration e.g. from 12.8 μM (mean fasting levels) to 30 
μM17. Moreover, an oral dose of 50 mg elemental zinc could raise serum zinc concentration 
about 2.5-fold within 2-3 h18. Thrice daily ingestion of 50 mg zinc is non-toxic in humans and 
has been suggested for the treatment of Wilson’s disease19.  
The ability of the bifunctional promoter to increase insulin secretion in response to 
glucose, zinc or to both stimuli provides a means of maintaining adequate basal interprandial 
insulin secretion with the additional capacity to stimulate insulin secretion in response to 
postprandial increase in blood glucose.  
2.1.5. Kinetics of glucose- and zinc-induced insulin secretion 
In contrast to neuroendocrine cells, protein secretion by hepatocytes is generally regarded 
as lacking the capacity for rapid response owing to absence of a regulated secretory pathway. 
Thus, insulin expression from hepatocytes which is solely regulated by the transcriptional 
activity of the bifunctional MT-IIA-ChoRE promoter would be expected to exhibit slow kinetic 
response. However, minute-to-minute insulin secretory response under these conditions has not 
been documented to date. We therefore characterised the kinetics of inducible insulin secretion 
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by primary hepatocytes co-transfected with the bifunctional promoter construct and pSEAP, a 
SV40 promoter-secreted alkaline phosphatase expression construct. This was performed in a 
series of perifusion experiments in which 1x106  and 2x106 hepatocytes cultured on 35 mm 
collagen I-coated dishes were stimulated by separate timed exposures to 60 µM zinc (30 
minutes) or 25 mM glucose (40 minutes), respectively, in continuously flowing medium (2 
ml/min). Human insulin in the perifusate rose at least 2.5-fold above baseline (defined as the 
mean insulin concentration during the washout period with 2.5 mM glucose zinc-free medium) 
for at least 3 consecutive time points 12 min after increasing glucose concentration in the 
perifusing medium from 2.5 mM to 25 mM (Figure 2C). However, insulin secretion declined 
more slowly when the glucose stimulus was removed, reaching basal levels only after 30 min. 
On re-stimulation with a second exposure to 25 mM glucose, insulin secretion again rose briskly 
above basal levels after 10 min and declined to baseline 32 min after the glucose stimulus was 
withdrawn. In separate experiments, primary hepatocytes were perifused with 2.5 mM glucose 
DMEM that was either zinc-free or supplemented with 60 μM zinc. Human insulin concentration 
in the perifusate significantly increased above basal levels 18 min after exposure to 60 μM zinc 
and declined to basal levels 30 min after zinc withdrawal (Figure 2D). A second exposure to 60 
μM zinc stimulated insulin secretion after 20 min, which declined to basal levels 30 min after 
zinc was removed.   
In contrast to the inducible response of insulin secretion by high glucose or zinc 
concentrations, SEAP activity in the same perifusate fractions did not change in tandem with 
glucose or zinc exposure (Figures 2C and 2D). This was consistent with the constitutive nature of 
the SV40 promoter in contrast to the inducible nature of our bifunctional promoter. ALT activity 
in the perifusate remained low and stable throughout all perifusion experiments (data not shown).  
Although the insulin secretion kinetics in modified primary hepatocytes did not exactly 
match that exhibited by normal β cells, it should not be considered to be unphysiological. In fact, 
the rapid first phase of insulin secretion by β-cells (<5 min) occurs only under non-physiological 
conditions, having been characterised principally in the setting of intravenous glucose tolerance 
testing20, but does not occur after mixed meals when insulin secretion is monophasic and peaks 
only after 30-60 min21,22. When considered in this light, the temporal responses we report were 
not unacceptably slow given that significant insulin secretion from modified primary hepatocytes 
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was clearly detectable after 10-20 min and peaked within 70 min of exposure to high glucose or 
zinc. Moreover, the decline in insulin secretion no more than 32 min after transfer to low glucose 
or zinc concentration represents the type of response that minimises  potential risks of 
hypoglycaemia - a likely consequence of unusually prolonged insulin secretion. 
The pattern of rapidly stimulated insulin secretion coupled with a slower decline that we 
observed was unexpected because insulin transgene-modified hepatocytes did not form storage 
granules of preformed insulin (secretory granules were not seen on electron microscopy, 
Appendix 3) and were therefore expected to rely on transcriptional induction and constitutive 
secretion. Our results differed in this respect from another study in which primary rat 
hepatocytes transduced with a different insulin transgene construct (regulated by rat albumin 
promoter and three copies of glucose regulatory elements from rat S14 gene) showed detectable 
but non-statistically significant increase in insulin level at 1 h (first time point) after exposure to 
27.5 mM glucose23.  Although the considerably slower temporal response obtained in that study 
may have been partly due to experimental design and technical reasons, more rapid onset of 
stimulated secretion achieved in our system may be ascribed to the known strength of the human 
MT-IIA promoter in directing transgene expression in liver, i.e. relative strength of the MT-IIA 
promoter was >10-fold higher than the albumin promoter in driving human α1-antitrypsin 
expression from murine hepatocytes24.  High promoter strength was consistent with distinct 
cytoplasmic immunostaining for human insulin in hepatocytes electroporated with p3MTChINS 
(Figure 4) whereas rat hepatocytes transduced with a rat albumin promoter-insulin expression 
construct failed to show insulin immunostaining and also responded slowly to glucose 
stimulation23.  It is possible that the combination of a strong promoter25, high plasmid copy 
number facilitated by electroporation26, faster transit through a constitutive secretory pathway of 
the HisB10Asp insulin variant7 used in this study and a putative rate-limiting step in the final 
stages of secretion by primary mouse hepatocytes resulted in substantial intracellular 
accumulation of pre-synthesised human insulin (Figure 4A-C). Thus, modified hepatocytes were 
poised to respond rapidly when extracellular concentrations of glucose or zinc were raised. 
2.1.6. Transcriptional response of transgene in vitro  
The transcriptional responsiveness of p3MTChINS to glucose and zinc stimulation was 
next investigated to determine if the rapid responses observed in perifused hepatocytes correlated 
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with upregulation of transgene mRNA.  Data from 3 separate experiments are summarised in 
Table 1.  A human insulin cDNA construct that was identical to p3MTChINS except that the 
CMV promoter replaced the metallothionein promoter and ChoRE (pCMVINS) was used as a 
non-responder control.  Insulin mRNA levels showed a clear increase (1.27- to 2.44-fold) over 
baseline 6-10 min after addition of 25 mM glucose (Table 1, Experiments A and B) and declined 
by 20 min after glucose withdrawal, concordant with perifusion data of Figure 2B.  Likewise, 
insulin mRNA levels rose 1.26-1.85-fold above baseline 6-10 min after addition of 60 μM zinc 
(Table 1, Experiment C) and declined to baseline 20-40 min after zinc withdrawal. In contrast, 
insulin mRNA expressed from the CMV promoter (pCMVINS) did not show consistent 
upregulation to either glucose or zinc. 
2.1.7 Diabetes induction in C57BL/6J mice 
We induced diabetes in C57BL/6J mice with streptozotocin (STZ), a nitrosurea derivative 
isolated from Streptomyces achromogenes that has broad-spectrum antibiotic and anti-neoplastic 
activity27. As a powerful alkylating agent that interferes with glucose transporter-2 (GLUT2) and 
glucokinase functions, the diabetogenic action of STZ results primarily from its targeted action 
on the β-cells, which spares other non-β-cells of the islets of Langerhans27,28,29. Compared to 
other diabetogenic substances such as alloxan, pyriminil, dithizone and 8-hydroxyquinolone, 
STZ is the drug of choice for inducing diabetes in animal models. It is more selective and 
associated with lower systemic toxicity, is capable of inducing graded intensity of β-cell damage 
according to the dosage used and the resulting hyperglycaemia is reversible by insulin 
alone28,30,31. Surgical induction of diabetes i.e. pancreatectomy has several disadvantages. For 
instance, in addition to the requirement for surgical and anaesthetic skills, pancreatectomy causes 
operative morbidity and mortality, and removes all the endocrine and exocrine cells of the 
pancreas thereby causing severe malabsorption31.  
In our experience, four daily STZ intraperitoneal injections of 100 mg/kg body weight 
was associated with highest diabetes induction rate and low mortality rate. However, we 
observed gender-associated differences i.e. male mice were more susceptible to STZ than female 
mice. Specifically, 10/12 (83.3%) male C57BL/6J mice became diabetic with 75-125 mg/kg STZ 
while only 4/9 (44.4%) female mice were susceptible to these doses. Moreover, while all 
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untreated diabetic male mice survived for 4 to 92 days, three of 4 untreated female mice died 
within 3 days after becoming diabetic, showing the influence of gender on responses to STZ. 
2.1.8 Implantation of transfected primary hepatocytes into diabetic C57BL/6J mice 
We next implanted transfected primary Gt(Rosa)26 mouse hepatocytes into STZ-diabetic 
male C57BL/6J mice. This allowed implanted hepatocytes to be identified more easily in the 
livers of recipients because the Gt(Rosa)26 strain is transgenic for β-galactosidase. 
Notwithstanding the superiority of hepatocytes from regenerating liver for plasmid uptake and 
transgene expression, we chose hepatocytes prepared from unresected liver for implantation in 
vivo in order to avoid loss of plasmid that would probably occur when transfected hepatocytes 
divide in vivo. Another reason was that partial hepatectomy prior to hepatocyte isolation is 
unlikely to be readily accepted should autologous hepatocyte implants become a future clinical 
option. 
The in vivo study was divided into three separate experiments of identical design. A 
different recipient implantation site was evaluated in each experiment as follows. Hepatocytes 
were implanted in: (a) right lateral and right medial lobes of unresected liver (group 1; n=7); (b) 
the same lobes of partially hepatectomised liver (group 2; n=6); and (c) in the abdominal 
mesentery (group 3; n=6). Viable hepatocytes (~8 x 105 after electroporation) were implanted by 
direct interstitial injection through a 29G needle in all sites. Control diabetic mice were 
implanted at the same sites with the same number of primary hepatocytes electroporated without 
plasmid (mock-implanted). We chose to implant donor hepatocytes by direct interstitial injection 
into liver or mesentery because infusion of donor hepatocytes through the portal vein was 
associated with high mortality while the transit of donor hepatocytes to the recipient liver after 
intrasplenic implantation was inconsistent in our experience. 
The outcome of hepatocyte implantation was assessed by survival, serial body weights, 
blood glucose concentrations, glucose tolerance, and plasma human insulin and mouse C-peptide 
levels. (a) Survival Thirty days after implantation with mock-electroporated hepatocytes, 8/15 
(53%) of control diabetic mice were alive compared with 19/19 (100%) of diabetic mice 
implanted with hepatocytes electroporated with p3MTChINS. Seventy-seven days after 
implantation, 2/15 (13.3%) and 12/19 (63.2%) of control diabetic mice and treated diabetic mice, 
respectively, were alive. All group 2 diabetic mice were alive (6/6; 100%) as were most group 1 
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diabetic mice (5/7, 71.4%) compared to only 16.7% mesenteric-implanted mice (1/6, group 3) 
(Figure 3A). Therefore, among the treated diabetic mice, cellular implantation in the liver was 
associated with superior survival compared to mesenteric implantation. (b) Body weights 
Weight loss was recorded in all diabetic mice (34/34). However, all mice implanted with 
transfected cells (19/19) began to gain weight after the third post-operative day whereas none of 
the control diabetic mice implanted with mock-electroporated hepatocytes (0/15) regained their 
original body weights (Figure 3B). Weight gain was greatest in group 2 mice whose mean body 
weight was significantly higher than all other groups from the 10th post-implantation day 
onwards. Their mean body weight gain was 1.46 g higher than group 1 mice (P=0.05) by day 30. 
Given that whole adult mouse liver weighed about 1.2 g, the increase in body weight among 
group 2 mice could not be ascribed entirely to liver regeneration. Among survivors, the ratio of 
day 30 body weight/nadir body weight (1.42 for group 2; 1.31 for group 1; 1.18 for group 3 and 
1.07 for control mice implanted in all sites) was significantly higher for all treated groups 
(P<0.0001, <0.0001 and 0.0445, respectively) compared with control diabetic mice. (c) Blood 
glucose Regardless of implantation site, all diabetic mice implanted with circular plasmid-
electroporated hepatocytes (19/19) became normoglycaemic 24 h after implantation (Figure 3C). 
Blood glucose concentrations of group 2 mice (n = 6) showed the steepest decline (27.7±6.3 to 
6.2±1.9 mM; -78%) followed by group 1 (n=7) (24.8±2.7 to 8.6±1.3 mM; -65%) and group 3 (n 
= 6) (30.8±6.7 to 11.4±2.2 mM; -63%). In contrast, all control diabetic mice (n = 15) became 
more hyperglycaemic (25.9±4.5 to 28.6±5.4 mM; +10%). Thirty days post-implantation, all 8 
surviving control diabetic mice were hyperglycaemic while 16/19 (84%) treated diabetic mice 
remained normoglycaemic. The only 3 of 19 treated diabetic mice that reverted to 
hyperglycaemia by day 30 were all implanted in the mesentery, suggesting poorer engraftment in 
the mesentery. This was consistent with group 3 mice having highest blood glucose values 24 
hours after implantation. The mean of 6 non-fasting blood glucose concentrations determined at 
intervals over the 30-day period after implantation was 9.2±0.6 mM (group 2), 10.3±0.8 mM 
(group 1) and 12.9±2.2 mM (group 3).  All were significantly lower (P<0.001) than diabetic 
mice implanted with mock-electroporated hepatocytes (25.9±2.7 mM). At no time were blood 
glucose levels < 3.8 mM recorded among treated mice. Although there was a slight rising trend, 
mean blood glucose levels on days 3 and 30 after hepatocyte implantation were not significantly 
different in any of the treated groups. Blood glucose concentrations on the 3rd post-implant day 
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[groups 1 (9.4±0.5 mM), 2 (8.1±0.6  mM) and 3 (11.7±0.9 mM)] were not significantly different 
from values obtained on the 30th post-implant day [groups 1 (10.3±0.5 mM), 2 (10.3±0.9 mM) 
and 3 (15.5±2.1 mM)] (P=0.2309, 0.0663 and 0.0851 for groups 1, 2 and 3, respectively).  (d) 
Glucose tolerance to an intraperitoneal load (1.5 mg glucose/g body weight) administered 30 
days after hepatocyte implantation is shown in Figure 3D. Using the area under the blood 
glucose concentration curve as an integrated measure of glucose tolerance, implantation of 
transfected hepatocytes at all 3 sites significantly improved glucose tolerance (P< 0.0001 for 
liver implantations; P=0.0051 for mesenteric implantation) compared to control diabetic mice. 
However, glucose tolerance of all treated animals was also significantly worse than non-diabetic 
mice (P≤0.0003), thus showing only partial metabolic correction by the implanted hepatocytes. 
Nonetheless, the fact that a majority of surviving treated mice maintained euglycaemia for at 
least 77 days (Figure 3A) indicated stable retention of the plasmid transgene within implanted 
hepatocytes. AUC was not significantly different for hepatocytes implanted in unresected or 
regenerating liver. Plasma human insulin levels in these groups were also not different 
(unresected liver 113.2±15.1 pM; regenerating liver 133.0±15.5 pM; two-tailed P value=0.3812) 
(see 3e). However, glucose tolerance in mesenteric-implanted diabetic mice was significantly 
worse than both liver-implanted groups (P<0.02). None of the mice was hypoglycaemic after a 
16-18 h fast at the commencement of glucose tolerance testing. (e) Plasma human insulin 
Human insulin peaked in the plasma of all treated groups 24 h after implantation with plasmid-
electroporated hepatocytes, the highest concentration being in group 2 (477±165 pM; n=6), the 
lowest in group 3 (62±16 pM; n=6) while group 1 was intermediate (190±91 pM; n=7) (Figure 
3E). However, plasma human insulin concentrations significantly declined in all groups by the 
third day after implantation. While this pattern was consistent with restoration of 
normoglycaemia but it probably reflected failure of some implanted hepatocytes to engraft. 
Nonetheless, within each treated group plasma concentrations of human insulin 30 days after 
implantation were not significantly lower than day 3 levels (P=0.3849, 0.0811 and 0.0635 for 
groups 1, 2 and 3, respectively). (f) Plasma mouse C-peptide Cognizant of the regenerative 
capacity of pancreatic islets32,33, we sought to exclude the possibility that recovery of 
euglycaemia in STZ-diabetic mice (Figure 3C) was unrelated to engraftment of insulin-secreting 
donor hepatocytes. Concurrent assays of plasma mouse C-peptide levels were performed to 
monitor endogenous insulin secretion, which also served as an index of islet regeneration of 
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recipient mice after STZ treatment. Mean plasma mouse C-peptide concentration before STZ 
administration was 591±151 pM (n=34) and declined by 86% to 81±38 pM after the STZ 
regimen, consistent with islet destruction (Figure 3F). Circulating C-peptide levels on the day of 
hepatocyte implantation and 30 days post-implantation were not significantly different 
(P=0.0972, 0.5016 and 0.0706 for groups 1, 2 and 3, respectively) indicating that islet 
regeneration was unlikely to have been a major factor in the outcomes detailed above.   
Overall, our data show that although all three implantation sites were effective in 
correcting hyperglycaemia acutely, implantation in regenerating liver produced the best outcome 
as judged by survival (Figure 3A), weight gain (Figure 3B), higher plasma human insulin levels 
(Figure 3E and Table 3) and better glycaemic control (Figure 3C). It is probable that implanted 
hepatocytes engrafted better in partially resected liver because vasculogenesis and tissue 
remodelling that accompany liver regeneration favoured incorporation of donor hepatocytes in 
liver lobules. Implantation into regenerating liver resulted in the highest mean plasma human 
insulin concentration after 24 h. This treatment group also maintained highest plasma human 
insulin concentrations throughout the period of observation compared to groups implanted in 
unresected liver (P=0.0006) or mesentery (P<0.0001) (Figure 3E). 
2.1.9 Glucose-induced insulin secretion in vivo 
 We investigated the temporal profile of human insulin secretion from transfected 
hepatocytes into the circulation of diabetic mice after a glucose stimulus administered as an 
intravenous bolus (1.5 mg/g body weight). Table 2 shows that mean plasma insulin 
concentrations increased by 17.8% over the unstimulated state 10 minutes after intravenous 
glucose and continued to rise for up to 30 minutes. Thus, the brisk response in vivo was quite 
comparable in onset to the kinetics of insulin secretion observed in vitro (Figure 2B). An 
identical volume of saline administered to the same mice in fact decreased mean plasma insulin 
concentration at 10 minutes.  The slight rise (12.1%) 30 minutes after intravenous saline 
injection may have been a stress effect of anaesthesia. 
To compare the different implantation sites and ascertain the functionality of the 
bifunctional glucose- and zinc-responsive promoter in vivo, we assayed plasma human insulin 
responses of diabetic mice 5 days after implantation of transfected hepatocytes in unresected 
liver, regenerating liver and mesentery immediately before and 3 h after a glucose challenge (i.p. 
103 
 
1.5 mg/g body weight). Non-diabetic mice implanted with transfected hepatocytes in the same 
sites were also challenged with glucose for comparison. Table 3 shows that plasma human 
insulin increased 9.6–33.2% in diabetic mice and 36.8–73.6% in non-diabetic mice 3 h after 
glucose challenge. In contrast, plasma human insulin decreased by 8% and 10% in diabetic and 
non-diabetic mice, respectively, after placebo challenge (i.e. intraperitoneal saline injection). 
These data further confirmed that the proinsulin transgene linked to three tandem copies of 
ChoRE was glucose-responsive in vivo as basal plasma insulin levels in all groups of diabetic 
mice implanted with transfected hepatocytes were higher compared to non-diabetic mice 
identically implanted and that insulin secretion was higher from hepatocytes implanted in liver 
compared to mesentery. The uniformly lower basal plasma human insulin levels in non-diabetic 
mice were not, due to a lower capacity for transgene expression since glucose challenge 
stimulated a proportionately higher response.  
2.1.10 Immunohistochemistry 
Two days after implantation into the right lateral and right medial lobes of partially 
hepatectomised diabetic mice, immunohistochemical staining with anti-human insulin antibody 
showed donor hepatocytes in liver lobules predominantly around the central veins. These 
observations suggest that donor cells were conveyed in the liver microvasculature to their sites of 
engraftment and that host liver remodeling and donor hepatocyte migration during active 
regeneration determined the eventual pattern of implantation (Figure 4A-B). All engrafted cells 
showed strong cytoplasmic staining for human insulin (Figure 4A-C).  Dual staining for β-
galactosidase activity and human insulin showed that insulin expression was not detected in 
recipient liver cells but was confined to donor cells only (Figure 4E-F).   
In conclusion, this phase of the study showed that we had developed cell-based diabetes 
treatment using syngeneic primary hepatocytes that achieved sustained euglycaemia in diabetic 
mice. Other investigators have recently shown that liver is capable of glucose-responsive insulin 
secretion22,34,35.  Our approach differed in not relying on virally-mediated gene transfer22,34, thus 
avoiding concerns of biosafety and immunogenicity. Cognizant of the potential for mutagenesis 
caused by randomly integrated vectors, the possibility of such integration was addressed in a 
later phase of the project in a pre-clinical system (Chapter 2.3.5). Moreover, modifying adult 
hepatocytes ex vivo enables examination of the modified cells before implantation in vivo. 
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Yasutomi et al. also used a non-viral vector but delivered the plasmid transgene by high volume 
and high pressure systemic intravascular administration35, a technique that is likely to have 
serious adverse haemodynamic effects in human subjects. Furthermore, restoration of 
normoglycaemia in their study was short-lived (less than 8 days) in contrast to our results. 
Indeed, while all diabetic mice implanted with mock-electroporated hepatocytes were dead by 
day 92, 3 of 19 mice implanted with plasmid-electroporated hepatocytes were alive for more 


























Figure 1A Electroporation of primary murine hepatocytes with pEGFP using Amaxa™ 
solution and programme T20 transfected 25-30% hepatocytes isolated from unresected liver. 




Figure 1B Electroporation of primary murine hepatocytes with insulin transgene. 106 cells 
isolated from Gt(Rosa)26 unresected liver, and 24- and 48-h after 30% partial hepatectomy were 
electroporated with 5 μg p3MTChINS in an equal mixture of Nucleofector™ #3551 and #3541 
solutions using different preset Amaxa programmes (T20, T28 and H22). Human insulin and 
ALT activity were assayed in conditioned media 48 h and 6 h, respectively, after plating. Control 
cells were mock-transfected (electroporated using programmes T28 and H22 in the absence of 
plasmid). Data are mean ± s.e.m. Significantly different from unresected liver, *P<0.0001, 
**P=0.002 (n=6). 
(C) Processing and secretion of mature human insulin by modified hepatocytes. Conditioned 
media (24 h) of 106 p3MTchINS-transfected hepatocytes plated in 35 mm matrix-coated dishes 
(25 mM glucose-DMEM) were assayed for human insulin and proinsulin using 
radioimmunoassays (RIAs), Linco Research, USA. Human insulin-specific RIA had <0.2% 
cross-reactivity with human proinsulin while human proinsulin RIA was <0.1% cross-reactive 
with human insulin.Taking the sum of the molar concentrations of human insulin and proinsulin 
to be 100%, the mature form of human insulin was the major secretory product on all matrices 
i.e. >90%. Hepatocytes cultured on rat tail collagen I-coated dishes secreted significantly more 




Figure 2 Glucose- and zinc-induced insulin secretion. Primary mouse hepatocytes transfected 
with p3MTChINS as described in Materials and Methods were plated in collagen I-coated 35 
mm dishes with 25 mM glucose DMEM (106 cells/well).  The medium was changed after 5 hours 
and replaced with fresh DMEM containing (A) increasing glucose (1, 2.5, 4, 7, 10, 15 and 25 
mM) or (B) zinc (0, 5, 10, 15, 20 and 60 μM) concentrations. Conditioned media (24 h) were 
assayed in duplicate for human insulin.  Data are the mean ± s.e.m. values of 3 separate 
experiments.  Insulin concentrations were significantly higher when glucose concentration 
increased from 1 to 2.5 mM (P=0.0039) and from 15 to 25 mM (P=0.0002), as well as at 
intermediate glucose concentrations. Compared to zinc-free medium, insulin concentrations 




Figure 2C Kinetics of glucose-induced insulin secretion. 2 x 106 primary mouse hepatocytes, 
isolated 24 h after partial hepatectomy, were electroporated with 5 µg p3MTChINS and 3 µg 
pSEAP using Amaxa program H22 and cultured on a 35 mm dish coated with collagen I in zinc-
free 5.6 mM glucose DMEM for 24 h. Cells were washed thrice with PBS before continuous 
perifusion (2 ml/min) at 37ºC with the following sequence of glucose concentrations in DMEM: 
2.5 mM (‘low glucose’) x 30 min / 25 mM (‘high glucose’) x 40 min / 2.5 mM x 40 min / 25 mM x 
40 min  / 2.5 mM x 40 min.  Perifusate fractions were collected every 2 minutes throughout and 
assayed for human insulin, SEAP and ALT activity. Insulin values are background subtracted for 
levels detected in unperifused medium. Mean ± s.d. of insulin concentrations are shown. Data 
are representative of 3 different experiments. 
(D) Kinetics of zinc-induced insulin secretion. Experimental conditions were identical to Figure 
2C except that 1 x 106 primary mouse hepatocytes were electroporated and cultured in zinc-free 
5.6 mM glucose DMEM. Continuous perifusion (2 ml/min) at 37ºC was performed with 5.6 mM 
glucose DMEM in the following sequence: no zinc x 30 min / 60 µM zinc x 30 min / no zinc x 30 
min / 60 µM zinc x 30 min /no zinc x 30 min.  Mean ± s.d. of insulin concentrations are shown.  
Data are representative of 4 different experiments. 
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Table 1 Transcriptional response of transgene to glucose and zinc induction. 
 
Fold change of insulin mRNA 
  Glucose (25 mM)           Zinc (60 µM) 
  Experiment A  Experiment B           Experiment C 
Minutes  p3MTchINS pCMVINS  p3MTchINS pCMVINS  p3MTchINS pCMVINS
0  1.00 1.00  1.00 1.00  1.00 1.00 
+3  1.00 1.50  0.91 0.84  1.03 1.05 
+6  1.75 0.92  1.27 1.25  1.26 1.13 
+10  1.88 1.32  2.44 0.91  1.85 0.99 
+15  2.11 0.98  2.04 0.82  1.94 1.12 
-20  1.10 1.03  1.03 0.81  1.13 0.84 
-40  0.90 0.96  0.86 1.06  0.84 0.81 
 
RNA was isolated from primary C57BL/6J hepatocytes transfected with p3MTChINS (human 
Metallothionein IIA promoter and carbohydrate response element) or pCMVIns (CMV promoter) 
before addition of 25 mM glucose or 60 μM zinc, 3, 6, 10 and 15 minutes after addition of 
glucose or zinc; and 20 and 40 minutes after glucose or zinc withdrawal.  Semi-quantitative RT-
PCR was performed as detailed in Materials and Methods (section 4.6.1.1) using SYBR® Green 
for PCR product detection. Data were analysed using the Opticon Monitor™ Analysis software, 
version 1.07 (MJ Research, USA).  Differences in RNA input for reverse transcription were 
normalized using Ct values obtained in parallel for mouse HPRT mRNA.  The ratio of mRNA at 
each time point after induction/mRNA before induction was given by the equation 2(b – y)[2(y – x) – 
1]/[2(b – a) –1], where a is the Ct value of the uninduced sample and x is the Ct value of an 
induced sample, b and y are, respectively, the minus reverse transcriptase controls for a and x.   
Time points after addition of glucose or zinc are denoted by + and time points after withdrawal 







Figure 3A Survival of mock-implanted and treated diabetic mice. Kaplan-Meier curves are 
shown for mock-implanted diabetic mice, diabetic mice implanted with transfected hepatocytes 
in regenerating liver, unresected liver and mesentery. 
(B) Body weight changes in mock-implanted and treated diabetic mice. Changes in body weight 
during the experimental period relative to body weights immediately before STZ administration 
(day – 5) are shown on the y-axis. Four daily injections of STZ (i.p. 100 mg/kg body weight) 
were administered (days –5 to –2).  8 x 105 hepatocytes were implanted on day 0.  Body weight 
changes of control diabetic mice implanted with null-electroporated hepatocytes at all 3 sites 
were pooled (mock-implanted). Data are mean ± s.e.m. Significantly different from mock-
implanted diabetic mice at day 30, *P=0.0028, **P=0.0010; not significantly different, 




Figure 3C Glycaemic profiles of mock-implanted and treated diabetic mice. Serial blood 
glucose concentrations were determined during the experimental period as described in the 
legend to Figure 3A. Data are mean ± s.e.m.. The dashed line is the diagnostic threshold for 
hyperglycaemia i.e. 5 s.d.’s above the mean blood glucose of all mice before the experiment 
commenced.  The mean blood glucose values during day 1 to day 30 for all treated diabetic mice 
was significantly lower than mock-implanted diabetic mice (P < 0.001). Blood glucose values on 
the 3rd and 30th day after implantation were not significantly different for all groups, 
*P=0.2309, **P=0.0663, ***P=0.1212, ****P=0.5120. 
(D) Glucose tolerance of mock-implanted and treated diabetic mice.  Glucose (i.p. 1.5 mg/g 
body weight) was administered after an overnight fast to diabetic mice 30 days after 
implantation with plasmid-electroporated or null-electroporated hepatocytes, and to control 
unimplanted non-diabetic mice of the same age and sex. Blood glucose levels were determined at 
0, 30, 60, 120 and 180 min.  Using the area under the curve (AUC), glucose tolerance was 
significantly improved in all groups of treated diabetic mice compared to mock-implanted 




Figure 3E Plasma human insulin of mock-implanted and treated diabetic mice. Serial insulin 
concentrations were determined in mouse plasma using a human insulin specific 
radioimmunoassay during the experimental period as described in the legend to Figure 3A. 
Human insulin was undetectable in plasma of mock-implanted diabetic mice. Data are mean ± 
s.e.m.. The sum of all plasma human insulin levels of diabetic mice implanted with hepatocytes in 
regenerating liver was significantly higher than diabetic mice implanted with hepatocytes in 
unresected liver (P=0.0006) and mesentery (P<0.0001).  The sum of all plasma insulin levels 
was also significantly higher in mice implanted in unresected liver compared to mesentery 
(P<0.0001). Plasma human insulin concentrations on the 6th and 30th day after implantation 
were not significantly different in all groups, *P=0.3849, **P=0.0811, ***P=0.0635. 
(F) Plasma mouse C-peptide of mock-implanted and treated diabetic mice. Serial plasma C-
peptide concentrations were assayed over the experimental period described in the legend to 
Figure 3A. Data are mean ± s.e.m..  Plasma C-peptide levels of treated diabetic mice 30 days 
after implantation were not significantly different from levels on the day of hepatocyte 
implantation, *P=0.0972, **P=0.5016, ***P=0.0706.  Mean plasma C-peptide level on day 30 




Table 2 Time course of glucose-stimulated insulin secretion in vivo. 
  Plasma insulin levels, pM (mean ± s.d.) 
  Minutes after injection 
  0  10  20  30 
         






         







Diabetic C57BL/6 mice were implanted with ~ 8 x 105 viable transfected hepatocytes in 
regenerating liver.  Glucose solution (75 mg/ml; 1.5 mg/g body weight) was administered to 
three mice as a single intravenous bolus 3 days after hepatocyte implantation while two control 
mice received an identical volume of glucose-free saline.  Blood was drawn for plasma insulin 
radioimmunoassay just before, 10, 20 and 30 min after glucose or saline injection.  Parentheses 
are % change where + denotes increase and – decrease in insulin concentrations after bolus 












Table 3 Glucose-stimulated insulin secretion in vivo. 
 
 
   Plasma human insulin (pM) 
Diabetic  Implantation site  Pre-glucose  Post-glucose 
       
Yes  Regenerating liver  265.7±8.0  338.2±15.3 (+27.3%) 
Yes  Unresected liver  162.0±16.5  215.9±10.9 (+33.2%) 
Yes  Mesentery    55.5±3.2    60.9±19.8 (+  9.6%) 
No  Regenerating liver  112.2±9.4  153.5±18.7 (+36.8%) 
No  Unresected liver    75.3±6.6  110.6±3.6   (+46.9%) 
No  Mesentery    40.6±4.7    70.6±7.9   (+73.6%) 
 
Diabetic and non-diabetic C57BL/6 mice were implanted with ~ 8 x 105 viable transfected 
hepatocytes at the sites indicated.  Glucose solution (75 mg/ml; 1.5 mg/g body weight) was 
administered as a single intraperitioneal injection 5 days after hepatocyte implantation.  Blood 
was drawn for plasma insulin radioimmunoassay just before and 3 h after glucose challenge 
(n=3 for all groups). Data are mean ± s.e.m.. Parentheses are % change in plasma insulin 
levels.  Controls were diabetic (n=3) and non-diabetic (n=3) mice implanted with transfected 
hepatocytes and injected with same volume of saline instead of glucose. Percentage change was 











Figure 4 Immunohistochemical staining of engrafted hepatocytes. (A) Positive cytoplasmic 
staining for human insulin in transfected donor hepatocytes implanted in partially 
hepatectomised liver.  
(B) Higher magnification of (A).   
(C) Positive cytoplasmic staining for human insulin in transfected donor hepatocytes implanted 
in unresected liver.   
(D) Negative immunohistochemical staining for human insulin in unresected mouse liver 2 days 
after implantation with null-electroporated donor hepatocytes. The host liver in each case was of 
a diabetic mouse. The primary antibody was monoclonal mouse anti-human insulin antibody. 








Figure 4 Immunohistochemical staining of engrafted hepatocytes. (E) Double staining for β-
galactosidase activity and human insulin in partially hepatectomised liver implanted with 
transfected Gt(Rosa)26 hepatocytes. Blue arrowheads: hepatocytes stained blue with X-gal; 
yellow arrowheads: hepatocytes stained blue with X-gal and reddish-brown with anti-human 
insulin antibody; red arrowheads: hepatocytes without X-gal and anti-insulin antibody staining.  
The counterstain was haematoxylin.  Original magnification 200X.  
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2.2. Primary Porcine Hepatocytes 
2.2.1 Electroporation of primary porcine hepatocytes 
As with primary murine hepatocytes, efficient gene transfer was achieved in primary 
porcine hepatocytes using the proprietary Amaxa™ solutions i.e. equal volume mixture of 
Nucleofector™ solutions #3551 and #3541 (Amaxa Biosystems, Germany). Electroporation with 
programme T20 typically yielded 40-50% transfection efficiency with 70-80% cell viability 
(Figure 5A). The setting of programme T20 was identified as a single pulse of 2000 V for 70 µs 
followed immediately by a single pulse of 180 V for 37 ms. However, in view of the high cost 
incurred for each transfection (Singapore $33 per transfection of 2x106 cells) and the possibility 
that superior transfection efficiency and cell viability were possible, we resorted to developing 
our own electroporation solution i.e. NC solution.  
The equal volume mixture of Nucleofector™ solutions #3551 and #3541 was hypertonic 
(osmolality 332 mmol/kg H2O cf. normal plasma osmolality 275-290 mmol/kg H2O1,2) and had 
the following partial ionic composition: Potassium 8 mM, sodium 200 mM, calcium 0.5 mM, 
magnesium 10 mM, iron 15 µM and Zinc 2 µM. In contrast, NC buffered solution (pH 7.6) was 
hypotonic (osmolality 250 mmol/kg H2O) and was composed of only 100 mM K+ (as KH2PO4 
and K2HPO4) and 20 mM Na+ (as NaCl). Incubation of hepatocytes in hypotonic solutions 
causes transient regulatory volume increase (RVI) as water crosses the plasma membrane to re-
establish osmotic equilibrium3. Cell swelling might allow cell membrane permeabilisation at a 
moderate electrical voltage i.e. with lower electrical force. Indeed, compared to electroporation 
with Nucleofector™ solutions, gene transfer in primary porcine hepatocytes was more efficient 
with NC solution even when a lower voltage was applied i.e. a single pulse of 1400 V for 70 µs 
followed by a single pulse of 160 V for 37 ms. Specifically, >50% transfection efficiency 
(assessed by GFP+ cells) and higher insulin secretion (P=0.0026) were consistently achieved 
(Figure 5B). Therefore, all electroporation experiments thereafter were performed at the above 
settings in NC solution. 
High potassium concentration in NC solution may serve three purposes, i.e. 1) it 
increases intracellular [K+] via active and passive transport before electroporation, 2) it maintains 
cell swelling by inhibiting volume recovery during the RVI phase in hypotonic buffer3,4 and 3) it 
reduces egress of intracellular K+ down the concentration gradient while the plasma membrane is 
permeabilised. As increased extracellular [K+] causes influx of K+ into the intracellular 
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compartment and thus stimulates active efflux of Na+ via the Na+-K+-ATPase channel before 
electroporation, 20 mM Na+ in NC solution would  maintain intracellular [Na+] at relatively 
normal levels while the plasma membrane is permeabilised (physiological intracellular [K+]~150 
mM, [Na+]~15 mM)2. In addition, divalent ions such as Ca2+ and Mg2+ that may interfere with 
resealing of the plasma membrane5 are omitted from NC solution. The pH of 7.6 (i.e. slightly 
above physiological for extracellular fluids), could protect viable cells from the noxious effects 
of released acidic intracellular contents from electroporation-induced necrosis. Although freshly 
prepared ATP and reduced glutathione were reported to prevent leakage of cytoplasmic contents, 
protect membranes against oxidation and facilitate resealing of pores6, these effects were 
inconsistent in our experience and when omitted, did not compromise transfection efficiency and 
cell viability.     
  Taken together, the composition of NC solution not only increased transfection 
efficiency, but also better preserved cell viability i.e. >80% compared to electroporation with the 
Nucleofector™ solutions. Furthermore, NC solution was also useful in transfecting a diverse 
range of different cell types at low voltage (typically 500-1250 V/cm for <50 µs) with high 
efficiency and cell viability (Appendix 4).  
 
2.2.2 Regulated insulin production in vitro 
Similar to primary murine hepatocytes, the glucose- and zinc-responsive promoter in 
p3MTChINS was functional in primary porcine hepatocytes. Insulin secretion by electroporated 
hepatocytes in vitro was stimulated by glucose (4-25 mM) (Figure 6A) or zinc (5-20 μM) alone 
(Figure 6B), with highest induction by glucose and zinc combined (Figure 6B). These glucose 
and zinc concentrations were within the physiological ranges in pig blood, 3.4-15.3 mM (J. 
Laukkarinen, unpublished data) and 13-20 μM7, respectively. Insulin secretion rate rose from 
0.01 to 0.14 ng/103 hepatocytes/min (p<0.0001) from the 5th to 10th minute after increasing 
glucose from 2.5 to 25 mM while in a parallel incubation it remained stably low in 2.5 mM 
glucose (Figure 6C). Insulin transcription increased 1.58-fold within10 min in 25 mM glucose, 
and decreased by about 1.53-fold within 20 min of restoring glucose concentration to 2.5 mM 
(Figure 6D). 




While induction of diabetes was inconsistent with 150 mg/kg STZ alone, administration 
of ammonium chloride to produce systemic acidosis (pH 7.0-7.1) prior to injection8 of an 
identical dose of STZ was successful in 14 of 15 Yorkshire-Landrace pigs (93.3%). 
Hyperglycaemia (17.11±0.93 mM) developed within 48 h of STZ administration and diabetes 
was stable for at least 49 wk. AUC20-90PCP (area under the curve of porcine C-peptide 
concentration in 20-90 minutes of a glucose tolerance test; an index of glucose-stimulated 
porcine insulin secretion) in the post-STZ and late treatment phases were not significantly 
different (P=0.6394), evidence that endogenous β-cells had not regenerated throughout the study 
(Figures 7A and 8F). Consistent with selective β-cell ablation in STZ-diabetic pigs, insulin 
mRNA by RT-PCR was significantly decreased in the pancreas (P< 0.0001; Figure 7B), 
somatostatin and pancreatic polypeptide transcript levels were unaltered, while glucagon mRNA 
showed the characteristic increase associated with diabetes (P<0.0001) [34] (Figure 7B). 
Pancreatic islets of diabetic swine did not stain for insulin, unlike normal pig pancreas (Figure 
7C).  
2.2.4 In vivo metabolic effects after implantation of p3MTchINS-modified autologous 
hepatocytes 
In this study, we chose to isolate hepatocytes in adequate number and quality from a 
surgically resected wedge of autologous liver in a planned procedure performed in diabetic pigs. 
By using autologous cells, our approach was independent of a cell donor, technically facile, did 
not require long-term immunosuppression, and was thus clinically appealing. The amount of 
excised tissue (less than 10% of the entire liver) was well within the regenerative capacity of the 
liver to restore9. We chose to reimplant hepatocytes directly into the liver parenchyma instead of 
via the portal vein, as practised by most investigators, because more than 70% of portal vein-
infused hepatocytes are known to be trapped within the liver vasculature and quickly destroyed 
by blood macrophages, leaving only a small fraction to engraft successfully10, while up to 50% 
disseminated to extrahepatic organs11. Other investigators have reported that portal infusion of 
hepatocytes in adult pigs was associated with intraportal thrombosis and pulmonary embolism 
with infarction12. In contrast, hepatocytes implanted directly into the liver parenchyma did not 
distribute to other organs and integrated normally into liver lobules13.  
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Fourteen diabetic pigs were implanted with autologous hepatocytes. In 10 pigs, 
hepatocytes were electroporated with p3MTChINS (treated group) while hepatocytes of the 
remaining 4 pigs were mock-electroporated without plasmid (untreated group).  In vivo 
implantation data (Figure 8) were grouped into four temporally sequential phases: pre-STZ (non-
diabetic; ≥ 4 wk); post-STZ (diabetic; 10 d); early and late treatment (≤12 and 13-47 wk, 
respectively, post-implantation). No animal received insulin injections in the early or late 
treatment phases. 
Glycaemic correction. Mean fasting glycaemia was significantly lower in treated than in 
untreated pigs (p<0.0001) over the entire study period of at least 47 wk (Figure 8A. See 
Appendix 5 for details of Figure 8 and other biochemical data). Hypoglycaemia (< 2.8 mM) was 
not recorded in >320 separate fasting and random blood glucose measurements over this period, 
demonstrating that the bifunctional promoter was indeed glucose-sensitive in vivo. Glycaemic 
profiles from intravenous glucose tolerance tests (IVGTT) of treated animals were restored 
almost to their non-diabetic status (Figure 8B). IVGTT data were expressed as AUC for blood 
glucose 20-90 min after intravenous glucose (AUC20-90BG), an integrated measure of in vivo 
glucose handling. Among treated pigs, mean AUC20-90BG decreased 42.56±0.87% from pre-
implantation diabetic values, an effect that persisted into the late treatment phase when it was 
comparable to AUC20-90BG of the non-diabetic phase (P=0.1348) (Figure 8C). Although no 
glucose reading or clinical signs indicative of hypoglycaemia were ever observed during the 
course of IVGTT, prolonging the duration of the test by measuring blood glucose concentrations 
beyond the conventional period of the IVGTT (e.g. to 180 minutes) is necessary to confidently 
exclude hypoglycemia.  
Regulated insulin secretion in vivo. Improved glucose tolerance was accompanied by 
near-normalisation of the temporal profile of serum transgenic human C-peptide (HCP) during 
IVGTT. It was noteworthy that, similar to glucose-stimulated insulin secretion in vitro (Figure 
6C), serum HCP levels of treated pigs rose within 5 min during IVGTT (Figure 8D), comparing 
favourably to the rise in serum PCP within 1 min of the same animals before diabetes induction 
(Figure 7A). Comparing IVGTT data of the pre-STZ (serum porcine C-peptide; PCP) and post-
implantation (serum HCP) phases, these concentrations declined 40 min (0.0036 ng-1ml-1min-1) 
and 60 min (0.0020 ng-1ml-1min-1), respectively, after glucose stimulation. IVGTT data of treated 
diabetic pigs showed that the AUC for serum HCP 20-90 min after intravenous glucose (AUC20-
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90HCP), an integrated measure of human insulin secretion by implanted hepatocytes, was 54% that 
of AUC20-90PCP (a comparable measure of endogenous insulin secretion from porcine pancreatic 
islets) of the same animals before induction of diabetes. Taken together, these data demonstrated 
that implanted modified primary porcine hepatocytes showed dynamic changes in insulin 
secretion in tandem with changes in extracellular glucose concentrations that were sufficiently 
rapid to be near-physiological in onset and offset. Using species-specific C-peptide 
radioimmunoassays, glycaemic improvement was attributed to human insulin secreted from 
transfected hepatocytes (Figure 8E) rather than recovery of endogenous β-cells as AUC20-90PCP 
values were not significantly different between treated and untreated groups, and were 
consistently <16% of pre-STZ values (Figure 8F).  
Metabolic correction. As pig erythrocytes are impermeable to blood glucose14, serum 
fructosamine was used instead of glycated hemoglobin as an index of average glycemic control. 
Mean fructosamine concentrations fell significantly from diabetic levels in treated pigs 
(P=0.0014 early treatment; P<0.0001 late treatment). Unlike untreated diabetic controls, serum 
fructosamine did not rise significantly during the late treatment phase (P=0.1500 cf. early 
treatment phase) (Figure 8G).  
Emaciation is a known somatic consequence of the global metabolic effects of severe 
insulin deficiency. Our data showed that clinically effective restoration of insulin production was 
accompanied by a higher rate of body weight gain in treated animals (P<0.0001 early treatment; 
P=0.0002 late treatment cf. untreated controls) (Figure 8H). Consistent with greater body weight 
gain, treated pigs had higher late treatment phase serum creatinine levels compared to untreated 
controls (P<0.0001) whose serum creatinine levels did not change throughout all study phases 
(Figure 8I). There was, however, no significant difference in blood urea and serum electrolyte 
concentrations between the groups (Appendix 5). Thus, higher serum creatinine levels were the 
result of increased muscle mass in treated animals rather than impaired renal function15.  
Dyslipidaemia secondary to diabetes was also corrected. Among treated pigs, mean total 
serum cholesterol concentration was significantly reduced in the early treatment phase (P=0.0035 
cf. diabetic levels) while it remained unchanged in untreated animals (P=0.9793) (Figure 8J). 
Hypertriglyceridaemia developed acutely after induction of diabetes in both groups and 
significantly improved only in treated pigs during the early treatment phase (P<0.0001) (Figure 
8K) and was not significantly different from the pre-STZ phase (P=0.4935).  However, serum 
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cholesterol and triglyceride concentrations of untreated diabetic pigs also fell substantially 
during the late treatment phase (Figures 8J and K) – even to levels below their own non-diabetic 
values. Hypolipidaemia associated with severe diabetes is a known effect of prolonged starvation 
and weight loss on lipoprotein metabolism16.  
High serum ALT activities are typical of liver dysfunction in poorly controlled diabetes 
and readily reverse after correction of hyperglycaemia17. Mean serum ALT activities of treated 
animals during pre-STZ and late treatment phases were not significantly different (P=0.8508) 
showing that treatment had effectively prevented diabetes-related liver dysfunction. In contrast, 
serum ALT activity rose progressively in untreated controls and were higher during the late 
treatment phase compared to both the early treatment and pre-STZ phases (P=0.0086 and  
<0.0001, respectively) (Figure 8L). 
Treatment outcomes correlated with the number of hepatocytes implanted. Our data 
indicate a ‘dosing effect’ with regard to the number of implanted hepatocytes. Correction of 
disordered glucose metabolism by several objective measures - fasting glycaemia (Figure 8M), 
intravenous glucose tolerance (Figure 8N) and serum fructosamine levels (Figure 8O) – was the 
result of restored insulin production shown by fasting serum HCP levels (Figure 8P) and AUC20-
90HCP (Figure 8Q). All these outcome measures correlated significantly with the number of 
hepatocytes implanted.  In contrast, cell number did not correlate with serum total bilirubin 
concentrations (Figure 8R) or serum γ-glutamyltransferase activity (Figure 8S) showing that 
direct intrahepatic placement of hepatocytes, suspended in up to 15 ml, did not cause cholestasis. 
Overall restoration of normal liver functions in treated animals could be inferred from serum 
albumin trends. Serum albumin concentrations were positively and significantly correlated with 
the number of hepatocytes implanted (Figure 8T). They were also significantly lower in the late 
treatment phase of untreated animals compared to pre-STZ values (P<0.0001; Appendix 5). In 
contrast, serum albumin concentrations in the late treatment phase of treated animals were not 
significantly different from their corresponding pre-STZ values (P=0.1995). 
2.2.5 Engraftment of insulin-secreting hepatocytes 
  Despite clear evidence of continuing transgenic insulin expression and metabolic 
correction in the treated animals, autopsies were performed on healthy controls, untreated 
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diabetic and treated diabetic pigs 34-47 weeks post-implantation to systematically evaluate 
engraftment, vector persistence and target organ injury.  
  Autologous insulin-secreting hepatocytes had engrafted mainly, but not only, around 
portal triads and central veins (Figure 9A-C).  There were no features of disordered lobular 
architecture or cirrhosis in the implanted livers. No tumours were detected during careful 
examination of the liver, spleen, intestinal tract, peritoneal cavity, kidneys, adrenals, lungs and 
heart. Fasting serum HCP levels during the first week after implantation (0.44±0.03 ng/ml) 
stabilised at 0.31±0.02 ng/ml after 4 weeks, consistent with functional engraftment of about 70% 
of implanted hepatocytes. Consistent with persistent secretion of transgenic insulin (Figure 8E), 
plasmid DNA was detected 3 and 8 months post-implantation using vector-specific primers for 
PCR of total DNA extracted from thick sections of liver that showed insulin-producing 
hepatocytes (Figure 9D). In contrast, vector DNA was barely detectable in the same liver lobes 
distant from implantation sites.   
Physiological concentrations of insulin are mitogenic18 and liver tumours were reported 
in all diabetic animals intrahepatically transplanted with low numbers of pancreatic islets19. 
However we showed that, compared to liver from a healthy control, the liver of implanted 
animals did not show increased mitogenic activity as assessed by immunostaining for 
proliferating cell nuclear antigen and Ki67 (Figures 9B and C). Rare proliferating cell nuclear 
antigen and Ki67 staining was observed in both insulin-secreting as well as adjacent hepatocytes, 
indicating that ectopic insulin secretion in the liver did not have autocrine or paracrine mitogenic 
effects. Insulin-secreting hepatocytes were morphologically normal without features of cellular 
transformation.  
Overall, we show that intraparenchymal implantation of primary hepatocytes achieved 
significant engraftment, did not disrupt normal hepatic lobular architecture, did not alter normal 
biochemical indices of liver function, was safely performed percutaneously under ultrasonic 
guidance with comparable results to open implantation and thus was not inferior to portal venous 
infusion of cells. A single surgical death from intraabdominal haemorrhage due to iatrogenic 
liver laceration occurred during percutaneous implantation. This animal was excluded from 
analysis. There was no surgical mortality and morbidity after we adopted the reverse 
Trendelenburg position for percutaneous hepatocyte implantation. 
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2.2.6 Treatment attenuated target organ injury 
Despite continuing therapeutic effect, we performed planned autopsies on sex- and age-
matched normal healthy pigs, untreated diabetic and treated diabetic pigs (2 animals per group) 
to systematically evaluate effects of treatment on diabetes-induced target organ injury. To allow 
sufficient time for development of secondary micro- and macrovascular complications, both 
groups of diabetic animals were maintained for 34-42 weeks before autopsy. 
Treatment effects on tissue structure. Both untreated diabetic pigs had dense posterior 
subcapsular cataracts that were absent in both treated pigs (Figure 10A). The choroidal capillary 
basement membrane in the retinae of untreated diabetic pigs was thicker than that of both healthy 
and treated diabetic animals (Figure 10H; P<0.0001 for both comparisons). In contrast, there was 
no difference between capillaries of healthy and treated diabetic animals (P=0.8260). Another 
striking feature of choroidal capillaries in untreated diabetes was the presence of an additional 
cell layer invested with its own basement membrane (Figure 10C). These structural changes in 
choroidal capillaries were likely early events in the development of diabetic microangiopathy as 
retinal capillary permeability by fluorescein angiography was normal in all animals examined 
(Figure 10B).  
Kidneys of untreated diabetic pigs showed mesangial hyperplasia and arteriolar 
thickening, characteristics of diabetic nephropathy that were absent in healthy and treated 
diabetic animals (Figure 10D). Glomerular basement membranes were thicker in untreated 
diabetic pigs compared to healthy (P=0.0002) and treated diabetic pigs (P=0.0007) (Figure 10E). 
Notably, glomerular basement membrane thickness of treated diabetic pigs was not different 
from healthy controls (P=0.9023) (Figure 10H).  
Scanning electron microscopy (SEM) of carotid arteries from an untreated diabetic pig 
showed a smoothened endothelial surface, abnormal microvilli and clumped erythrocytes with 
fibrin adhering to the endothelium while carotid arteries of a treated diabetic pig appeared more 
similar to a healthy animal (Figure 10F).  
Hepatocytes of untreated diabetic pigs stained more intensely with periodic acid-Schiff 
stain (Figure 10G) indicative of glycogenic hepatopathy, a known but less well-recognized 
complication of diabetes17. 
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Treatment effects on target organ transcriptomes. Transcriptional changes are sensitive 
molecular sentinels of the injurious effects of diabetes on organs targeted for developing 
secondary complications20 e.g. renal failure, blindness and vascular insufficiency. Retina, kidney, 
aorta and liver of healthy normal pigs, untreated diabetic and treated diabetic pigs were flash 
frozen in liquid nitrogen and transcriptionally profiled because these organs are known targets 
for the microvascular, macrovascular and metabolic complications of diabetes.  We compared 
each tissue transcriptome among the three animal groups. Of 20,201 genes represented on the 
microarray, subsets of 625, 233, 419 and 69 genes were identified as diabetes-associated in aorta, 
kidney, liver and retina, respectively, using two filters of significance (Figure 11A). Among the 
most highly dysregulated diabetes-associated genes were protein kinase C and vascular cell 
adhesion molecule in aorta, retinol-binding protein and angiopoietin-like protein in kidney, 
lipoprotein lipase and apolipoprotein A-IV in liver, vasoactive intestinal peptide receptor and 
serpin peptidase inhibitor in retina. Implantation of insulin-secreting autologous hepatocytes in 
diabetic pigs corrected dysregulated expression of 58% (363 of 625), 38% (89 of 233), 48% (203 
of 419) and 54% (37 of 69) genes in aorta, kidney, liver and retina, respectively (Figure 11B). 
Unsupervised clustering of diabetes-associated genes in each tissue transcriptome showed that 
treated diabetic pigs generally clustered with healthy controls than with untreated diabetic pigs 
(Figure 11C). Further, we have bioinformatically matched the porcine diabetes-associated genes 
to the corresponding human genes and categorised these genes according to their implicated 
biological functions. As shown in Figure 12, the transcription of genes implicated in the 5 most 
significantly altered biological functions (i.e. cell cycle, infection and inflammation, insulin 
resistance, hypoxia and oxidative phosphorylation) in treated diabetic pig kidneys were less 
altered compared with untreated diabetic pig kidneys.  
Taken together, these data demonstrate that the therapeutic efficacy in this study 
extended beyond glycaemic and metabolic (including dyslipidaemia) correction to protection 
against complications secondary to tissue injury. Our data provide evidence that early and 
effective restoration of normal metabolism in diabetes prevents microvascular and macrovascular 
abnormalities in the eye, kidney and large vessels21, as well as diabetic hepatopathy17. Basement 
membrane thickening was more severe in choroidal capillaries than in renal glomeruli probably 
because choroidal capillaries have much higher blood flow22, and suggests that ocular tissue 
injury from ischemia is a likely early complication of poorly controlled diabetes. These findings 
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should discourage procrastination and advocate more aggressive clinical management to attain 
and maintain normoglycaemia early in the course of diabetes as effective protection against 
serious target organ injury. 
 In summary, this study has demonstrated that autologous primary adult 
hepatocytes of a large preclinical animal can be efficiently, simply and safely electroporated ex 
vivo with a nonviral vector to physiologically express, process and secrete insulin in vivo with 
substantial therapeutic efficacy for at least 47 weeks. Furthermore, we provide evidence that 
such treatment attenuated tissue injury secondary to diabetes i.e. metabolic, micro- and 
macrovascular complications. In addition, our data show a ‘dosing effect’ i.e. glycaemic 
correction, glucose tolerance and human C-peptide secretion were each correlated significantly 
with the number of implanted hepatocytes.  
The number of autologous hepatocytes we implanted was about 10-fold lower than the 
number of allogeneic donor hepatocytes that partially corrected inherited factor VII deficiency in 
two children23. Although short-term transgene expression is generally expected from non-
integrating vectors, several reasons explain the surprisingly sustained therapeutic effects we 
achieved; namely, our use of physiological mammalian promoters that, unlike viral promoters, 
are less susceptible to silencing24, high vector copy number transfer by electroporation25 and 
durable plasmid retention by non-mitotic hepatocytes26.  
Use of a porcine model that resembles humans in size, anatomy, physiology and 
pathophysiology has moved our approach closer to clinical application. Despite many past 
attempts at developing gene- and autologous cell-based diabetes treatments, none of the 
approaches that are effective in murine diabetes has been successfully adapted to large animals, 
let alone human subjects. This longstanding impasse highlights the problem of scalability, among 
others, that continue to impede clinical development of genetic and cellular therapies27,28. 
We recognise that our approach could have greater clinical appeal if the method for 
procuring autologous primary hepatocytes was less invasive. In this regard, it may be possible to 
employ laparoscopic resection of an even smaller liver wedge (currently about 10% of total liver 
mass) in future. This adaptation will require hepatocyte isolation in higher yield and greater 







Figure 5 Electroporation of primary porcine hepatocytes. (A) Electroporation using NC 
solution transfected 40-50% hepatocytes with pEGFP. Merged brightfield and fluorescence 
images; original magnification, 200X. (B) Human insulin concentration in 24 h conditioned 
media of primary hepatocytes electroporated with p3MTChINS (2 μg/106 cells) in Amaxa™ or 




Figure 6 Regulated human insulin transcription and secretion by modified primary porcine 
hepatocytes. (A) Human insulin concentrations in 24 h conditioned media of p3MTChINS-
electroporated hepatocytes. Thresholds for stimulating insulin secretion were 4 mM glucose 
(p=0.0018 cf. 2.5 mM glucose) and (B) 5 μM zinc in 2.5 mM glucose-DMEM (p<0.0001 cf. no 
zinc). Data of cumulative insulin concentrations are means ± s.e.m. of quadruplicate 
experiments.  
(C) Time course of insulin secretion by electroporated hepatocytes. Insulin secretion rate 
increased from 0.01 to 0.14 ng/103 hepatocytes/min (p<0.0001) after 5 min in 25 mM glucose 
but not in 2.5 mM glucose over 85 min. Data are means ± s.e.m of quadruplicate experiments 
from 2 primary hepatocyte preparations.  
(D) Insulin mRNA, quantified by real time RT-PCR after subtracting a parallel minus-RT control 
and normalising to HPRT1 mRNA as described in Materials and Methods (section 4.6.2.1), rose 
within 5 min in 25 mM glucose (p<0.0001) and fell within 10 min in 2.5 mM glucose (p=0.0149). 




Figure 7 Absence of insulin expression in pancreatic β-cells of STZ-diabetic pigs.  
(A) Persistent abolition of IVGTT-induced rise in serum PCP in the late treatment phase (13-47 
wk after hepatocyte transplantation). Data are from 14 pigs.  
(B) Transcript analyses of islet hormones from pancreata of healthy, untreated diabetic (38-46 
wk post-STZ) and treated diabetic (38-49 wk post-STZ) pigs (n=2 per group) by real time RT-
PCR (Materials and Methods, section 4.8.6.1). Insulin mRNA was significantly decreased and 
glucagon mRNA significantly increased in both groups of diabetic pigs compared to healthy 
controls (p<0.0001 for all comparisons). Both diabetic groups had similar expression of insulin 
and glucagon (p=0.4041 and 0.2308, respectively). Somatostatin and pancreatic polypeptide 
expression was not significantly different among all groups.  





Figure 8 Glycaemic and metabolic correction after implantation of insulin-secreting 
autologous hepatocytes. Aggregated data are presented from four sequential phases: pre-STZ 
(non-diabetic phase); post-STZ (≤10 d after STZ injection); early treatment (≤12 wk post-
implantation) and late treatment (13-47 wk post-implantation) for 10 treated and 4 untreated 
pigs. See Appendix 5 for number of animals (N), separate analyses (n), means, s.e.m. and range 
for all biochemical tests performed.  
(A) Mean fasting glycaemia in early and late treatment phases were significantly lower in 
treated pigs (p<0.0001 for both phases). As only two pigs were continued to 47 weeks in the 
study, for statistical analysis, data are shown in this panel for a larger group of animals studied 
up to 36 weeks. 
(B) Glycaemic profiles during IVGTT in the 4 study phases. Pre- and post-STZ profiles are 
pooled data from all pigs. Profiles of treated and untreated pigs were from the late treatment 
phase.  
(C) Glycaemic data from panel (B) expressed as AUC20-90BG. Implanted insulin-secreting 
hepatocytes improved glucose tolerance (*, p<0.0001) with durable effect (p=0.3481 early vs 
late treatment phase).  
(D) Serum HCP levels in treated pigs increased 5 min after intravenous glucose (p=0.0124 and 




Figure 8 Glycaemic and metabolic correction after implantation of insulin-secreting 
autologous hepatocytes. 
(E) AUC20-90HCP of treated pigs was comparable in both treatment phases (p=0.8279).  
(F) AUC20-90PCP  confirmed β-cell ablation in STZ-diabetic pigs throughout the study (p<0.0001 
both treatment phases cf. pre-STZ phase); *, p=0.8279.  
(G) Mean serum fructosamine levels were lower in treated pigs in the early and late treatment 
phases (p=0.0014 and <0.0001, respectively. cf. untreated pigs). Fructosamine levels did not 
rise significantly in treated pigs (p=0.1500) but did increase among untreated pigs (p=0.0015; 
early vs late treatment phase).  
(H) Body weight gain was higher among treated pigs (p<0.0001 early treatment and p=0.0002 





Figure 8 Glycaemic and metabolic correction after implantation of insulin-secreting 
autologous hepatocytes. 
(I) Mean serum creatinine concentration in treated pigs during the late treatment phase was 
significantly higher than untreated diabetics (p<0.0001).  
(J) Total serum cholesterol was higher in untreated pigs during the early treatment phase 
(p=0.0035). Treated pigs maintained normocholesterolaemia during the late treatment phase. 
Reduced serum cholesterol levels in untreated pigs during the late treatment phase were 
associated with marked weight loss.  
(K) Hypertriglyceridaemia developed acutely in all pigs after onset of diabetes (p=0.0002). It 
declined significantly in treated pigs during the early phase (p<0.0001 cf. untreated pigs). 
Marked reduction in serum triglyceride concentrations during the late treatment phase was 
associated with severe weight loss in untreated pigs.  
(L) Mean serum ALT activities in treated pigs during pre-STZ and late treatment phases were 
comparable (p = 0.8508) but were significantly higher in untreated pigs (p<0.0001 pre-STZ vs 
both treatment phases). Serum ALT decreased in treated pigs (early vs. late treatment values, 





Figure 8 Glycaemic and metabolic correction after implantation of insulin-secreting 
autologous hepatocytes.  
The number of transplanted hepatocytes correlated with percentage decrease in (M) fasting 
hyperglycaemia, (N) decrease in AUC20-90BG, (O) stabilisation of serum fructosamine, (P) rise in 




Figure 8 Glycaemic and metabolic correction after implantation of insulin-secreting 
autologous hepatocytes. 
(R) Serum bilirubin and (S) γ-glutamyl transpeptidase levels did not correlate significantly with 
the number of implanted hepatocytes but (T) serum albumin levels correlated positively. One pig 






Figure 9 Engraftment of insulin-expressing autologous hepatocytes.  
Immunostained liver 36 wk after hepatocyte transplantation showed normal lobular architecture 
and insulin-producing hepatocytes engrafted around (A) the portal triads and (B) central veins.  
Panels (B) and (C) show co-staining for insulin and mitotic markers, proliferating cell nuclear 
antigen and Ki67, respectively. Mitotically positive cells were rare (arrowed).  
(D) Quantitative PCR using vector-specific primers detected p3MTchINS in liver 3- and 8-month 
after implantation. The amount of vector detected in each sample is expressed in ng plasmid 







Figure 10 Treatment attenuated target organ injury.  
(A) Example of a dense cataract observed only in untreated diabetic pigs.  





Figure 10 Treatment attenuated target organ injury.  
(C) Transmission electron microscopy (TEM) of retina showed thickened basement membrane of 
a choroidal capillary, duplicated basement membrane (red arrow) and an extra layer of cells in 









Figure 10 Treatment attenuated target organ injury.  
(D) H&E stained kidney sections showed enlarged glomeruli with mesangial expansion, and 








Figure 10 Treatment attenuated target organ injury.  










Figure 10 Treatment attenuated target organ injury.  








Figure 10 Treatment attenuated target organ injury.  









Figure 10 Treatment attenuated target organ injury.  
(H) Basement membrane thickness, measured in 20 choroidal capillaries and 20 renal glomeruli 
of each group (n=2), was significantly greater in untreated diabetes cf. both treated and healthy 










Figure 11 Transcriptional profiling of aorta, kidney, liver and retina.  
(A) Venn diagram of genes whose expression was significantly different in pairwise 
comparisons: N vs U; N vs. T and T vs. U (N, healthy controls; T, treated diabetic; U, untreated 
diabetic pigs. n=2 per group). Genes ≥1.5-fold different in expression in pairwise comparisons 
were analysed by SAM (significance analysis of microarray) based on 1,000 permutations (false 
discovery rate < 1%). See Materials and Methods section 2.9.8 for more details. Shaded areas 






Figure 11 Transcriptional profiling of aorta, kidney, liver and retina. 
(B) Expression of diabetes-affected genes in untreated and treated pigs grouped in increasing 
order of differential expression relative to healthy pigs. Genes represented by multiple probe sets 
were merged and averaged. 
(C) Unsupervised hierarchical clustering of diabetes-affected genes showed a distinct tendency 
for tissue transcriptomes of treated diabetic and healthy pigs to cluster together. Replicate 
transcriptional profiles of the same animal are designated 1 and 2, or 3 and 4 (i.e. 2 pairs of 
transcription datasets per group of 2 animals). Numbers on selected nodes of each dendrogram 




Figure 12 An example of how might one gain biological insights from porcine transcriptomes  
 Significant diabetes-affected genes as described in Figure 11A were matched to their 
corresponding human genes by applying bioinformatics algorithms to databases of the National 
Center for Biotechnology Information (NCBI) and Mamalian Gene Collection (MGC) of the 
National Institutes of Health, USA (A collaborative project with the Bioinformatics Group, 
Nanyang Polytechnic, Singapore). These gene sets were analysed with Gene Set Enrichment 
Analysis programme (GSEA)29,30 to identify diabetes-altered pathways and their implicated 
biological functions. Shown are the 5 most significantly altered biological functions in diabetic 
porcine kidney transcriptome. The fold change of genes significantly upregulated in untreated 
(U) and treated (T) diabetic pig kidneys in pairwise comparison with normal, non-diabetic pig 
kidneys is illustrated in a discontinuous colour intensity chart. Note that transcription of 
diabetes-affected genes in treated diabetic pig kidneys were less altered compared with 
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2.3 Primary Porcine Bone Marrow-derived Mesenchymal Stromal Cells (PBMMSCs) 
2.3.1 Selection of  BMMSC-specific glucose-responsive promoter 
To select a suitable promoter that could drive glucose-regulated insulin secretion in 
primary human BMMSCs, glucose-responsive genes from these cells were first identified using 
whole genome expression arrays. In order to enrich for transcripts that are rapidly induced in the 
presence of high glucose and reversed upon its withdrawal, we processed the cells for total RNA 
within minutes of exposure to the glucose stimulant. This level of stringency for near-
physiological kinetic responses yielded, on average, only 14.6% of rapidly upregulated probesets 
from a total of 10 arrays (Table 4). Four transcripts, namely early growth response-1 and -3 
(EGR1 and EGR3, respectively), v-fos murine osteosarcoma viral oncogene homolog (FOS) and 
a cDNA clone of unknown function, DKFZp547G099, were glucose-sensitive. Further analysis 
of the same samples by semi-quantitative RT-PCR showed comparable levels of induction as 
data obtained from the array studies. EGR1, a zinc finger transcription factor, was particularly 
attractive because it showed a near-physiological response to glucose stimulus. Fifteen minutes 
after exposure to 20 mM glucose, EGR1 mRNA levels showed a clear increase (4.9-8.1-fold) 
over baseline and continued to rise to 8.3-14.8-fold over baseline after 30 minutes in high 
glucose. Although the transcript levels did not decrease 30 minutes after withdrawal of the 
glucose stimulus (9.2-11.4-fold over baseline), it did decline to basal levels 60 minutes after 
glucose concentration in the medium was returned from 20 mM to 3 mM. There are similarities 
between our data and earlier data of Josefsen et al. of glucose-induced Egr-1 mRNA in insulin-
secreting β-cells. These authors reported maximum glucose-stimulated Egr-1 expression within 
30 minutes and a return to baseline 3 hours after stimulation1. EGR1 binds to its own promoter 
thus giving rise to feed forward regulation that may explain the slower decline in transcript levels 
in the de-induction phase. In contrast, FOS transcription did not show clear glucose 
responsiveness in the semi-quantitative RT-PCR analysis. Although DKFZp547G099 showed 
consistent glucose upregulation, its expression levels were too low to confidently predict the 
practical utility of its promoter for transgenic insulin expression. 
EGR1 (also known as NGF-1A, zif268, Krox-24, or TiS8) is one of the immediate-early 
genes that is induced by a variety of stimuli within 5 to 10 minutes in the absence of de novo 
protein synthesis2. Stimuli that induce EGR1 expression include growth, osmotic stress, hypoxia 
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and mechanical injury3.  Binding of this protein to promoter regions, in turn, induces the 
transcription of many downstream genes, including those encoding growth factors and cytokines. 
Indeed, EGR1 is essential for cell growth, proliferation and differentiation4. The full EGR1 
promoter (GenBank accession number: AJ245926) has been well-studied and contains multiple 
response elements (REs) and regulatory sites common to many cellular immediate-early gene 
promoters. It has one EGR1 and two Sp1 binding sites, five serum REs, two cyclic AMP REs, 
one 12-O-Tetradecanoyl phorbol 13-acetate RE and six putative ChoREs3. 
2.3.2 Isolation and culture of porcine BMMSCs 
To demonstrate efficacy of non-virally modified autologous BMMSCs in restoring 
euglycaemia in diabetic animals, we first modified porcine (P) BMMSCs to serve as xenogeneic 
insulin-producing cells in NOD-SCID mice. PBMMSC lines were established successfully from 
BM aspirates collected from pig’s iliac crest. Two methods of isolation were explored. The first 
protocol relied on using Ficoll-Hypaque density gradients and multiple centrifugations to enrich 
for BM mononuclear cells. The second protocol simply involved plating BM aspirates that had 
been sieved through a 40 µm cell strainer, after adding culture medium to the liquid aspirate in a 
1:1 (v/v) ratio. While the first protocol gave reproducible and more predictable results, a 
significant number of cells were lost after multiple centrifugations. Moreover, it was 
considerably more laborious and time-consuming. In contrast, the second protocol could retain 
every single mononuclear cell capable of attaching and proliferating on a plastic surface. A 
caveat of the second protocol is that the actual number of cells plated is not known with certainty 
initially. However, once the culture was established, the attached cells from multiple flasks were 
detached using a mild enzyme preparation such as Accutase™ and pooled to obtain the 
recommended plating density (1,000 cells/cm2)5 for subsequent re-plating and culture. Discrete 
colonies with a fibroblast-like morphology were evident at 4–5 days after initial plating, and 
grew progressively to reach confluence within 10-12 days (Figure 13A). 
To define the optimal growth medium for the culture and expansion of PBMMSCs, three 
media were evaluated: (1) α-MEM with Glutamax™ supplemented with 20% FCS; (2) Serum-
free StemPro™ medium (a proprietary product for the culture of mesenchymal stem cells); and 
(3) α-MEM with Glutamax™  and StemPro™ in a 3:1 (v/v) ratio, supplemented with 10% FCS. 
Growth rates in these media were 1.79x105±0.10x105 cells/day, 2.73 x 105±0.22x105 cells/day 
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and 2.86x105±0.23x105 cells/day, respectively (Figure 13B). The initial plating efficiency, 
evaluated on day 1, was lowest (70.44±4.62%) in StemPro™ medium, possibly due to the 
absence of serum, which is known to facilitate attachment of cells to plastic surfaces. However, 
in addition to having higher proliferation rate, growth in this proprietary medium also produced 
more cells than α-MEM with Glutamax™ (total cell number 4 days post-plating: 
9.27x105±0.36x105 cells vs. 7.11x105±0.18x105 cells; p<0.0001). Nonetheless, combining both 
media in a 3 (α-MEM with Glutamax™):1 (StemPro™) (v/v) ratio for economy, also yielded 
comparable plating efficiency as using α-MEM with Glutamax™ alone (p=0.2451). Moreover, 
this combined formulation produced the highest number of cells, i.e. 10.08 x 105±0.38 x 105 cells 
(p=0.0153 cf. α-MEM with Glutamax™, p=0.6202 cf. StemPro™). Hence, this formulation was 
used thereafter to culture PBMMSCs. 
2.3.3 Characterisation of porcine BMMSCs 
Cells with features of mesenchymal precursors from bone marrow aspirates can be 
enriched in culture because they proliferate in vitro as adherent fibroblastic cells, eliminating 
haematopoietic cells that normally remain in suspension. However, to confirm that the adherent 
cells were true PBMMSCs, bivariate FACS was performed on detached single cells using 
positive and negative markers of porcine mesenchymal cells, CD90 (THY1) and CD11b 
(ITGAM), respectively6 (Figure 14). Virtually all cells expressed CD90 (99.80±0.07%) and did 
not express CD11b (0.08±0.01%), a haematopoietic marker expressed in monocytes, 
granulocytes, natural killer cells and subsets of T- and B-cells7. These immunophenotyping 
results also exclude the possibility that these cells were fibroblasts because the latter do not 
express either of the surface antigens tested. CD90 and CD11b are good markers for the 
identification of PBMMSCs because they are conserved across species, i.e. human, mouse and 
rat. These findings also showed that substantially pure PBMMSC cultures can be established 
using a simple isolation protocol (vide supra).           
2.3.4 Electroporation of  human and porcine BMMSCs 
We achieved high efficiency of electrogenetransfer in primary human and porcine 
BMMSCs using NC solution (Figure 15). Two million HBMMSCs electroporated with a single 
electrical pulse of 150 V for 15 ms in a 2 mm cuvette (field strength: 750 V/cm) secreted the 
highest amount of SEAP (149.4±9.0 ng/ml) compared to other electric pulse settings. These 
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electrical parameters were also associated with good cell viability (87.2±2.2%). We achieved 
comparable outcomes in electroporated PBMMSCs (148.5±24.7 ng/ml SEAP and 87.7±3.0% 
cell viability), albeit with different pulsing settings i.e. 200 V for 10 ms (field strength: 1000 
V/cm) (Figure 15A). These levels of gene transfer efficiency and cell viability were comparable 
to the performance of a proprietary solution developed by Amaxa Biosystems8. The foregoing 
results demonstrated the feasibility of highly efficient gene transfer in primary adult MSCs using 
a non-viral cell transfection system. Our electroporation protocols showed that the pulse duration 
was crucial in determining cell viability, pulses longer than 30 ms induced high cell mortality 
regardless of the voltage applied. However, transfection efficiency was primarily determined by 
voltage for pulses of identical duration. Thus, a carefully optimised combination of both pulse 
duration and electrical field strength is prerequisite for efficient gene transfection in primary 
BMMSCs. This study showed that optimal parameters for electroporation must be tailored to 
different primary cell types. For example, while primary murine and porcine hepatocytes 
expressed transgenic human insulin at potentially therapeutic levels after insulin gene transfer at 
high voltages, i.e. 1400 V, primary BMMSCs of both species could be transfected at lower 
voltage, albeit with a longer pulsing duration i.e. in a millisecond rather than a microsecond 
range for primary hepatocytes. 
Electroporation of BMMSCs with pEGFP had also showed evidence of efficient 
transfection (Figure 15B). Although this reporter facilitates visual assessment of transfection, 
pSEAP enables rigorous quantitative assays of gene transfer efficiency. Therefore, it is our view 
that electroporation protocols are best optimised with a quantifiable reporter protein. For 
instance, a high transfection efficiency as judged by counting the number of EGFP+ cells does 
not necessarily translate to high protein production because electroporated cells express EGFP 
heterogeneously depending on vector copy number, cell viability and culture conditions.  
2.3.5 No evidence of genomic integration of electroporated circular plasmid DNA 
To address the concern that electroporation caused genomic integration of the transfected 
DNA, we designed 2 pairs of PCR primers to amplify two separate regions of the electroporated 
plasmid using semi-quantitative PCR (primer set 1: between EGR1 promoter and human 
(pro)insulin cDNA, and primer set 2: within the neomycin resistance gene). As shown in Figure 
15C, discrete bands of amplification were seen in genomic DNA isolated from PBMMSC clone 
157 
 
5 stably integrated with linearised  pTopo3EGR1chINS (CT value for primer set 1 = 28.19716± 
0.15090, primer set 2 = 29.18261±0.16150; assays were performed in quadruplicates), while no 
detectable amplification (50 cycles) was observed in the genomic preparations obtained from 
PBMMSCs electroporated with the same plasmid in circular form (10 µg DNA/2 x 106 cells). 
This is consistent with many published and unpublished observations that genomic integration of 
naked plasmid DNA (especially in circular form) is extremely rare. A recent report of the 
possible integration of plasmid into host genomic DNA following electroporation indicated that 
the integration events were at least three orders of magnitude less frequent than the spontaneous 
rate of genome mutation, and that the effects of such rare integrations on transgene expression 
and the host cell could not be determined9.  
2.3.6 Human EGR1 promoter is glucose-responsive in human and porcine BMMSCs 
    To investigate the suitability of the human EGR1 promoter for driving quasi-
physiological glucose-dependent human insulin secretion from BMMSCs, the promoter was first 
cloned into pSEAP-basic plasmid (Clontech Laboratories, Inc.) to drive SEAP expression 
(EGR1-SEAP). Unlike secreted insulin that may be removed from the culture medium by re-
uptake into transfected cells via receptor-mediated endocytosis, SEAP is not subject to 
endocytosis. Moreover, as a modified, heat stable reporter protein, SEAP is a reporter gene that 
lends itself to reliable and simpler quantification of the performance of EGR1 promoter-regulated 
transgene transcription and protein secretion by transfected cells.  
In a static culture experiment, temporal glucose-regulated SEAP expression from 
PBMMSCs modified with EGR1-SEAP was examined. Ten minutes after exposure to 20 mM 
glucose, SEAP activity rose 2.3±0.4-fold over the basal level (i.e. SEAP activity detected in 3 
mM glucose-medium in which the modified PBMMSCs had been cultured for 48 hours) (Figure 
16A). The transgene expression from EGR1-SEAP was further increased to 7.0±0.7-fold higher 
than the basal level, 30 minutes after high glucose induction. Upon removal of the high glucose 
medium and replaced with a fresh medium containing 3 mM glucose, the SEAP activity from 
EGR1-SEAP-modified cells did not increase but rather decreased over time. In contrast, SEAP 
activity from PBMMSCs modified with a control SEAP vector (under the regulation of SV40 
viral promoter) showed a characteristic pattern of time-dependent but glucose-independent 
response because SEAP levels continued to rise even after withdrawal of high glucose. 
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Concordant with the increase in SEAP activity, relative amount of transcript from EGR1-SEAP-
modified cells was 10.7±1.0 fold higher than in control cells maintained in 3 mM glucose, 30 
minutes after exposure to 20 mM glucose (Figure 16B). Moreover, the transcript level was found 
to reach almost basal level, 90 minutes after removal of the high glucose (1.68±0.64-fold). In 
contrast, transcripts for SV40-SEAP remained unchanged throughout the experiment. This 
decline in transcript level was similar to that observed by Josefsen et al.1, albeit more rapidly 
possibly with the absence of the feed forward mechanism induced by EGR1 protein.         
As multiple regulatory DNA motifs are embedded within the EGR1 promoter sequence, 
truncated variants of the full length promoter bearing different motifs in combination were 
differentially amplified from EGR1-SEAP plasmid, and cloned upstream of human (pro)insulin 
cDNA to ascertain whether some or all motifs were required for optimal human insulin 
expression in PBMMSCs. Three EGR1 promoter segments were constructed and evaluated 
alongside with the full length promoter (703 bp; GenBank accession AJ245926). Compared to all 
EGR1 promoter variants tested, full length EGR1 promoter mediated highest glucose-responsive 
increase in human insulin secretion in PBMMSCs (Figure 17A). The threshold for stimulating 
insulin secretion was 5 mM glucose (P=0.0145 cf. 2.5 mM glucose, P=0.0037 cf. 10 mM 
glucose). EGR1 promoter segment A, (EGR1(A); nucleotides 18 to 215 of the full length 
promoter. Nucleotides numbered as in AJ245926.) did not respond to glucose while EGR1 
promoter segments B (EGR1(B); nucleotides 215 to 424 of the full length promoter) and C 
(EGR1(C); nucleotides 402 to 677 of the full length promoter) showed more moderate increase 
in 20 mM glucose. While all three promoter segments contained at least one putative ChoRE, it 
is possible that the longer full length promoter provided a conformationally more stable structure 
for the binding of transcription factors.  
As EGR1 expression has been reported to be stimulated by insulin, it was possible that a 
construct in which the EGR1 promoter is used to drive insulin expression could have undesirable 
feed forward characteristics and could cause hypoglycaemia in vivo. We therefore tested the 
characteristics of human insulin transgene secretion from PBMMSCs transfected with such a 
construct (Figure 17B). We showed no significant increase of C-peptide secretion when the 
transfected cells were incubated for an hour with 5 mM glucose supplemented with physiological 
concentrations of insulin added in recombinant form (human reference range: 1-30 µU/ml or 6-
180 pM). However, in agreement with reports of stimulated EGR1 expression by nanomolar 
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concentrations of insulin10,11,12, we also detected significant increases in C-peptide secretion 
when cells were incubated with recombinant insulin in concentrations that were more than 25-
fold higher than the physiological range in humans i.e. 5 nM. These insulin concentrations have 
never been reported, even in patients with pathological hyperinsulinaemia13. Insulin induction 
was nonetheless not seen in EGR1(B)-modified cells even when stimulated with 5 nM insulin, 
possibly because this promoter segment has only three copies of serum REs and does not contain 
binding sites and response elements such as Sp1 binding site and cAMP REs (implicated in 
insulin-regulated gene transcription).  
EGR1 expression has also been reported to be stimulated by a range of stressful 
conditions. We thus also examined the effect of a potent glucocorticoid, dexamethasone, on the 
activity of the EGR1 promoter (Figure 17C). Possible stimulation by glucocorticoids (cortisol) is 
a greater clinical concern than other known stimuli of EGR1 expression because stressors are 
common, and if shown to activate the EGR1 promoter to induce insulin transgene transcription, 
may well cause inappropriate and significant hypoglycaemia. In contrast to recent reports that 
demonstrated dexamethasone regulation of EGR1-directed gene transcription14, we did not 
observe similar results. This discrepancy may be due to differences in glucocorticoid 
concentrations that we and other investigators used. We showed that, at 2.5 to 20 nM 
dexamethasone (human reference range: 5–53 nM serum free cortisol; 1 nM dexamethasone =38 
nM cortisol), no significant increase in insulin secretion was observed in all modified cells. 
We characterised the kinetics of glucose-inducible insulin secretion by PBMMSCs 
electroporated with pSEAP under the SV40 promoter (as control) and a human insulin construct 
having either the full length EGR1 promoter (Figure 18A) or the EGR1(B) promoter segment 
(Figure 18B) in a series of perifusion experiments similar to those described with insulin-
secreting primary mouse hepatocytes (section 2.1.5). The only difference in experimental design 
in these experiments compared to earlier kinetic perifusion studies was that changes in glucose 
concentration during perifusion were made to occur gradually instead of the abrupt transitions 
between low and high glucose concentrations in our earlier experiments (Figure 2C) (Appendix 6 
shows the experimental set-up). This pattern of more gradual increase and decrease in 
extracellular glucose levels was intended to simulate post-prandial glucose excursions in vivo. 
Human insulin in the perfusate collected from EGR1 full length promoter-modified cells rose 
steadily concurrently with the increase in glucose concentration. In contrast, neither the insulin 
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concentration in the perifusate collected from EGR1(B)-modified cells nor SEAP activity levels 
in both perifusates increase in tandem with glucose exposure. When the glucose concentration 
perifusing the cells was gradually lowered by constant addition of glucose-free medium, insulin 
levels declined more slowly, resembling our earlier observation in the murine hepatocyte 
experiments (Figure 2C). Insulin secretion did not return to the basal level even after 120 
minutes of exposure to reduced glucose concentration, possibly because the glucose 
concentration was still higher than the threshold for insulin induction, i.e. 5 mM. Nonetheless, 
the insulin levels did decline after exposure to lower glucose concentrations. It is interesting to 
note that the insulin secretion from EGR1(B)-modified cells declined more rapidly than its full 
length counterpart, probably because these cells made less insulin transcript during which they 
were induced by high glucose concentration, consistent with the data obtained from the static 
glucose induction experiment (Figure 17). 
These results were in agreement with recent findings indicating that EGR1 expression is 
rapidly induced by glucose. For instance, several reports showed that EGR1 is rapidly expressed 
to regulate a cascade of downstream multiple promoters involved in transcribing genes important 
for glucose homeostasis. Specifically, EGR1 regulates the promoters of insulin15, Pdx-116, malic 
enzyme10 and gonadotropin-releasing hormone genes11, among others4. Thus, EGR1 promoter 
activation is a rapid event upstream of the transcription of many genes implicated in glucose 
regulation.      
Taken together, these results indicated that human EGR1 promoter is glucose-sensitive 
and thus is a good candidate promoter for insulin gene therapy using BMMSCs. 
2.3.7 Stably-modified porcine BMMSCs secreted less human insulin than circular 
plasmid-electroporated porcine BMMSCs 
As PBMMSCs are mitotic cells, genomic integration of the insulin expression construct 
in transfected cells could be expected to maintain its stable propagation and could theoretically 
confer durable insulin expression, while non-integrating plasmids will be lost as transfected cells 
divide. A total 10 insulin-expressing stable clones were generated by electroporation of 
linearised pTopo3EGR1chINS encoding a neomycin/kanamycin resistance gene, followed by 
selection and enrichment with Geneticin®. These clones were tested for glucose-inducible insulin 
secretion compared to circular plasmid-electroporated cells. Stably-modified cells secreted 
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significantly less insulin than circular plasmid-electroporated cells (Figure 19A). PCR 
amplification of the full length insulin cassette in all 10 insulin-expressing clones indicates that 
integration of a truncated insulin cassette was not the cause of the low insulin expression levels 
observed (Figure 19C).              
Concomitant with lower insulin secretion, the most productive stable clone also did not 
show characteristic glucose-induced insulin secretion in contrast to PBMMSCs electroporated 
with the same insulin construct in circular form (Figure 19B). Lower levels of insulin secretion 
in stably-modified cells was likely due, in part, to lower copy number of the insulin construct 
compared to cells electroporated with the same construct in circular form. This explanation 
appears plausible given that electroporation is capable of delivering thousands of DNA 
molecules into nuclei17.  Another possible reason for lower insulin production was integration of 
the transgene into genomic regions that were less accessible to transcription factors that drive 
insulin expression. However, we consider this to be less probable because genomic integration in 
mitotic cells usually occurs in transcriptionally active euchromatin18,19.  
2.3.8 Xenogeneic implantation of pTopo3EGR1chINS-modified primary PBMMSCs into 
NOD-SCID mice 
The performance of modified primary PBMMSCs in vivo was evaluated in a small 
animal model by xenogeneic implantation into non-diabetic and STZ-diabetic NOD-SCID mice. 
The EGR1 promoter-human insulin construct was evaluated in non-diabetic mice in vivo to 
assess the risk of induced hypoglycaemia from glucose-independent insulin expression. 
Inappropriately high levels of transgenic human insulin secretion in the face of hypoglycaemia 
would disqualify the modified PBMMSC as a quasi-physiological source of insulin. In contrast, 
low and stable human insulin output associated with normoglycaemia, without incurring 
hypoglycaemia, would go some way to confirming acquired glucose-sensitivity and, particularly, 
demonstrate the desired functional characteristics of insulin expressed from the EGR1 promoter.  
STZ-induced diabetes in NOD-SCID mice 
NOD-SCID mice were used as the recipient host for the modified PBMMSC xenografts. 
Being T and B lymphoid cell-deficient20, NOD-SCID mice could be expected not to mount any 
significant cell-mediated immune destruction of transplanted xenogeneic cells. In contrast to 
NOD mice that spontaneously develop T-cell mediated T1D, NOD-SCID mice do not naturally 
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become diabetic. Therefore, diabetes was induced with STZ. In contrast to C57BL/6J mice that 
require four consecutive daily intraperitoneal (IP) injections of STZ (100 mg/kg body weight) to 
become hyperglycaemic, diabetes in NOD-SCID mice can be induced with only three 
consecutive daily IP injections of the same STZ dose. This is likely due to the greater sensitivity 
of NOD-SCID mice to β-cell ablation by STZ21. In this study, the diagnostic threshold for 
hyperglycaemia in NOD-SCID mice was 19.34 mM (5 s.d.’s above the mean blood glucose of all 
mice before the experiment commenced). In general, male mice were more susceptible to STZ 
insult (83.0% cf. 62.5% in female NOD-SCID mice), an observation that was made also in 
C57BL/6J mice. Our experience with the incidence of STZ-induced diabetes in mice confirmed 
the known dependence on animal strain and sex of susceptibility to STZ22. Even though the dose 
of STZ used induced sustained hyperglycaemia (25.31±0.81 mM) in a majority of male mice, 
17% (8/47) failed to develop diabetes even after an additional STZ injection at the same dose.  
STZ dosage based on body weight does not always induce diabetes, regardless of animal 
species.  Work on non-human primates appears to have shed some insights into this 
phenomenon. Until recently, diabetes was induced in non-human primates by STZ dosed by 
body weight (i.e. mg STZ/kg body weight). However, Wijkstrom et al. reported that regimen of 
STZ dosed by body surface area, i.e. mg/m2, was more reliable in inducing diabetes and was 
associated with lower toxicity23.  
Efficacy of insulin-secreting PBMMSCs in vivo: intrahepatic implantation  
In view of the positive results of our work on hepatocytes, we first implanted the 
modified PBMMSCs into the liver parenchyma (intrahepatic, IH) by direct interstitial injection 
using a 27G needle. The outcome measures of PBMMSC implantation were (a) moderation of 
hyperglycaemia; (b) improved glucose tolerance; (c) detection of plasma human insulin; (d) and 
(d) serial body weights as evidence of metabolic restitution. Plasma mouse C-peptide levels were 
monitored to confirm total functional ablation and non-regeneration of endogenous β-cells 
during the study period. An additional variable in the experimental design was to implant 
different cell numbers, i.e. 2 and 5x106 cells. This was to determine if therapeutic efficacy was 
“dose-dependent” in light of our data from the diabetic porcine model that treatment outcomes 
correlated with the number of modified hepatocytes implanted. For ease of explanation, Table 5 
provides an overview of the experimental design. 
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Similar to results from the murine hepatocyte work, we observed normalisation of 
hyperglycaemia 3 days after implantation of plasmid-electroporated PBMMSCs (Figure 20A). 
Concurrently, human insulin was clearly detected in the plasma of both groups of diabetic mice 
implanted with either 2 or 5x106 cells (96.84±27.75 and 306.47±33.53 pM, respectively) (Figure 
21B). Glucose tolerance also improved during the 1st post-implantation week (P=0.0015 and 
<0.0001 for 2 and 5x106 cells, respectively, cf. the untreated diabetic phase of all mice) (Figures 
22A,B&D). Interestingly, non-diabetic mice also had significant reductions in blood glucose 
concentrations 3 days after IH-implantation of modified cells (2x106 cells: 7.42±0.31 mM cf. 
10.19±0.75 mM before implantation; 5x106 cells: 6.91±0.28 mM cf. 10.26±0.40 mM before 
implantation. P<0.0001 for both comparisons) (Figure 20B). In interpreting these findings, it 
should be noted that non-diabetic NOD-SCID mice had significantly higher glycaemic levels 
(10.23±0.58 mM) than C57BL6/J (6.51±0.77 mM) that were clearly above the threshold of 5 
mM for glucose-activation of the EGR1 promoter established from in vitro experiments (Section 
2.3.6, Figures 17&18). Circulating human insulin was also detected, albeit at concentrations 
significantly lower than diabetic mice implanted with similar cell number (36.81±4.84 pM cf. 
212.62±40.08 pM in IH-implanted diabetic mice) (Figures 21A&B). However, glucose tolerance 
of these control non-diabetic mice was unaltered by implantation of modified PBMMSCs 
(Figures 22A&C). Taken together, these data from comparably implanted non-diabetic and 
diabetic mice indicate that the EGR1 promoter-insulin construct functions in an appropriate 
glucose-sensitive manner in vivo.  
Xenotransplantation limited durability of efficacy: intrahepatic implantation 
These encouraging results were however not durable in both diabetic and non-diabetic 
mice. Compared to the third post-implantation day, blood glucose concentrations increased 
(Figure 20B) and plasma human insulin concentrations declined (Figure 21B) in both cell-treated 
groups from day 7 onwards. Autopsies were therefore performed on some of these mice to 
investigate the cause. We observed evidence of liver necrosis i.e. patches of white and hard 
tissue. Further, histopathological examinations of H&E sections showed gross features of 
multiple venous thrombi (Figure 24A), which may have caused tissue ischaemia and a pattern of 
geographical necrosis with a centrilobular distribution in the liver (Figure 24D). Moreover, 
thrombi were engulfed by inflammatory cells (Figure 24C), suggesting that acute rejection of the 
164 
 
transplanted PBMMSCs may have occurred24. Unlike T-cell-mediated rejection, no 
endothelialitis was observed in the hepatic central veins (Figure 24B). All these histopathological 
features strongly indicate activation of an innate immune response provoked by implanting 
xenogeneic cells in the liver. Although this might appear surprising in an immunocompromised 
host recipient that is deficient in T and B lymphoid cells, recent evidence showed that NOD-
SCID mice retain the capacity to mount a competent innate immune response by mobilising 
monocyte, macrophage and neutrophil populations25. Neutrophils and monocytes were shown to 
activate resident macrophages (such as Kuppfer cells in the liver), which were rapidly deployed 
to target implanted xenogeneic cells26. However, as it is known that macrophages are unable to 
induce cell killing efficiently in the absence of T-cells, this could explain the less destructive 
innate immune response we observed in the NOD-SCID mice. This was reflected by a gradual 
rather than an abrupt decline in the performance of the implanted PBMMSCs. For instance, 
human insulin secretion from these cells was still detected 12 days post-implantation (Figures 
21A&B).  
Intraperitoneal xenotransplantation  
In an attempt to prolong the therapeutic efficacy, we implanted the modified PBMMSCs 
intraperitoneally (IP) into NOD-SCID mice to avoid rapid stimulation of the innate immune 
response. Direct implantation of modified PBMMSCs into the peritoneal cavity also minimises 
the complications and morbidity of IH implantation. Notwithstanding that IP implantation is 
surgically less invasive, it has several limitations. Firstly, it is not possible to quantitatively 
recover the cells once they are implanted; secondly, implanted cells may not engraft and survive 
if they fail to vascularise promptly; thirdly, human insulin is not secreted directly into the blood 
and thus the time course of glucose-induced systemic insulin activity may be delayed.  
Two variables were tested in intraperitoneal implantation experiments. These were (a) the 
nature of transgenic modification of PBMMSCs i.e. whether electroporated with circular plasmid 
DNA or selected for stable integration of the linearised insulin transgene, and (b) cell number. 
Independent of all other experimental variables, mean blood glucose levels (on days 3, 7, 
12, 16, and 21 post-implantation) of all IP-implanted diabetic mice were significantly lower than 
mock-implanted diabetic mice (IP=18.93±1.05 mM; mock-implanted=27.81±1.08 mM; 
P<0.0001) (Figure 20A).  
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(a) The method of cell modification had also influenced the tempo of glycaemic trends. 
Specifically, hyperglycaemia of mice IP-implanted with circular plasmid-electroporated cells 
improved sooner than mice IP-implanted with stably-modified cells (circular plasmid-
electroporated=13.87±0.61 mM; stably-modified=16.05±0.70 mM on day 7; P=0.0087) (Figure 
20C) consistent with higher human insulin expression in vitro (Figure 19). However, reversal of 
glycaemic improvement in diabetic mice implanted with circular plasmid-electroporated cells 
also occurred before that of diabetic mice implanted with stably-modified cells (circular plasmid-
electroporated=22.58±0.60 mM; stably-modified=17.03±0.48 mM on day 16; P<0.0001) (Figure 
20C). GTT data confirmed the more rapid loss of therapeutic effect. While glucose tolerance was 
similar in both groups of diabetic mice in the 1st week post-implantation (P=0.6173), mice IP-
implanted with circular plasmid-electroporated cells had significantly poorer glucose tolerance 
compared with mice IP-implanted with the same number of stably-modified cells by the 3rd week 
post-implantation (P<0.001) (Figure 22E). Notwithstanding rising glycaemic and declining 
plasma human insulin levels in both groups over the 30-day observation period, therapeutic 
efficacy was more durably sustained in diabetic mice IP-implanted with stably-modified cells 
(Figures 20C, 21C and 22E).  
Failure to maintain glycaemic improvement was likely due to immunological rejection of 
xenogeneic cells. Exacerbating the loss of efficacy in diabetic mice implanted with circular 
plasmid-modified cells was possibly due to concomitant vector loss if cell division occurred in 
vivo. Although the doubling time of PBMMSCs in vitro is 2-5 days, our data suggest that in vivo 
proliferation rate of these circular plasmid-transfected cells may be much slower. Thus, they 
were still sustaining plasma human insulin levels (129.55±14.99 pM) on day 12 (Figure 21D) 
sufficient to maintain an improvement in hyperglycaemia (18.28±0.42 mM) that was not 
significantly different from that on day 3 (18.30±0.68 mM, P=0.8783) (Figure 20C). In contrast, 
we infer that stably-modified cells did not proliferate in vivo as glucose tolerance had 
deteriorated by the 3rd week post-implantation compared to the 1st week (P<0.0001) (Figure 22E). 
The likely explanation for this was that in vitro selection required multiple cell doublings prior to 
implantation and this process had brought these primary cells to near-senescence27.    
(b) IP-implantation with higher cell number may moderate the decline in therapeutic 
efficacy. For instance, IP-implantation with 5x106 circular plasmid-electroporated cells was 
associated with significantly higher plasma human insulin concentrations than implantation with 
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2x106 cells for at least 16 days (plasma human insulin: AUCday3-16= 2558±277 (5x106 cells) cf. 
1664±109 (2x106 cells); P=0.0065) (Figure 21D) with concomitant reduction in blood glucose 
concentrations (Figure 20D). Similarly, IP-implantation of a larger number of stably-modified 
cells yielded higher concentrations of plasma human insulin (Figure 21E) and lower blood 
glucose levels (Figure 20E) throughout the observation period. Consistent with these results, the 
“cell-dosing” effect was also observed in GTTs. Specifically, diabetic mice IP-implanted with 
5x106 stably-modified cells had significantly better glucose tolerance than mice implanted with 
2x106 cells (AUC0-90 = 4587±716 [5x106 cells] cf. AUC0-90 = 6361±508 [2x106 cells]; P=0.0487) 
(Figure 22H). Similarly, diabetic mice IP-implanted with 5x106 circular plasmid-electroporated 
cells had better, albeit not quite significant, overall glucose tolerance than mice implanted with 
2x106 cells (AUC0-90 = 4174±613 [5x106 cells] cf. AUC0-90 = 5438±482 [2x106 cells];  P=0.1781) 
(Figure 22G). However, we noted that mice implanted with the higher cell number did show 
significantly improved glucose tolerance in the second phase of the glucose challenge i.e. from 
30 minutes onwards of the GTT (AUC30-90 = 3638±423 [5x106 cells] cf. AUC30-90 = 4811±338 
[2x106 cells]; P for AUC30-90 = 0.0039). This was consistent with a “cell-dosing” effect that 
appeared slightly delayed in onset in this experiment.  
As in IH-implantation, IP-implantation of modified PBMMSCs in non-diabetic NOD-
SCID mice also had a blood glucose-lowering effect (Figure 20F). Low but detectable levels of 
human insulin were assayed in the plasma of these implanted mice (Figures 21A&C). These 
results further strengthen our contention that the EGR1 promoter, which directed expression of 
transgenic human insulin, was indeed sensitive to physiological glucose concentrations. The fact 
that the lowest blood glucose level ever measured in these mice i.e. 6.4 mM is worth noting and 
provides additional evidence to support the safety of the EGR1 promoter.   
As in streptozotocin-diabetic mice, a similar trend of glucose tolerance was observed in 
non-diabetic mice IP-implanted with cells that were modified differently. Specifically, while 
glucose tolerance was comparable in all non-diabetic mice in the 1st  week post-implantation 
regardless of the method of cell modification, mice implanted with stably-modified cells had 
better glucose tolerance than mice implanted with circular plasmid-electroporated cells in the 3rd 
week after implantation (P=0.1789) (Figure 22F). This is consistent with the observation in 
diabetic mice that IP-implantation of stably-modified PBMMSCs provided more durable 
glycaemic improvement than IP-implantation of circular plasmid-electroporated cells.    
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Intrahepatic vs. intraperitoneal xenotransplantation 
The site of cellular implantation had no significant influence on mean blood glucose 
concentrations of diabetic mice monitored for 21 days (P=0.8298) (Figure 20A). However, the 
temporal profiles of glycaemic improvement were different in IH- and IP-implanted diabetic 
mice. Hyperglycaemia was more rapidly corrected in IH- than in IP-implanted mice i.e. 
significantly lower blood glucose levels 3 days after implantation (14.97±1.15 mM cf. IP-
implanted diabetic mice 18.41±0.42 mM; P=0.0026) (Figure 20A). This early effect was likely 
due to prompt vascularisation of implanted cells by liver sinusoids and consequently, a higher 
proportion of early engrafted cells compared to cells placed within the peritoneal cavity. 
However, this trend was reversed from day 7 onwards such that, by day 21, blood glucose values 
of IP-implanted diabetic mice had become significantly lower than IH-implanted diabetic mice 
(IH=23.70±0.23 mM; IP=19.96±0.79 mM; P=0.0313) (Figure 20A). IP-implanted mice also had 
better glucose tolerance than IH-implanted mice on day 7th post-implantation (P=0.0581) (Figure 
22C). All IH-implanted mice showed an unremitting upward glycaemic trend after the 3rd post-
implantation day regardless of the number of modified cells implanted (Figure 20B) and the 
nature of cellular modification (Figure 20C).The gradual loss of efficacy was consistent with the 
onset of an acute innate rejection of xenogeneic cells (Figure 24). In contrast, IP-implanted 
diabetic mice showed a slower loss of efficacy over a 30-day observation period, possibly from 
delayed macrophage recruitment into this less vascularised compartment. Compared to IP-
implanted cells, contact of IH-implanted cells with Kupffer cells in the recipient liver may have 
rendered donor cells more readily poised for destruction by macrophages.  
Concomitant with their improved glycaemic status, body weight loss was arrested in all 
IP-implanted diabetic mice (P=0.2378, nadir body weight cf. body weight on day 30) (Figure 
23A). Consistent with the foregoing differences in durability of therapeutic effect, diabetic mice 
implanted with circular plasmid-electroporated cells had lost significant weight by day 30 
(P=0.0303 cf. nadir body weight) unlike mice implanted with stably-modified cells whose body 
weights remained stable throughout the experiment (P=0.5674 cf. nadir body weight) (Figure 
23B).  
In contrast to IP-implanted animals, all IH-implanted and mock-implanted diabetic mice 
had significant weight loss over 21 days (P<0.0001) (Figure 23A).  
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Absence of endogenous mouse insulin expression 
To determine if secretion of residual endogenous mouse insulin contributed to the 
foregoing outcome measures in any group of animals, we obtained plasma samples from all mice 
on the day of sacrifice. Mouse C-peptide levels were quantitated using mouse C-peptide 
radioimmunoassay kit that did not cross-react with human insulin and was <0.1% cross-reactive 
with human C-peptide (Linco Research). Endogenous mouse C-peptide levels in plasma samples 
of diabetic mice were 4.22±0.87% of control non-streptozotocin treated mice, indicating that 
incomplete ablation and/or regeneration of endogenous β-cells was unlikely (Figure 21F).      
2.3.9 Bioactivity of secreted transgenic human insulin 
 To determine if the secreted transgenic human insulin possessed bioactivity, we 
performed IPGTT on diabetic mice injected with conditioned medium aspirated from PBMMSCs 
in culture. Glucose tolerance was improved in diabetic mice injected with 400 and 800 µl of 
conditioned medium aspirated from stable insulin-secreting PBMMSC culture (medium with 
insulin) compared with mice injected with 800 µl of conditioned medium aspirated from 
unmodified PBMMSCs (medium without insulin) (P=0.0118 and 0.00012 for 400 and 800 µl, 
respectively, cf. medium without insulin) (Figure 25A). The glucose tolerance data showed a 
dose dependent trend as injection with higher volumes of medium with insulin resulted in 
significantly improved glucose tolerance (Figure 25B) (P=0.0428 and 0.0172, respectively, 200 
cf. 400 µl  and 400 cf. 800 µl medium). In contrast, injection with smaller volumes i.e. 100 and 
200 µl of medium with insulin did not improve the glucose tolerance of the diabetic mice.      
 In conclusion, notwithstanding the challenging conditions attending transplantation of 
xenogeneic cells into NOD-SCID mice, our data demonstrate that human insulin transgene-
modified PBMMSCs were capable of secreting human insulin in response to pathophysiological 
blood glucose levels, and improved the glycaemic profiles of STZ-diabetic mice for at least 30 
days. We envisage that implantation of autologous PBMMSCs stably-modified with insulin 
transgene under the regulation of EGR1 promoter could provide an in vivo source of quasi-
physiological glucose-regulated insulin secretion to restore euglycaemia durably in diabetic pigs, 





Table 4 Glucose-induced transcripts in cultured human bone marrow-derived 
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Human BMMSCs cultured overnight in DMEM/3 mM glucose (as the low glucose baseline) were 
exposed to DMEM-20 mM glucose (high glucose) for 15 or 30 mins, and then returned to 
DMEM-3 mM glucose for 30 or 60 mins (5x105 cells/plate, 3 plates for each time point). Cells 
from each time point were pooled and lysed for RNA isolation. Total RNA was processed for 
microarray hybridisation on Affymetrix U133 Plus 2.0 ArrayGeneChip®. Significant changes in 
signal intensities (expressed as -fold change) relative to the baseline (cells cultured overnight in 
3 mM glucose) are shown for each condition of glucose exposure and are the means of data from 
two arrays. EGR1 and FOS were confirmed to be glucose-induced transcripts by semi-
quantitative RT-PCR performed on cDNAs hybridised to the arrays. The fold change of mRNA 
for each experimental condition after glucose stimulus/mRNA at baseline was calculated by 
standard ∆∆CT analysis using human HPRT mRNA as internal control. Mean and s.d. of 




Figure 13 Characteristics of porcine BMMSC in culture. (A) Adherent PBMMSCs adopted a 
fibroblast-like morphology in culture 10 days after initial plating; original magnification 100x. 
(B) Passage 3-4 PBMMSCs were trypsinised and 1 x 105 cells were seeded in each 60 mm dish, 
cultured with one of three media: (1) α-MEM with Glutamax™ supplemented with 20% FCS; (2) 
Serum-free StemPro™ medium; and (3) α-MEM with Glutamax™  and StemPro™ in 3:1 (v/v) 
ratio supplemented with 10% FCS. All media contained 100 µg/ml streptomycin and 100 IU/ml 
penicillin. On the days indicated, cells were detached and the total cell number was enumerated 




Figure 14 Fluorescence-activated cell sorting (FACS) analysis of porcine BMMSCs. Adherent 
porcine bone marrow-derived cells were detached from culture flasks and dissociated into single 
cells with Accutase™ (eBioscience, USA). Cells were stained with either anti-CD90 (THY1) 
antibody conjugated with FITC, anti-CD11b (ITGAM) antibody conjugated with APC or co-
stained with both antibodies for bivariate analysis (left panels). Control scatter plots of 
fluorescence from matched isotype staining of each sample are shown in panels on the right. A 
total of 10,000 events were acquired for each sample on the FACSCalibur (BD Biosciences) and 
data were plotted using FlowJo software (Treestar). Data shown are representative of 3 separate 





Figure 15 Electroporation of primary human and porcine BMMSCs. Primary human (left 
panel) and porcine (right panel) BMMSCs were electroporated with endotoxin-free pSEAP or 
pEGFP plasmids, 5 µg DNA/2x106 cells in NC solution using a commercial pulse generator 
(BTX Instrument Division, Harvard Apparatus, Inc.) and 2-millimeter gap cuvettes.  
(A) Optimisation of gene transfer into HBMMSCs and PBMMSCs at different electrical pulse 
settings. SEAP activities were assayed from culture aspirates 48 h after electroporation with 
pSEAP (2x105 cells/plate, 3 plates for each pulse setting; SEAP activity was assayed in 
duplicate). Cell viability after each electroporation (n=2) was measured by trypan blue 
exclusion test and a haemocytometer. The optimum gene transfer settings for HBMMSCs and 
PBMMSCs were 150 V for 15 ms and 200 V for 10 ms, respectively. Data are mean ± s.e.m.. 
Original magnification 100X for both images.  
(B) Representative appearance of pEGFP-electroporated HBMMSCs and PBMMSCs. High 
transfection efficiency and viability (>80% for both) were reproducibly achieved in BMMSCs of 







(C) Semi-quantitative PCR (50 cycles) was performed on genomic DNA isolated from (i) 
unmodified (i.e. untransfected) PBMMSCs as negative control, (ii) pTopo3EGR1chINS-stably-
modified PBMMSC clone 5 generated by electroporating the linearised plasmid; and (iii) 
PBMMSCs electroporated with the same plasmid in circular form. To ensure no contamination 
of genomic DNA by circular plasmid DNA, electroporated cells were cultured for several cell 
doublings before isolation of genomic DNA. Two different concentrations of genomic DNA from 
the electroporated PBMMSCs (pooled from at least 3 separate electroporations) were used as 
template. Two pairs of PCR primers amplifying 2 different regions of the plasmid were tested, 
i.e. primers set 1: between EGR1 promoter and human (pro)insulin cDNA (165 bp); and primers 
set 2: within the neomycin resistance gene (117 bp). Amplified DNA, if present in each genomic 
DNA preparation, would be visualised in the left and right column with primer set 1 and set 2, 
respectively. Note that no amplification was observed from genomic DNA prepared from 
PBMMSCs electroporated with circular plasmid regardless of the concentration of input DNA 







Figure 16 Temporal response of EGR1 promoter to extracellular glucose concentrations in 
human BMMSCs. (A) Human EGR1 promoter (orange bars) mediates glucose-regulated 
expression of SEAP reporter protein in primary human BMMSCs, unlike the SV40 promoter 
(blue bars). Modified cells were first incubated with medium containing 20 mM glucose for 30 
min after which the high glucose medium was replaced with medium containing 3 mM glucose 
for 90 min. Significant increase in SEAP activity was observed 10 mins after exposure to high 
glucose and de-induction within 15 mins of transfer to low glucose. The vertical axis shows 
SEAP activity at each time point as a percentage of SEAP activity in pure medium. (B)  In a 
separate experiment, HBMMSCs co-transfected with either EGR1-SEAP and CMV-EGFP or 
SV40-SEAP and CMV-EGFP were cultured in 3 mM glucose for 48h before exposure to 20 mM 
glucose for the indicated durations. Cells were then lysed for total RNA isolation (2x105 
cells/plate, n=3 for EGR1-SEAP and n=2 for SV40-SEAP at each time point) and processed for 
semi-quantitative RT-PCR of SEAP mRNA (assayed in triplicate). Note that SEAP transcripts 
expressed from the EGR1 promoter increased 1.22±0.16-fold within 5 mins of exposure to 20 
mM glucose while SEAP and EGFP transcripts from SV40-SEAP and CMV-EGFP did not 
increase throughout the experiment. (CMV-EGFP expression served as a control for transfection 
efficiency.) Arbitrary units were derived from standard ∆∆CT analysis using human 




Figure 17 Glucose inducibility of EGR1 promoter segments. Three different EGR1 promoter 
constructs were assembled and evaluated: EGR1 (full): full length promoter, 703bp (GenBank 
accession number: AJ245926);  EGR1(A): nucleotide 18-215 [contains two Sp1 binding sites, a 
cyclic AMP response element, a 12-O-tetradecanoyl phorbol 13-acetate response element, an 
Egr-1 binding site and four putative carbohydrate response elements (ChoRE)]; EGR1(B): 
nucleotide 215-424 [contains three serum response elements and a putative ChoRE]; EGR1(C): 
nucleotide 402-677 [contains a cyclic AMP response element, two serum response elements and 
a putative ChoRE] (nucleotide numbers refer to the sequence deposited as AJ245926). The 
plasmid maps of these constructs are provided in Appendix 1. The reference construct that 
served as a comparator in these experiments was the human metallothionein IIA promoter in 
p3MTchINS, which drives insulin expression in hepatocytes.  
(A) PBMMSCs electroporated with the aforementioned plasmid constructs (5 µg DNA / 2x106 
cells) were cultured in DMEM with different glucose concentrations (figure inset) for 30 mins, 
after which the culture medium was aspirated for human insulin and human proinsulin 
radioimmunoassays (1.5x105 cells/well, 3 wells for each glucose concentration). Human 
proinsulin levels were below the sensitivity of detection of the human proinsulin assay kit used 
(all radioimmunoassay kits were from Linco Research, USA).  
(B) PBMMSCs transfected as described in (A) were cultured for 60 mins in 5 mM glucose 
DMEM, supplemented with cell culture grade recombinant insulin (Sigma-Aldrich, USA) at the 
concentrations indicated. Culture medium was assayed for human C-peptide using a 
radioimmunoassay that does not cross-react with either native or recombinant human insulin. 
Note the significant induction with 5000 pM insulin (P<0.0001 cf. 500 pM insulin for 
EGR1(full), EGR1(A) and EGR1(C); P=0.6063 cf. 500 pM insulin for EGR1(B)).  
(C) Modified PBMMSCs were supplemented with a potent glucocorticoid, dexamethasone, at the 
concentrations indicated and incubated for 60 mins in 5 mM glucose DMEM. The culture 
medium was then assayed for human insulin. All other experimental conditions and assays for 




Figure 18 Kinetics of glucose-induced human insulin secretion by porcine BMMSCs. 1x 106 
PBMMSCs were co-electroporated with pSV40-SEAP and either (A) human insulin construct 
having the full length EGR1 promoter (EGR1full-insulin) or (B) human insulin construct having 
the EGR1(B) promoter (nucleotides 215-424 of the full length promoter) (EGR1(B)-insulin). 
Continuous perifusion (1 ml/min) at 37ºC in DMEM medium was performed 48h after culture, 
first with a gradient of increasing glucose concentration over 90 mins, followed by gradually 
decreasing glucose concentration over 120 mins. Perifusate fractions were collected every 5 min 
throughout each perifusion experiment and assayed for glucose concentrations (Elite® 
glucometer), human insulin (ultrasensitive human insulin kit, Linco Research) and SEAP activity 
(Clontech™ SEAP kit). All assays were done in duplicate. Insets in both panels showed that 
SEAP activity levels were independent of ambient glucose concentrations throughout. Shown are 
representative data of two experiments. The experimental set-up is shown in Appendix 6. Human 
insulin secretion was rapidly induced in PBMMSCs modified with the EGR1full-insulin 





Figure 19 Characteristics of human insulin secretion by stably-modified porcine BMMSCs.   
(A) Stable insulin-secreting PBMMSC lines were generated by electroporation of linearised 
pTopo3EGR1chINS bearing a neomycin/kanamycin resistance gene (Appendix 1), followed by 
enrichment of different clones with Geneticin® selection. (A) Ten stable clones were cultured in 
DMEM with different glucose concentrations for 30 mins, after which the culture medium was 
aspirated for human insulin radioimmunoassay (2.5x105 cells/plate, 3 plates for each glucose 
concentration). PBMMSCs electroporated with the same plasmid construct in circular form (5 
µg DNA/ 2x106 cells) served as control (2.5x105 electroporated cells/plate, 3 plates for each 
glucose concentration). Note that circular plasmid-electroporated cells secreted more human 





(B) The kinetic profile of glucose-induced insulin secretion was studied in stable clone 5. All 
experimental conditions, settings and assays were as described in Figure 6 except that control 
stable cells were electroporated with only pSV40-SEAP. Shown is the representative data of two 
experiments.  
(C) PCR using specific primers spanning the human (pro)insulin expression cassette (2.9 kb) 
was performed on genomic DNA isolated from each PBMMSC line. The positive control was 
pTopo3EGR1chINS circular plasmid while genomic DNA isolated from untransfected 
PBMMSCs served as the negative control. Note that the intact human (pro)insulin expression 




Table 5 Overview of xenogeneic implantation of modified porcine bone marrow-derived 
mesenchymal stromal cells in NOD-SCID mice. 
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Several variables were studied in vivo : (1) The number of PBMMSCs i.e. 2 x 106 or 5 x 106 were 
(2) modified by electroporation of circular plasmid DNA or of linearised plasmid followed by 
selection of cells stably integrated with the human insulin transgene, and implanted into (3) non-
diabetic or STZ-induced diabetic NOD-SCID mice. The modified cells were either (4) injected 
into the liver (intrahepatic, IH) or the peritoneal cavity (intraperitoneal, IP). The numbers in 
unshaded cells of the table indicate the number of mice in each group. Mice implanted with 
unmodified PBMMSCs were served as controls (mock-implanted). Serial body weights and blood 
glucose concentrations were determined during the experimental period as follows: day -10 
(non-diabetic phase), day -5 (diabetic phase after three STZ injections on day -9 to day -7), day 
0 (day of cell implantation), day 3 (3rd day post-implantation), day 7 (1st week post-
implantation), day 12 (12th day post-implantation), day 16 (16th day post-implantation), day 21 
(3rd week post-implantation) and day 30 (1 month post-implantation). Human insulin 
concentrations were assayed from day 3 onwards using a human-specific insulin 
radioimmunoassay. Intraperitoneal glucose tolerance tests (IPGTTs) were performed on days -






Figure 20 Glycaemic profiles of porcine BMMSC-implanted and mock-implanted non-diabetic 
and diabetic NOD-SCID mice. (A) Insulin-secreting PBMMSCs reduced hyperglycaemia in 
vivo. All blood glucose values of IH- or IP- implanted non-diabetic or diabetic mice (days 3-30) 
were pooled for analysis regardless of the implanted cell number and mode of cell modification. 
The mean blood glucose concentrations were significantly lower in IH- and IP-implanted 
diabetic mice compared with mock-implanted diabetic mice, P<0.0001 for * cf. ** and * cf. ***. 
The mean blood glucose concentration of IH-implanted diabetic mice was significantly lower 
than IP-implanted diabetic mice on day 3, P=0.0026 (both groups received 5x106 cells). This 
situation was reversed on day 21 when the mean blood glucose concentration of IP-implanted 
mice was significantly lower, P=0.0313. PBMMSC-implanted non-diabetic mice had lower 
blood glucose values than mock-implanted non-diabetic mice, P=0.0128 (# cf. ##)  
(B) The effect of cell number on therapeutic efficacy of IH-implantation was evaluated. Diabetic 
mice implanted with 5x106 cells were significantly less hyperglycaemic than mice implanted with 
2x106 cells on day 12  (P=0.0431). However, the effect waned after the first 12 days and the 
difference was not significant (P=0.2801) by day 21. In contrast, cell number had no significant 




(C) The effect of the mode of modification, i.e. circular plasmid-electroporated or stably-
modified cells was investigated by comparing the outcome of IP-implantation of 5x106 cells into 
diabetic or non-diabetic mice. From day 16 until day 30, stably-modified PBMMSCs induced 
significantly lower blood glucose concentrations in diabetic mice (P=0.0475, * cf. ** from days 
3-30) (P<0.0001 for days 16, 21 and 30) but not in non-diabetic mice (P=0.7630, # cf. ##).   
(D) The influence of cell number on ameliorating hyperglycaemia was evaluated in IP-implanted 
diabetic mice. Cells were electroporated with circular plasmid immediately before implantation. 
Overall, the number of cells implanted did not significantly influence glycaemic improvement 
obtained  (P=0.3160, * cf. **). Nonetheless, significantly lower blood glucose levels were 
recorded in diabetic mice IP-implanted with higher cell number on day 3 post-implantation 




(E) An analysis similar to panel (D) was performed on stably-modified cells IP-implanted into 
diabetic mice. The generally lower blood glucose levels achieved by implanting 5x106 cells did 
not quite reach significance (P=0.0560, * cf. **). However unlike cells electroporated with 
circular plasmid, stably-modified cells had a more durable therapeutic effect in diabetic mice 
implanted with the higher cell number (P=0.0487 on day 30).  
(F) IP and IH implantation of non-diabetic mice with 5x106 circular plasmid-electroporated 
cells did not induce hypoglycaemia. The lowest blood glucose levels recorded exceeded 6 mM, 




Figure 21. Plasma human insulin in PBMMSC-implanted mice. Human insulin was quantified 
in plasma of mice implanted with modified cells using a radioimmunoassay for human insulin 
that had no cross-reactivity with mouse insulin and mouse C-peptide. AUC, derived from graphs 
of plasma human insulin concentrations vs. time, was an integrated measure of insulin secretion 
over the observation period and, where indicated, was used for analyses of significance.  
(A) Sites of cell implantation were compared in non-diabetic and diabetic mice. Generally, 
diabetic mice IP-implanted with modified PBMMSC had higher human insulin concentrations 
than IH-implanted mice (P=0.0003, * cf. **). However, plasma human insulin concentrations 
increased more promptly after IH implantation (P<0.0001, * cf. ** on day 3) while IP-implanted 
cells secreted significantly more human insulin from day 7 onwards (P<0.0001, * cf. ** on day 
7). Plasma human insulin concentrations in IH-implanted diabetic mice declined rapidly after 
day 3 (P<0.0001, day 3 cf. day 7). IP-implanted non-diabetic mice also had significantly higher 
plasma human insulin concentration than IH-implanted mice (P=0.0018, # cf. ##).  
(B) The effect of IH-implanted cell number (circular plasmid-electroporated )on plasma human 
insulin concentration was evaluated . Plasma insulin levels were significantly higher in diabetic 
mice implanted with 5x106 cells (P=0.0007, * cf. **). This difference did not persist beyond the 
12th day after implantation (P=0.1087, * cf. ** on day 12). Plasma human insulin concentrations 
in these mice declined rapidly from day 3 onwards (P<0.0001, day 3 cf. day 7 of **). In contrast 
to diabetic mice, the number of implanted cells did not significantly influence plasma human 




(C) The method of cell modification on human insulin secretion was analysed in IP-implanted 
mice. Stably-modified cells were associated with significantly higher plasma human insulin 
levels in both diabetic (P=0.0044, * cf. **) and non-diabetic mice (P=0.0087, # cf. ##). Circular 
plasmid-electroporated cells induced significantly higher plasma human insulin levels sooner 
after implantation (P=0.0453, * cf. ** on day 7). However, this declined sharply after day 7 such 
that by day 12, plasma human insulin concentration in these diabetic mice was lower than 
corresponding plasma samples from mice implanted with stably-modified cells (P=0.0014,  * cf. 
** on day 12). Human insulin output from IP-implanted stably-modified cells also declined 
steadily from day 12 onwards, reaching a significantly lower level on day 21 cf. day 7 
(P=0.0389). Modified cells implanted in non-diabetic mice likewise showed a declining trend of 
human insulin secretion, especially circular plasmid-electroporated cells from which insulin 
secretion was almost undetectable by day 16.  
(D) The effect of plasmid-electroporated cell number on human insulin secretion was assessed in 
IP-implanted diabetic mice. Mice implanted with more cells had higher plasma human insulin 
concentration (P=0.0291). The difference was significant in the early treatment period i.e. days 




(E) The outcome of implanting higher number of stably-modified cells in the peritoneal cavity of 
diabetic mice was evaluated. Plasma human insulin concentrations were higher in animals 
implanted with 5x106 cells than with 2x106 cells (P=0.0149). In contrast to circular plasmid-
electroporated cells, the therapeutic efficacy of IP-implanted stably-modified cells was quite 
stable throughout the experimental period (P=0.0097 * cf. ** on day 30). (F) Plasma mouse C-
peptide of all NOD-SCID mice in the experiment. Plasma samples obtained from all mice before 
killing were assayed for mouse C-peptide to ascertain the degree of endogenous insulin 
production. The radioimmunoassay for mouse C-peptide did not cross-react with human insulin 
and was <0.1% cross-reactive with human C-peptide (Linco Research).  Both treated and mock-
implanted diabetic mice had significantly lower levels of plasma mouse C-peptide than non-
diabetic controls (P<0.0001 for all comparisons). Treatment of non-diabetic mice was not 
associated with significant differences in mouse C-peptide levels compared with control 





Figure 22 Glucose tolerance of PBMMSC-implanted and mock-implanted non-diabetic and 
diabetic NOD-SCID mice. Glucose (75 mg/ml saline) was administered to all mice (i.p. 1.5 mg/g 
body weight) on day -10 (normal, non-diabetic phase), day -5 (diabetic phase), day 7 (1st week 
post-implantation) and day 21 (3rd week post-implantation). Blood glucose levels were 
determined at 0, 10, 20, 30, 45, 60 and 90 min. AUC values, derived from graphs of blood 
glucose concentration vs. time, were used to calculate statistical significance.  
(A) All mice had significantly worse glucose tolerance after STZ-induction of diabetes cf. the 
non-diabetic phase (P<0.0001). While all diabetic mice had improved glucose tolerance after 
cell implantation (P<0.0001, ** cf. #), cell implantation in non-diabetic mice had no measurable 
effect on glucose tolerance (P=0.6981, * cf. ##). Nevertheless, cell treatment in diabetic mice did 
not completely restore glucose tolerance to that in the non-diabetic phase (P=0.0246, * cf. #). 
(B) At the 1st week post-implantation, all mice implanted with modified cells regardless of the 
mode of modification, cell number and implantation site, had improved glucose tolerance 
compared with mock-implanted diabetic mice (P<0.0001, * cf. **). However, although the 
therapeutic effect had waned partially by the 3rd week post-implantation (P=0.0027, * cf. ***), 
the improvement compared with mock-implanted diabetic mice continued to be significant at the 
same level (P<0.0001, ** cf. ***). Glucose tolerance of cell-implanted non-diabetic mice in the 





(C) The outcome of cell implantation site on glucose tolerance was evaluated in mice implanted 
with 5x106 circular plasmid-electroporated cells. Intraperitoneal implantation was more 
effective than intrahepatic implantation in normalising glucose tolerance of diabetic mice 
(P=0.0851, * cf. **) but had no effect on glucose tolerance of cell-implanted non-diabetic mice 
(P=0.5417, # cf. ##).  
(D) Glucose tolerance tended to be better in diabetic mice IH-implantated with 5x106 than 2x106 




(E) The mode of cell manipulation was not a significant variable factor influencing glucose 
tolerance of treated diabetic mice one week after implantation (P=0.6173, * cf. **). However, 
stably-modified cells improved glucose tolerance more than circular plasmid-electroporated 
cells in the 3rd week post-implantation (P<0.0001, # cf. ##).  
(F) Similar analysis was performed on non-diabetic mice implanted with 5x106 cells. 
Notwithstanding the observation that modified cells IH- and IP-implanted into non-diabetic mice 
secreted human insulin and slightly reduced blood glucose levels, the glucose tolerance of these 




(G) Early phase (0-30 minutes) glucose tolerance in diabetic mice IP-implanted with 2x106 and 
5x106 circular plasmid-electroporated cells was similar  (P=0.3876; AUC0-30 * cf. AUC0-30 **). 
However, AUC values derived from glycemic profiles from the 30th to the 90th minute showed 
significantly better glucose tolerance with the higher cell number (P=0.0039, AUC30-90 * cf. 
AUC30-90 **).  
(H) In contrast to circular plasmid-electroporated cells, IP-implantation of stably-modified cells 
in higher number i.e. 5x106 cells, resulted in significantly improved glucose tolerance in diabetic 
mice than implantation with 2x106 cells (P=0.0487). Nonetheless, similar to (G), the difference 
was more apparent at later time points of the GTT (P=0.0496, AUC0-30 * cf. AUC0-30 **; 




Figure 23 Body weight trends of NOD-SCID mice in the experiment. (A) Body weights of all 
IH-, IP- and mock-implanted diabetic mice, and non-diabetic cell-implanted and mock-implanted 
mice were pooled for analysis regardless of the cell number implanted and the method of cell 
modification. Nadir body weight and that on the last day of the experimental period i.e. before 
the animal was sacrificed, were compared. Both cell- and mock-implanted non-diabetic mice 
were heavier than all other groups on day 30 (P<0.0001). While IP-implanted diabetic mice had 
a similar mean body weight on day 30 as the mean nadir body weight (P=0.2378) (i.e. 
continuing weight loss was arrested), mock- and IH-implanted diabetic mice lost significant 
weight post-implantation.  
(B) The effect of cell modification on body weight change was analysed in IP-implanted mice. 
Diabetic mice implanted with circular plasmid-electroporated cells showed a trend of continuing 
weight loss (P=0.0303; nadir body weight cf. body weight on day 30) while the decline in body 
weight of mice implanted with stably-modified cells was arrested (P=0.5674; body weight on 





Figure 24 Immunorejection of porcine BMMSCs xeno-transplanted into the livers of NOD-
SCID mice. (A) Formation of thrombi in branches of the portal vein (         ) causing tissue 
ischaemia and regions of liver cell necrosis (          ) near veins. A non-necrotic region (         ) 
was present peripheral to a branch of the portal vein; original magnification 100X.  
(B) Absence of endothelialitis in the hepatic central vein surrounded by peripheral necrotic 
cells; original magnification 200X.  
(C) A thrombus with engulfed inflammatory cells and red blood cells in a central vein; original 
magnification 200X.  
(D) Geographical necrosis with a centrilobular distribution. Multiple thrombi were evident in 






Figure 25 Bioactivity of secreted transgenic human insulin. The bioactivity of  human insulin 
secreted by the insulin-expressing PBMMSC stable line 5 in vitro was determined by direct IP 
injection of the conditioned medium (100, 200, 400 and 800 µl) into diabetic NOD-SCID mice 
(n=4 for each injection volume). Blood glucose was determined at 0, 10, 20, 30, 45, 60 and 90 
min after injection.  
(A) Glucose tolerance profiles of diabetic mice after injection of medium conditioned by 
PBMMSC stable line 5 (insulin-containing) or medium conditioned by unmodified PBMMSCs 
(insulin-free control). The profiles show dose-dependent effects on normalising the glucose 
intolerance of diabetic mice.  
(B) AUC values derived from the glucose tolerance profiles were subjected to analyses of 
significance. Diabetic mice injected with 800 or 400 µl of insulin-containing medium had 
significantly better glucose tolerance than mice injected with 800 µl of medium without insulin 
(*P=0.0118, **P=0.0012). Glucose tolerance was also better with a higher injected volume of 
insulin-containing medium (P=0.0172, * cf. **). Injection of smaller volumes i.e. 100 or 200 µl 
of the same medium did not improve the glucose tolerance of diabetic mice (P=0.3871 and 
0.8974 for 100 and 200 µl, respectively, cf. #). Overall, mice injected with different volumes of 
the insulin-containing medium had better glucose tolerance than mice injected with medium 
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A succession of reports demonstrating correction of metabolic abnormalities and cirrhotic 
liver failure by hepatocyte transplantation in experimental animals1,2,3,4 led naturally to clinical 
attempts to achieve comparable or better outcomes in human patients about 15 years ago5,6,7. As 
of 2006, 21 patients worldwide had received either autologous (5 patients) or allogeneic (16 
patients) hepatocyte transplantation for liver-directed metabolic disorders with, however, only 
modest success8.  Several reasons may explain the incommensurate clinical outcomes of 
hepatocyte transplantation in human subjects compared with murine models. Metabolic 
correction in experimental animals is greatly favoured under conditions of therapeutic liver 
repopulation (i.e. when donor hepatocytes have a natural or iatrogenic proliferative advantage 
over hepatocytes of the recipient host)9. However, such conditions rarely occur naturally in 
humans and, if induced, carry unacceptable clinical risks. Most hepatocyte transplantations have 
used allogeneic donors. Despite allografts from living-related donors and attempts at optimising 
immunosuppresion regimens10,11,12, allograft rejection is another reason for the limited success of 
hepatocyte transplantation to date. Although conventional gene therapy methods that employ in 
vivo vector administration might appear to overcome these difficulties, they present other 
problems. These are the general inability to limit vector delivery only to specific cell types and 
the known risks of immunogenic and genotoxic adverse effects. These concerns are especially 
germane to in vivo viral vector therapy. Moreover, transduced cells that express viral proteins are 
targets for host immunological destruction – one cause, among others, of transient transgene 
expression13.  
Unlike those inborn errors of metabolism in which the liver is the primary organ of 
disease, other inherited and acquired disorders caused by the lack of specific proteins e.g. 
diabetes mellitus and the haemophilias, could benefit more readily from hepatocyte 
transplantation since liver repopulation is not required to correct these diseases. Moreover, as the 
liver is structurally and functionally normal, therapeutic autologous hepatocyte transplantation 
could be feasible. Combining autologous rather than allogeneic hepatocytes with ex vivo gene 
transfer has several advantages. Hepatocytes from well-planned liver resections are likely to be 
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of higher quality, can be used fresh rather than cryopreserved and allow the use of effective 
techniques for transfecting primary somatic cells e.g. ex vivo high voltage electroporation that 
would cause tissue necrosis in vivo. Autologous cells also overcome the problem of donor 
scarcity and would not subject patients to chronic immunosuppression. 
We have chosen insulin-deficient diabetes mellitus (DM) as a clinically relevant model to 
investigate the ability of nonvirally-modified primary adult somatic cells to reconstitute normal 
metabolism in animal models of diabetes. Type 1 DM is a model disease that demonstrates the 
debilitating consequence of a single protein deficiency, affecting millions of people worldwide. 
Despite multiple treatment methods, a lifetime of euglycaemic control is achievable only with 
intensive efforts and high cost that are difficult to sustain by both diabetic patients and their 
healthcare providers. Moreover, intensive insulin therapy, the only efficacious treatment 
modality for T1D patients, has significant limitations i.e. causes hypoglycaemia14 and lacks C-
peptide. C-peptide has recently been identified to play key roles in preventing/ameliorating 
diabetes vascular complications and therefore is not merely a by-product of mature insulin 
synthesis15.   
Notwithstanding evidence from experimental model systems that have demonstrated 
proof-of-concept, cellular therapy of DM remains a treatment option struggling to advance into 
clinical trials because of unduly harsh scepticism16. This is partly due to the fact that replicating 
physiologic insulin secretion, ideally in the portal circulation, demands strict temporal control 
that has proved to be far more difficult to achieve than anticipated.  The fact that current 
experimental therapies lack these functional attributes and suffers from other limitations (e.g. 
donor scarcity, requirement for immunosuppression, potential tumorigenicity, unphysiological 
protein expression and poor scalability), largely accounts for their failure to progress to clinical 
trials. In this study, we sought to surmount the barriers to widespread clinical application of 
cellular therapy of DM by addressing and combining four key elements in our strategy, namely 
choice of cell type, promoter selection, vector delivery and scalability. Challenging as it may be, 
we foresee that a safe and effective approach developed initially for DM could have broader 
future applications for the treatment of other acquired and inherited diseases for which systemic 
reconstitution of a specific protein deficiency is critical. Moreover, it could be especially facile 
for diseases that do not require tightly regulated transgene expression.  
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Restoring lost β-cell reserve by implanting new β-cells was once considered a sound and 
pragmatic solution. However, several well-recognised limitations seriously hamper the true 
utility of this treatment option. These are the scarcity of donor pancreata, the need for chronic 
immunosuppression (which itself may be diabetogenic) and recurrent immune-mediated 
destruction of transplanted islets. The use of insulinoma-derived β-cell lines to increase the 
supply of “donors” invites unacceptable risks of tumour formation and unphysiological insulin 
secretion. In contrast, non-β cells are plentiful, can be obtained from diabetic patients themselves 
(i.e. are autologous) and are likely to resist autoimmune destruction17. For these reasons, many 
investigators have opted to modify non-β somatic cells as replacements for endogenous β-cell 
function.  
By introducing furin-cleavage sites for proinsulin processing18 or by adopting single 
chain insulin analogues19, non-neuroendocrine cells can be modified to synthesise and secrete 
insulin. However, clinically useful surrogate β-cells ideally should be derived from an 
autologous source and possess a cellular phenotype that combines biosafety with reasonable 
functional mimicry of β-cell function. Such a favourable profile includes being mitotically 
quiescent or, at most, having limited proliferative capacity in vivo, having a long lifespan in vivo, 
being easily procured in therapeutically sufficient number preferably without in vitro expansion, 
and most important, being capable of stable expression and rapid induction of insulin secretion in 
response to circulating levels of glycaemia. While many non-β cells have been modified for 
insulin secretion, few have the essential glucose-sensing biochemistry and cellular phenotype 
required to render them potentially useful as surrogate β-cells for clinical application. In this 
regard, hepatocytes are particularly attractive candidates because of their proven physiological 
glucose-sensing and glucose-responsive characteristics, and proficiency in protein biosynthesis 
and secretion. Murine studies suggest that insulin-expressing hepatocytes may be protected from 
the anti-β-cell specific immune response underlying autoimmune diabetes20. As the dominant 
cell type in the organ that regenerates, hepatocytes are theoretically an inexhaustible source of 
cells amenable to manipulation. Moreover, the liver’s prime anatomic location at the head of the 
portal venous system confers a natural advantage for nutrient-regulated insulin secretion. Indeed, 




Notwithstanding these advantages, invasive surgery is required to obtain autologous 
primary hepatocytes. This could be regarded as an unappealing disadvantage on the grounds that 
it may not be clinically justifiable to procure hepatocytes surgically for a disease that is not 
imminently fatal and for which there is already a plethora of standard treatment options. To 
address this objection, we have developed another cellular bioimplant, i.e. primary bone marrow-
derived mesenchymal stromal cells (BMMSCs) for glucose-regulated insulin secretion. 
BMMSCs are intrinsically proliferative albeit with limited capacity, can be readily and less 
invasively procured and non-immunogenic21. The latter characteristic has permitted routine co-
transplantation of either autologous or allogeneic BMMSCs with haematopoietic stem cells to 
treat a variety of haematological diseases. Moreover, we identified a subset of BMMSC-
expressed genes that responded within minutes to changes in ambient glucose concentrations, 
thereby establishing them as glucose-responsive cells. Other cells that may be amenable for 
modification to serve as safe insulin-secreting bioimplants include cord-lining and cord blood 
cells. These placenta-derived cells are abundant and immunogically privileged.  
Although autologous non-β-cells may be modified to secrete insulin and are likely to 
resist autoimmune attack, a major challenge prevents most from functioning as true surrogate β-
cells. Sceptism of the clinical utility of surrogate β-cells has centred on two deficiencies, namely 
weak glucose responsiveness since they are not all equipped for glucose-sensing and glucose-
stimulated insulin transcription, and much slower secretion kinetics via the constitutive pathway 
since, unlike neuroendocrine cells, surrogate β-cells do not secrete preformed insulin from 
storage granules.  
However, we have shown that the relatively slower kinetics of insulin secretion may be 
substantially improved by combining three favourable features: using an intrinsically glucose-
sensing and glucose-responsive cell type, expressing transgenic insulin from a strong yet 
glucose-regulatable promoter, and employing a gene transfer technique capable of delivering a 
high vector copy number into the target cells. Beta-cells do not respond to glucose per se, but to 
the rate of glucose metabolism controlled by the high Km glucose transporter-2 (GLUT2) and 
glucose-phosphorylating enzyme, glucokinase (GK)22. Both elements allow β-cells to establish 
direct proportionality between extracellular glucose levels and the formation of metabolisable 
glucose 6-phosphate in the cells. Increased glucose metabolism in turn activates insulin gene 
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transcription mediated by the transcriptional activators, PDX1 and MafA. Hepatocytes naturally 
express GLUT2 and GK that initiate the same glucose signalling as in β-cells. However, in 
contrast to β-cells, increased glucose metabolism in hepatocytes predominantly regulates 
transcription of lipogenic enzyme genes whose promoters consist of a regulatory sequence 
termed the carbohydrate response element (ChoRE)22. Transcription of these genes is mediated 
by a transcription factor, ChoRE-binding protein (ChREBP)23. The function of pre-synthesised 
ChREBP is controlled by its phosphorylation state that, in turn, determines its DNA-binding 
activity and intracellular localisation24. 
Mechanisms independent of glucose transport and phosphorylation may also mediate 
glucose responsiveness in hepatocytes and other glucose-sensitive cells. For instance, a 
hepatocyte cell line that lacked GLUT2 and GK expression, when transfected with a CMV 
promoter-insulin construct, showed glucose-induced insulin secretion in 5.6-25 mM glucose25. 
Conversely, an insulin-secreting cell line derived from adrenocorticotropic hormone-secreting 
cells did not respond to physiological glucose levels even with overexpression of the β-cell 
isoforms of GLUT2 and GK26. These observations suggest that GLUT2 and GK are not the only 
determinants of cellular glucose responsiveness and may explain our observation of a subset of 
glucose-induced transcripts in BMMSCs.  
Promoter selection is crucial in driving tightly-regulated and rapid induction/de-induction 
of the insulin transgene. Most previous studies utilised non-physiological viral promoters, 
glucose-insensitive promoters or insulin-repressed promoters. Unsurprisingly, studies of these 
transgenic systems reported the extremes of often fatal hypoglycaemia or sub-therapeutic insulin 
expression. In addition, viral promoters were associated with early transcriptional silencing. In 
contrast, use of cell-specific endogenous promoters supported sustained transgene 
expression27,28,50.  
We combined a strong yet regulatable endogenous promoter, human metallothionein IIA, 
with ChoRE to independently and synergistically regulate insulin gene transcription in primary 
hepatocytes. This dual-functionality directed basal and glucose-induced insulin expression in 
interprandial and postprandial periods, respectively. We showed that this bifunctional promoter 
accomplished increased (pro)insulin gene transcription and insulin secretion from the modified 
cells within 10 and 20 min, respectively, in response to high glucose. Cessation of transcription 
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and secretion occurred within 20 and 32 min, respectively, after withdrawal of the high glucose 
stimulus. The temporal scale of these responses is consistent with the dynamic modulation of 
ChREBP by cAMP-dependent protein kinase A. The phosphorylation status of ChREBP is 
known to determine its intracellular localisation and ChoRE-binding activity. Specifically, 
phosphorylated ChREBP is confined to the cytoplasm and thus rendered it transcriptionaly 
inactive within 7 min while dephosphorylation reactivates ChREBP within 3 min in vitro, in 
which state it migrates into the nucleus and regains ChoRE-binding activity24. Consistent with 
the foregoing in vitro timescales, the same study showed abolition of DNA-binding activity of 
ChREBP within 10 min in vivo24.   
Similarly, zinc induction of the bifunctional promoter increased (pro)insulin gene 
transcription and insulin secretion within 10 and 20 min, respectively. Both declined to basal 
levels within 20 and 30 min, respectively, after removal of the zinc stimulus. Human 
metallothionein IIA promoter has seven copies of the metal-responsive element (MRE), which 
are co-regulated by a zinc finger transcription factor i.e. MRE-binding transcription factor-1 
(MTF-1)29,30,31. Binding of MTF-1 to MREs is essential for both basal and zinc-inducible 
metallothionein gene expression30. The DNA-binding capacity of MTF-1 is controlled by a zinc-
sensing kinase transduction cascade, which increases phosphorylation of MTF-1 resulting in 
enhanced nuclear localisation and transcriptional activity31. Interestingly, the transcriptional 
activity of human MTF-1 is increased (>10-fold) within 15 minutes only by micromolar 
concentrations of zinc (e.g. 30 µM) but not by other transition metals, and could function as a 
sensor for cellular “free” zinc29. In contrast, inactivation of MTF-1 transcriptional activity is less 
well-studied, but is presumed to occur via dephosphorylation. Since induced metallothioneins 
bind “free” zinc thereby reducing its intracellular accumulation, a feedback loop that functions to 
alter the activity of zinc-sensing kinases is plausible. 
In contrast to hepatocytes, much less is known about glucose-regulated gene transcription 
in BMMSCs. Our data from whole genome transcriptome profiling, showing a subset of glucose-
inducible genes, has established BMMSCs as, albeit unconventional, glucose-responsive cells. 
The human EGR1 promoter showed high basal transcriptional activity and rapid glucose 
induction and de-induction, as evidenced by EGR1 transcript levels. While the exact mechanism 
of this effect is unclear, we showed that changes in transgene transcription and secretion 
occurred within minutes in response to ambient glucose concentrations both in vitro and in vivo, 
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possibly due to the presence of multiple basic regulatory elements and at least six copies of 
putative ChoREs in this promoter (section 3.2.1)32. Indeed, glucose upregulates EGR1 
expression. De novo synthesised EGR1, in turn, activates transcription of PDX-1 that induces 
insulin transcription in β-cells by binding to regulatory elements in the insulin promoterEto. Since 
glucose (4-5 mM) stimulates insulin gene transcription within 10-15 minutesDM text, it is therefore 
not suprising that the EGR1 promoter could drive the insulin and SEAP gene transcriptions of 
our constructs within 10 minutes in PBMMSCs cultured in high glucose. Although we showed 
that physiological and pathological concentrations of insulin and dexamethasone had no effect on 
EGR1 promoter activity and that hypoglycaemia was not recorded even in non-diabetic mice 
implanted with modified porcine BMMSCs (PBMMSCs), more studies are needed to ensure that 
the promoter is only maximally activated by glucose and/or glucose derivatives. Given that 
EGR1 expression is increased by genotoxic stress and many extracellular signalling molecules35, 
it will be critical to avoid non-glucose induced insulin transgene expression that could cause 
serious or even fatal hypoglycaemia. 
Reservations about the somewhat delayed insulin secretion observed in both cell types 
should be considered in the context of the known kinetic features of physiological insulin 
secretion. So far as can be determined, biphasic insulin release occurs only under non-
physiological conditions, typically during intravenous glucose testing36. In fact, the response 
time of our modified cells to high glucose challenge closely mimics pancreatic response to a 
mixed meal challenge in normal human subjects37. For instance, circulating insulin levels peak 
approximately 15-30 minutes after food ingestion begins38. Furthermore, acceptable glycaemic 
control has been achieved in diabetic recipients of pancreas allografts or islet transplants despite 
abnormal insulin secretion kinetics39,40,41, as do those treated with conventional regimens of 
insulin injection that generally demonstrate more delayed insulin activity42 compared to that 
achieved in our study.   
To summarise, the glucose-sensitive property of these promoters drove quasi-
physiological secretion of human insulin and correspondingly reduced blood glucose in treated 
diabetic animals. Most importantly, no blood glucose reading indicative of hypoglycaemia was 
ever obtained in all three in vivo models in this study, even after prolonged fasts. Although the 
feeding behaviour of mice might have been protective against hypoglycemia, this was not the 
case in the pigs of this study which were fed only twice a day. This was a good simulation of 
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conventional meal patterns of humans in which significant periods occur without food intake. 
That the pigs were not observed to show signs of hypoglycemia during this study of several 
months suggests that the modified hepatocytes did not exhibit uncontrolled insulin secretion. 
This is noteworthy as current clinical practice aimed at achieving tight glycaemic control often 
increases the risk of symptomatic hypoglycaemia. Thus, diabetic children on conventional 
insulin therapy sustain about 20 hypoglycaemic comas and convulsions per 100 patient years43. 
Moreover, recent data from the NIDDK and JDRF-funded Collaborative Islet Transplant 
Registry indicated that 31-53% of a total of 325 adult islet recipients suffered severe 
hypoglycaemic episodes44.  
Unlike normal β-cells that may lose the capacity for glucose regulation after chronic 
exposure to high glucose levels45,46, modified primary hepatocytes maintained steady insulin 
secretion for days in the continuous presence of high glucose and zinc. This lack of 
desensitisation should not be considered a disadvantage since withdrawal of one or both stimuli 
did reduce insulin production. Rather, this inherent feature will work for insulin-resistant T2D in 
which a steady output of insulin in the face of hyperglycaemia may be therapeutically desirable.  
Therapeutically effective levels of insulin secretion achieved in this study were due, in 
part, to the gene delivery method we employed, i.e. electroporation. This gene transfer 
technology is known to increase transgene dosage in the cell nucleus by several orders of 
magnitude, which in turn enhances expression of the transgene product47. Indeed, insulin was 
secreted in higher amounts and thus was detected with apparently faster onset in circular 
plasmid-electroporated PBMMSCs compared to PBMMSCs stably-modified with the same 
construct. Conventional nonviral gene delivery methods, for example direct injection of plasmid 
DNA in naked form or complexed with cationic lipids, polymers or peptides, have significant 
limitations that typically resulted in low transfection efficiency. For instance, intravenously 
administered naked or complexed supercoiled plasmid DNA rapidly decays to open circular 
forms48. Furthermore, these plasmids are usually delivered into the cytoplasm, where the DNA 
may need to be released from the delivery vehicle while escaping destructive subcellular 
compartments, such as endosomes and lysosomes. In the naked and/or open circular forms, 
plasmid vectors are exposed to the hostile cytoplasmic environment and run the gauntlet of 
nucleases before nuclear entry. In addition, the presence of unmethylated CpG dinucleotides on 
plasmids retained in the endosome may activate the innate immune system mediated by the Toll-
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like receptor 9, thereby stimulating an inflammatory cytokine cascade49. In contrast, 
electroporation facilitates rapid nuclear entry of the vector and is thus less provocative of the 
inflammatory response50 while simultaneously accelerating the rate-limiting process of 
cytoplasmic-nuclear transit.  
Cell electroporation offers several other advantages that are appropriate for clinical 
applications. First, it allows facile ex vivo gene transfer. Second, ex vivo electrotransfer largely 
eliminates the risks of in vivo dissemination of viral vectors and other potentially toxic polymer- 
complexed vectors with the attendant risks of adverse immunogenic or genotoxic effects. These 
risks are not obviated by ex vivo transduction since viral vectors may contaminate transduced 
cells during in vivo implantation. Third, confirming many published reports, we have shown that 
electroporation does not lead to genomic integration of circular plasmid DNA and should thus 
have little or no mutagenic potential. Indeed, histological examinations in our study showed that 
implanted plasmid-electroporated hepatocytes were morphologically normal without features of 
cellular transformation, demonstrating the biosafety of this gene transfer technique i.e. being 
neither oncogenic nor mutagenic. Fourth, electroporation is a simple, quick, unlaborious and 
inexpensive technique. As such, we were able to complete porcine hepatocyte isolation, 
transfection and reimplantation of the electroporated cells in a single 3-hour procedure, and 
implantation of electroporated primary murine hepatocytes and PBMMSCs within an hour.  
A therapeutically useful gene transfer technique should accomplish durably high levels of 
transgene expression coupled with low cell mortality rates. Determinants of successful 
electroporation include plasmid DNA preparation, the physiological state of cells, 
electroporation buffer and electrical pulse settings. First, plasmid preparation determines vector 
quality. Specifically, a high quality preparation should yield plasmids that are predominantly 
supercoiled and free from contaminants such as bacterial DNA, RNA, proteins and endotoxins. 
These contaminants are toxic and immunogenic, inducing innate immune responses that destroy 
the plasmid-bearing cells46. Second, preparing healthy cells for electroporation minimises the 
inevitable cell killing induced by a high electrical field, favours prompt recovery from the 
electrical insult and eventual engraftment in vivo. Dead cells release cell-degrading enzymes that 
could destroy surrounding live cells. Third, the composition of an electroporation buffer serves 
two functions of paramount importance for high transfection efficiency. It should allow 
reversible permeabilisation of plasma membranes at relatively low voltages while causing least 
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perturbation to intracellular milieu e.g. maintaining the ionic balance of cells. The former 
facilitates intracellular delivery of DNA, while the latter enables quick cell recovery and 
minimises cell death. The electroporation buffer we developed fulfilled both requirements i.e. it 
significantly reduced cell mortality while transgene expression was higher compared to a 
proprietary solution, even when transfecting at lower voltage. It is also noteworthy that using our 
solution, we achieved efficient electrogenetransfer in a wide range of cell types, thus 
demonstrating its universality. Fourth, electrical field intensity and pulse duration determine cell 
membrane permeability to exogenous DNA51. This usually occurs in a narrow range as too high 
a voltage increases cell death, while too low a voltage impedes gene transfer because of 
insufficient membrane permeabilisation.  
The use of plasmids as transgene expression vectors is particularly suitable for mitotically 
quiescent cells, especially as significant advances have been made in the design and production 
of plasmids that render these vectors less toxic, immunogenic and pathogenic (reviewed in 
ref.48, Gill DR, et al.). Moreover, pharmaceutical grade plasmid vectors can be produced readily 
and at a fraction of the cost required to produce viral vectors. Despite the common belief that 
non-integrating DNA is short-lived and hence transgene expression is transient, we showed that 
retention of plasmid DNA and durable transgene expression can be achieved in terminally 
differentiated, non-proliferating cells such as primary hepatocytes and in cells with limited 
proliferative capacity in vivo such as primary BMMSCs. Several reasons may explain the 
surprisingly sustained therapeutic effects we achieved in this study. Favourable factors included 
our use of physiological mammalian promoters that, unlike viral promoters, are less susceptible 
to silencing27,28,52, electrotransfer of the vector in high copy number45 and durable retention of 
the vector by non-mitotic hepatocytes53. 
      A deliberate combination of all elements important for clinical cellular and gene 
therapy has allowed us to demonstrate the feasibility of our approach in xenogeneic, syngeneic 
and autologous settings involving small laboratory animals i.e. C57BL/6J and NOD-SCID mice, 
and large preclinical animals i.e. Yorkshire-Landrace pigs. The strategy we devised achieved 
sustained and significant therapeutic efficacy, which simultaneously addresses several major 
challenges in the field i.e. donor scarcity, requirement for specialised skills and costly facilities, 
complications of chronic immunosuppression, tumorigenicity of bioimplants derived and/or 
differentiated from cell lines and embryonic stem cells, risks of non-targeted effects from direct 
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in vivo cell transfection/transduction, chemical, immuno- and genotoxicity of gene transfer 
vectors, transient transgene expression as well as poor scalability of experimental approaches 
from the bench to a preclinical animal model.       
       Notwithstanding the fact that only about 50% of basal and glucose-stimulated insulin 
secretion was reconstituted in both diabetic mice and swine, we note that normoglycaemia can be 
achieved and maintained in human subjects after 50% pancreatectomy54. This level of insulin 
replacement is clinically meaningful, particularly in type 1 diabetics in whom life-threatening 
diabetic ketoacidosis is prevented with merely 10% of normal circulating insulin55. Moreover, in 
addition to glycaemic and other metabolic (including dyslipidaemia) corrections, therapeutic 
efficacy in this study extended to protection against complications secondary to tissue injury, 
which are the major causes of morbidity and mortality in diabetics.  
However, it is evident that improvement in reconstituting insulin secretion beyond what 
we have achieved in this study is needed for a more substantial therapeutic effect. This may be 
achieved by implanting more insulin-expressing cells since the number of modified primary cells 
we implanted into diabetic animals was several fold lower compared to a clinical trial of FVII 
deficiency56, for instance. Moreover, our data in both mice and pigs indicate a ‘dosing effect’ in 
that the extent of metabolic correction correlated with the number of insulin-expressing cells 
implanted. Three areas need to be further optimised to attain the goal of advancing to clinical 
trials, namely optimising conditions for better cell engraftment, cell isolation and/or culture 
protocols that yield therapeutically sufficient viable cells, and gene transfer techniques that yield 
a larger number of transgene-expressing cells. In contrast, we do not consider high transgene 
expression to be a viable option because increased protein trafficking from forced overexpression 
could cause abnormal processing of the transgene product, which leads to ER stress, activation of 
mitochondrial apoptotic pathways and eventually cell death57. 
In addition to increasing circulating insulin levels, we recognise that our approach could 
have greater clinical appeal if the insulin expression vector could be permanently retained in both 
hepatocytes and BMMSCs. Theoretically, at least three strategies can be employed to prevent 
vector loss, namely modifying the sequences of the plasmid, construction of human artificial 
chromosomes (HACs) and integrating the expression vector into the genome. For instance, 
inclusion of a scaffold matrix attachment region (S/MAR) to plasmid DNA has been proven to 
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overcome transcriptional silencing58 and to drive the replication of episomal plasmids in work 
done to generate transgenic pigs from plasmid-transfected embryos59. HACs behave as 
independent minichromosomes that replicate without integrating into the genomic DNA60. Site-
specific genomic DNA integration of transgene may be achieved with phiC31 integrase-61, 
modified Sleeping Beauty transposase-62 or zinc finger nuclease-mediated integrating systems63. 
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Materials and Methods 
4.1. Materials 
4.1.1. Chemicals and reagents 
All chemicals and reagents were of analytical or ultrapure grade, and where appropriate, 
were cell-culture tested. The following suppliers (in square parentheses) were sources of: 
Dulbecco’s modified Eagle’s medium (DMEM), ethylene glycol-bis[β-aminoethyl ether]-
N,N,N’N’-tetraacetic acid, reduced L-glutathione, dimethyl sulphoxide, aprotinin, collagenase 
IV-S, all reagents for ALT activity assay and all molecular biology grade reagents for RNA 
preparations (guanidine thiocyanate, 2-mercaptoethanol, phenol:chloroform 5:1 and diethyl 
pyrocarbonate) [Sigma-Aldrich, USA]; Dulbecco’s phosphate-buffered saline, liver digest 
medium, RNAse- and DNAse-free distilled water, α-MEM with Glutamax™ medium, serum-
free StemPro™ medium, Geneticin (G418) and all reagents for mRNA transcriptome profiling 
(DNA polymerase I, E.coli DNA ligase, ribonuclease H, T4 DNA polymerase, second strand 
buffer, Superscript II™ RNAse H reverse transcriptase, dNTP mix, streptavidin, R-
phycoerythrin conjugate) [Invitrogen Life Technologies, USA]; potassium dihydrogen phosphate 
(KH2PO4), di-potassium hydrogen phosphate anhydrous (K2HPO4) and sodium chloride (NaCl) 
[Fluka GmbH, Germany]; foetal calf serum (FCS) [Hyclone, USA]; Percoll [Amersham 
Biosciences, Sweden]; Ficoll-Hypaque [Beckman Coulter, Inc., USA]; rat tail collagen I, 
collagen IV and Matrigel® dishes [Becton Dickinson, USA]; rat tail collagen I dish [Iwaki, 
Japan], Glucometer Elite® XL and blood glucose test strips [Bayer, USA], Accu-Chek Go™ 
blood glucose meter and test strips [Roche Diagnostics GmbH, Germany]; all restriction 
endonucleases were from New England Biolabs, Inc. and Fermentas (USA); all hormone 
radioimmunoassay (RIA) kits (ultrasensitive human insulin, human insulin, C-peptide and 
proinsulin, mouse and porcine C-peptides) were from Linco Research, USA. All plasmid, 
genomic DNA and RNA isolation kits were from Qiagen, Germany. 
4.1.2.  Plasmids 
pEGFP encoding green fluorescent protein (GFP) expressed from the CMV promoter, 
pSEAP encoding secreted alkaline phosphatase (SEAP) expressed from the SV40 promoter and 
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pSEAP-Basic (promoter-less pSEAP) [Clontech, USA]; pCR®2.1-TOPO® [Invitrogen Life 
Technologies, USA]; StrataClone™ blunt PCR cloning vector (pSCB) [Stratagene, USA]; 
p3MTchINS encoding human proinsulin expressed from a bifunctional promoter (human 
metallothionein IIA promoter linked to three tandem copies of carbohydrate response element)1. 
The human proinsulin cDNA was modified to incorporate furin cleavage sites at the B chain/C-
peptide and C-peptide/A chain junctions, and a third mutation i.e. substitution of histidine at the 
tenth position of the B chain with aspartate, i.e. HisB10Asp. These modifications were made by 
a colleague, Jaichandran Sivalingam. pCMVINS encoding the same furin-cleavable human 
proinsulin (i.e. from p3MTchINS), expressed from the CMV promoter was used as a control 
when indicated. The vector maps for p3MTchINS and pCMVINS are illustrated in Appendix 1.   
4.1.3. Animals 
Six- to eight-week-old male C57BL/6J and Rosa26 mice were housed in the animal 
holding unit, National Cancer Centre, Singapore (NCCS). Four- to eight-week-old male NOD-
SCID mice were housed in the specific pathogen-free rooms in NCCS and SingHealth 
Experimental Medicine Centre, Singapore (SEMC), an Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC)-accredited facility. All mice were exposed 
to 12-h cycles of light and dark at 18-24ºC. Water and standard rodent chow were provided ad 
libitum, unless otherwise specified.  Three- to four-month-old male and female Yorkshire-
Landrace pigs were housed in SEMC and were fed standard chow (5% body weight) twice daily. 
All animal handling procedures, animal husbandry and experimental protocols were approved by 
the Institutional Animal Care and Use Committee of the Singapore General Hospital. 
4.2. Isolation and culture of primary adult somatic cells 
4.2.1. Primary murine hepatocytes 
We isolated primary hepatocytes from adult male C57BL/6J or Rosa26 mice as described 
by Bumgardner et al.2 with the following modifications. Liver was sequentially perfused in situ 
with 2.5 mM ethylene glycol-bis[b-aminoethyl ether]-N,N,N’N’-tetraacetic acid in calcium-free 
Dulbecco’s phosphate buffer (3-4 ml/min for 7 min at 37oC for intact liver; 2-3 ml/min for 5 min 
for partially hepatectomised liver) followed by liver digest medium (Invitrogen Life 
Technologies, USA) at the same flow rate (13 min for intact liver; 10 min for partially 
hepatectomised liver). When hepatocytes were isolated from hepatectomised liver, the procedure 
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was performed 24 – 48 h after partial liver resection. A cellular fraction enriched in hepatocytes 
was obtained as a pellet after centrifugation (140 g, 15 min at 4oC) on a discontinuous Percoll 
gradient (15-30-45-60%). Primary murine hepatocytes were cultured as monolayers on matrix-
coated (collagen I, collagen IV or Matrigel®) dishes (35 or 60 mm diameter) in antibiotic-free 
DMEM supplemented with 10% FCS and incubated in 5% CO2 at 37°C. Medium was changed 
every 48 h.  
4.2.2. Primary porcine hepatocytes 
A surgically excised liver wedge (approximately 50cm3) was sequentially perfused (8-10 
ml/min) with 2.5 mM ethylene glycol-bis[b-aminoethyl ether]-N,N,N’N’-tetraacetic acid in 
calcium-free Dulbecco’s phosphate buffer (8-10 min) and 0.3% (w/v) collagenase IV-S (15-20 
min) through two cannulated blood vessels visible on the cut surface. Uncannulated vessels were 
closed off by sutures. The perfused liver was diced and scraped to release the cells. A cellular 
fraction enriched in viable hepatocytes was obtained as a pellet after centrifugation (150 g, 15 
min at 4°C) on a discontinuous Percoll gradient (15-30-45-60%). Cell viability by trypan blue 
exclusion was 75–90%. Primary porcine hepatocytes were cultured as monolayers on collagen I-
coated 35 or 60 mm dishes as described for primary murine hepatocytes.  
4.2.3. Primary porcine bone marrow-derived mesenchymal stromal cells (BMMSCs) 
 Approximately 20 ml of heparinised bone marrow were extracted from the iliac crest 
using an 18 G Jamshidi needle (Johnson & Johnson, USA) and filtered through a 40-µm cell 
strainer (Becton Dickinson, USA) to remove debris and clots. Two isolation methods were 
evaluated, i.e. with or without Ficoll-Hypaque. With Ficoll-Hypaque: 20 ml bone marrow filtrate 
was layered on Ficoll-Hypaque (20 ml; density 1.077g/L) and centrifuged at 1200 g for 20 min at 
room temperature. Erythrocytes formed a pellet. Other cells that formed a pale band near the 
middle of the gradient were collected and washed thrice in DMEM (250 g for 5 min). Cells were 
then seeded at a density of 1x104 cells/cm2 in 75 cm2 flasks (Becton Dickinson, USA) and 
cultured in one of three media: (1) α-MEM with Glutamax™ supplemented with 20% FCS; (2) 
serum-free StemPro™ medium; and (3) α-MEM with Glutamax™ mixed with StemPro™ in a 
3:1 (v/v) ratio, supplemented with 10% FCS. All media contained 100 µg/ml streptomycin and 
100 IU/ml penicillin. Cells were incubated at 37°C in 5% CO2. Non-adherent cells were removed 
4 days after plating. Cultures were fed every 3-4 days by half-medium change. Attached cells 
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reached 80% confluence 4-6 days after plating and were lifted with Accutase™ (eBioscience, 
USA). Cells were subcultured at a 1:3 splitting ratio. Without Ficoll-Hypaque: The same volume 
of each of the three media described above was added to bone marrow filtrate before plating in 
75 cm2 flasks (30 ml cell suspension/flask). Cell culture conditions were as described above. 
Attached cells reached 80% confluence approximately 10 days after plating and were detached 
with Accutase™. Cells were subcultured at a density of 5x103 cells/cm2 at the first passage and at 
1:3 ratio thereafter.     
4.3. Plasmid construction 
Human EGR1 promoter was first amplified from genomic DNA extracted from human 
(H) BMMSCs (HBMMSCs were a gift from Prof. Gerald Udolph, Institute of Medical Biology, 
Singapore) using high fidelity polymerase, PfuUltra II® fusion hot start DNA polymerase 
[Stratagene, USA] and cloned into StrataClone™ blunt PCR cloning vector, pSCB. The construct 
was named pEGR1-SCB. NheI and SalI restriction sites were incorporated in the forward and 
reverse primers, respectively (F: 5’ ggt tcg cta gca cgg tcc ctg ag 3’; R: 5’ gga tct ctg tcg act ccc 
cgg atc 3’). The cloned EGR1 promoter was confirmed by sequencing. 
4.3.1. Assembly of pEGR1-SEAP 
EGR1 promoter was excised from pEGR1-SCB with NheI and EcoRI restriction 
endonucleases, and ligated to pSEAP-Basic vector digested with the same enzymes. Ligated 
products were transformed into E. coli DH5α competent cells. Recombinant clones were selected 
by growth in LB agar plates containing ampicillin (100 µg/ml). The sequence and orientation of 
the promoter was confirmed by sequencing. The vector map is illustrated in Appendix 1. 
4.3.2. Assembly of p3EGR1chINS 
EGR1 promoter was excised from pEGR1-SCB with NheI and SalI restriction 
endonucleases, and ligated to p3MTchINS digested with the same enzymes (hence removing the 
human metallothionein 2A promoter). All other details were as described in section 4.3.1. 
4.3.3. Assembly of pTopo3EGR1chINS 
Human insulin expression cassette, comprised of the EGR1 promoter, modified human 
proinsulin cDNA, three tandem copies of the carbohydrate response element (ChoRE) and rabbit 
β-globin poly A, was excised from p3EGR1chINS with NotI and KpnI restriction endonucleases, 
and ligated to pCR®2.1-TOPO® vector digested with the same enzymes. Recombinant clones 
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were selected by growth in LB agar plates containing ampicillin (100 µg/ml) and kanamycin (50 
µg/ml). All other details were as described in section 4.3.1.   
4.3.4. Assembly of p3EGR1(A)chINS, p3EGR1(B)chINS and p3EGR1(C)chINS 
Human EGR1(A) promoter segment (nucleotides 18-215; nucleotide numbers refer to the 
sequence deposited in GenBank as AJ245926), EGR1(B) promoter segment (nucleotides 215-
424) and EGR1(C) promoter segment (nucleotides 402-677) were differentially amplified by 
PCR from pEGR1-SCB and ligated to pSCB as described in section 2.4. Primer sequences were: 
EGR1(A) (F: 5’ ggt gcg gcc gct tcg aat gtg gaa ttc 3’; R: 5’ ggt cga cct tta tat taa ccc ggg agc c  
3’), EGR1(B) (F: 5’ ggt agt gcg gcc gcc ttg gaa cca gg 3’; R: 5’ gat ccg tcg act tta tat taa ggg gaa 
gcc tag ag 3’) and  EGR1(C) (F: 5’ gga ttg cgg ccg cgg gaa ctc c 3’; R: 5’ gat ccg cgt cga ctt gaa 
ggg tct gg 3’). All forward and reverse primers specified NotI and SalI restriction sites, 
respectively. All reverse primers, except for EGR1(C), contained a TATA box sequence 
(tttatattaa). EGR1 promoter segments were excised from each resulting construct with NheI and 
SalI restriction enzymes and ligated to p3MTchINS digested with the same enzymes. All other 
details were as described in section 4.3.1. 
4.4. Gene transfer in primary adult somatic cells 
4.4.1. Primary murine hepatocytes 
Primary mouse hepatocytes were transfected using the Nucleofector™ system (Amaxa 
Biosystems, Koln, Germany). Five-7 μg of endotoxin-free plasmid DNA were added to 1 x 106 
hepatocytes in 0.1 ml Nucleofector™ solutions #3551 and #3541 mixed in equal volumetric ratio. 
Electroporation was performed using preset Amaxa programs, T20, T27 and H22. Electroporated 
cells were immediately removed from the cuvette and plated in DMEM. Transfection efficiency 
was expressed as the average percentage of GFP+ cells in at least 3 randomly selected 
microscopic fields (100x original magnification). Cell viability was assessed by trypan blue 
exclusion test after the electroporated cells were incubated in culture medium for at least 30 min 
at 37°C in 5% CO2.    
4.4.2. Primary porcine hepatocytes 
Isolated porcine hepatocytes were electroporated using the Nucleofector™ system (equal 
volume mixture of solutions #3551 and #3541; program T20) or with sterile NC solution having 
the following composition: 19.8 mM KH2PO4 / 80.2 mM K2HPO4 / 20 mM NaCl, pH 7.6. 
Freshly prepared 2 mM ATP (New England Biolabs, Inc.) and 5 mM reduced L-glutathione were 
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added to NC solution just before use. Electroporation with NC solution was performed in a 
sterile cuvette (4 mm gap; BTX Instrument Division, Harvard Apparatus, USA) with a single 
pulse of 1400 V for 70 µs followed immediately by a single pulse of 160 V for 37 ms delivered 
from a custom-made pulse generator. Eight µg endotoxin-free plasmid DNA (p3MTChINS or 
pEGFP) was added to 4 x 106 viable hepatocytes in 0.2 ml electroporation solution before 
electrical pulsing. Electroporated cells were immediately removed from the cuvette and plated 
into serum-free DMEM containing 25 mM glucose. Transfection efficiency and viability were 
assessed as described in section 4.4.1. 
4.4.3. Primary human and porcine BMMSCs 
HBMMSCs and PBMMSCs were transfected with sterile NC solution. Five µg 
endotoxin-free plasmid DNA were added to 2 x 106 HBMMSCs or PBMMSCs in 0.2 ml 
electroporation solution and the mixture was transferred to a sterile cuvette (2mm gap) before 
electrical pulsing. A single electrical pulse (150 V, 15 ms for transfection of HBMMSCs and 200 
V, 10 ms for transfection of PBMMSCs) was delivered from an Electro Square Porator™ ECM 
830 (BTX Instrument Division, Harvard Apparatus, USA). Electroporated cells were 
immediately removed from the cuvette and plated in tissue culture flasks with growth medium. 
Transfection efficiency and viability were assessed as described in section 4.4.1.  
4.5. Generation of stable insulin-expressing porcine BMMSCs 
pTopo3EGR1chINS (section 4.3.3) was restricted with ApaLI endonuclease. The 
restriction products, including the human insulin expression cassette and kanamycin resistance 
cassette (5464 bp), were separated by DNA electrophoresis in agarose from which the 5464 bp 
fragment was purified using GeneAll® Expin™ DNA purification kit (GeneAll Biotechnology 
Co., Ltd., Korea). Five µg of this DNA, dissolved in DNAse-free water, was electroporated into 
2x106 PBMMSCs as detailed in section 4.4.3. Two x106 PBMMSCs were mock-electroporated 
without DNA to serve as controls. Electroporated PBMMSCs were cultured in 12-well plates 
(1x105 cells/well) containing culture medium i.e. Glutamax™-supplemented α-MEM mixed with 
StemPro™ in 3:1 (v/v) ratio supplemented with 10% FCS. Forty-eight hours later, the culture 
medium was replaced with the same fresh medium to which was added Geneticin (G418) in 
increasing concentrations (0, 25, 50, 100, 200, 400, 600, 800, 1000 and 1200 µg/ml; 2 wells for 
each concentration), cultured for two weeks with half-medium change and subculturing as 
detailed in section 4.2.3, when applicable. Surviving linearised plasmid-electroporated cells in 
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wells containing ≥200 µg/ml G418 were trypsinised and pooled before dispensing in equal 
aliquots into a 96-well plate (≤ 500 cells/well). Cells were cultured in the same medium without 
G418 until ~50% confluence before replacement with fresh medium containing G418 (200 
µg/ml). Cells from the most confluent well were trypsinised and aliquoted into a new 96-well 
plate (≤ 10 cells/well), and cultured in the same medium containing maintenance G418 i.e. 50 
µg/ml until ~80% confluence. As StemPro™ medium contains insulin, cells were cultured in α-
MEM with Glutamax™ for 3 days before conditioned media were aspirated for human insulin 
radioimmunoassay. PBMMSCs with the highest detected levels of secreted human insulin (10 
wells) were further propagated and designated as clones 1-10. To confirm the presence of the 
full-length insulin expression cassette, polymerase chain reaction (PCR) was performed on 
genomic DNA isolated from each of these clones, as detailed in section 4.8.4.        
4.6. In vitro characterisation of plasmid-modified primary adult somatic cells 
4.6.1. Primary murine hepatocytes 
4.6.1.1. Time course of transcriptional induction of transgene expression 
Primary C57BL/6J hepatocytes were transfected with p3MTChINS or pCMVINS as 
described in section 4.4.1. Equal aliquots of hepatocytes were plated in 7 wells (106 cells/well) 
for total cellular RNA isolation (section 4.8.2) in a total volume of 30 μl at the following time 
points:  
before addition of 25 mM glucose or 60 μM zinc;  
3, 6, 10 and 15 min after addition of glucose or zinc; and  
20 and 40 min after glucose or zinc withdrawal.   
cDNA was synthesised using SuperScript II Rnase H- reverse transcriptase and the 
supplier’s recommended protocol.  Each 20 μl reaction contained 10 μl RNA. One μl from the 
reverse transcriptase reaction was used as template for semi-quantitative PCR comprising 0.8 
μM each of forward and reverse primers, 1.6 mM magnesium chloride, 6.25 μl Quantitect 
SYBR® Green PCR master mix (Qiagen, Germany) and DNAse- and RNAse-free water to a 
final volume of 12.5 μl. Primer sequences for human insulin mRNA were (F: 5’ ttt gtg aac caa 
cac ctg tgc 3’; R: 5’ ggt tca agg gct tta ttc cat ct 3’). Intron-spanning primer sequences for mouse 
hypoxanthine phosphoribosyltransferase (HPRT) mRNA were (F: 5’ gaa gag cta ctg taa tga tca 
3’; R: 5’ gac aca aac gtg att caa atc 3’).  Thermal cycling conditions (Opticon™, MJ Research, 
USA) were 95oC for 15 min followed by 49 cycles of 95oC x 30 sec/56 oC x 30 sec/72 oC x 30 
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sec.  Melting curves (65 –95 oC) confirmed amplification of a single product in all reactions. 
Data were analysed using the Opticon Monitor™ Analysis software, version 1.07 (MJ Research, 
USA).  Differences in RNA input for reverse transcription were normalized using Ct values 
obtained in parallel for mouse HPRT mRNA. The ratio of mRNA at each time point after 
induction/mRNA before induction was given by the equation 2(b – y)[2(y – x) – 1]/[2(b – a) –1], where 
a is the Ct value of the uninduced sample and x is the Ct value of an induced sample, b and y are, 
respectively, the controls without reverse transcriptase (minus RT) for a and x.  Insulin and 
HPRT mRNA, and minus RT controls were measured in quadruplicate RT-PCR assays. Each 
induction experiment was performed twice.  
4.6.1.2.  Static induction of human insulin secretion by glucose and zinc 
Fourteen x106 hepatocytes were pooled from separate transfections (5 µg p3MTChINS/2 
x 106 cells) and plated in collagen-coated 35 mm dishes in DMEM-25 mM glucose. The medium 
was changed after 5 h and replaced with fresh DMEM containing varying glucose (1, 2.5, 4, 7, 
10, 15 and 25 mM) or zinc (0, 5, 10, 15, 20 and 60 μM) concentrations. Twenty-four h 
conditioned media were assayed for human insulin.  
4.6.1.3. Kinetics of glucose- and zinc-induced human insulin secretion 
Primary hepatocytes electroporated with 5 µg p3MTChINS and 3 µg pSEAP were 
cultured on 35 mm collagen I-coated dishes 24 h before perifusion with 25 mM glucose (2 x106 
cells) or 60 μM zinc (1x106 cells) medium, respectively. A peristaltic pump delivered DMEM as 
a constant stream (2 ml/min) over the entire surface of the culture dish while the perifusate was 
collected through a small opening at the bottom of the dish located directly opposite the point of 
inflow. The perifusate was collected continuously in 2-minute fractions from the start of the 
washout period (2.5 mM glucose for 30 min) until the end of each experiment.  For glucose 
induction, hepatocytes were stimulated twice by 25 mM glucose (40 min each) separated by a 40 
minute period of 2.5 mM glucose. For zinc induction, two exposures to 60 μM zinc (30 min) 
were separated by 30 min of zinc-free perifusion. All perifusate fractions were assayed for 
human insulin, SEAP and ALT activity.  
4.6.2. Primary porcine hepatocytes 
4.6.2.1.Static induction of human insulin transcription and secretion in vitro 
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Two x 106 hepatocytes were cultured on collagen I-coated 35 mm dishes in DMEM-25 
mM glucose for at least 16 h. For static induction, DMEM-25 mM glucose was replaced with 
DMEM containing increasing concentrations of glucose alone or zinc combined with either 2.5 
mM or 25 mM glucose. Conditioned media (24 h) of quadruplicate plates were assayed for 
human insulin. To determine the time course of glucose-stimulated insulin secretion, DMEM-25 
mM glucose was replaced with DMEM-2.5 mM glucose 3 h before commencing induction. 
Replicate plates were then exposed to DMEM-25 mM glucose for 5 - 90 min.  The mean of 2 
baseline time points i.e. 10 min and immediately before cells were exposed to 25 mM glucose, 
was taken as the unstimulated value. A parallel series of plates, after exposure to DMEM-25 mM 
glucose for 90 min, was returned to DMEM-2.5 mM glucose for 5 - 90 min during the de-
induction phase.  At every time point during both induction and de-induction phases, 
quadruplicate plates (replicates from each primary hepatocyte preparation) were processed for 
human insulin radioimmunoassay in the conditioned media and total cellular RNA isolation 
(section 4.8.2). Semi-quantitative RT-PCR was performed as described in section 4.6.1.1, 
without minus RT controls. Primers for S. scrofa HPRT mRNA were: F: 5’gaa gag cta ctg taa 
tga cca g 3’; R: 5’gcc agt gtc aat tat atc ttc aac 3’).  
4.6.3. Primary porcine BMMSCs 
4.6.3.1.Porcine BMMSCs immunophenotyped by FACS 
Adherent porcine bone marrow-derived cells were dissociated into single detached cells 
with Accutase™ (eBioscience, USA). Five million cells were resuspended in 60 µl cold staining 
buffer and 20 µl human FcR blocking reagent (Miltenyi Biotech, GmbH Germany), and 
incubated at 4°C for 15 min. The cell suspension was then topped up to 500 µl with cold staining 
buffer. One hundred-µl was dispensed into each of the five tubes designated as tubes 1-5. Tube 1 
served as the unstained control; tube 2 was stained with 10 µl of mouse anti-CD90 conjugated 
with FITC; tube 3 was stained with 10 µl of isotype control for CD90, i.e. FITC-mouse IgG1, κ; 
tube 4 was stained with 10 µl of mouse anti-CD11b conjugated with APC; tube 5 was stained 
with 10 µl of isotype control for CD11b, i.e. APC-mouse IgG2a, κ (all antibodies and reagents for 
FACS analysis were from BD Biosciences, USA). All tubes were incubated at 4°C for 20 min. 
Tubes 2 and 3 each received additional staining buffer (100 µl) and were mixed well. One 
hundred-µl cell suspension from each of these tubes i.e. tubes 2 and 3 was then transferred to 
new tubes labelled tubes 6 and 7, respectively, for bivariate staining. To tube 6 was added 10 µl 
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of APC-mouse anti-CD11b and to tube 7, 10 µl APC-mouse IgG2a, κ isotype control. These 
tubes were further incubated for another 20 min at 4°C. All tubes were washed and resuspended 
in 1 ml cold staining buffer before filtering through 40-µm cell strainers (Becton-Dickinson, 
USA). Flow cytometry analysis was performed on FACSCalibur (BD Biosciences, USA). A total 
of 10,000 events were acquired for each sample. Data were plotted using FlowJo software 
(Treestar, USA). 
4.6.3.2.  Temporal response of human EGR1 promoter to extracellular glucose 
concentrations 
Six x106 HBMMSCs were cotransfected with pEGR1-SEAP (4 µg) and pEGFP (2 µg). 
The latter plasmid served for assessment of transfection efficiency. Electroporated cells were 
pooled (2x106 cells/transfection) before dispensing into a 12-well plate (2x105 cells/well) and 
cultured for 48 h in DMEM-3 mM glucose. Another 6x106 HBMMSCs were cotransfected with 
pSEAP (4 µg) and pEGFP (2 µg), and treated in identical manner as cells transfected with 
pEGR1-SEAP. For static high glucose induction, all wells were washed twice before incubation 
in DMEM-20 mM glucose at 37°C and 5% CO2 for 5, 10, 15, 20 and 30 min. At each indicated 
time point, conditioned medium was aspirated for SEAP activity assay (SEAP assay kit, 
Clontech, USA). Cells were lysed for total cellular RNA isolation (section 4.8.2) (pEGR1-SEAP 
transfected cells: 3 wells for each time point; pSEAP2-Control transfected cells: 2 wells for each 
time point). Thirty minutes after high glucose induction, DMEM-20 mM was replaced with 
DMEM-3 mM and the incubation was continued for 15, 30, 45, 60 and 90 min before SEAP 
activity assay and total cellular RNA isolation. Semi-quantitative RT-PCR was performed as 
described in section 4.6.1.1 using primers for GFP (F: 5’ gaa gtt cat ctg cac cac c 3’; R: 5’ gtg 
ctg ctt cat gtg gtc gg 3’) and SEAP (F: 5' gac cat tgg ctt gag tgc ag 3'; R: 5' ggt tac cac tcc cac 
tga c 3'). The fold change in mRNA at each time point after glucose induction/mRNA before 
glucose induction was calculated by standard ∆∆CT analysis3 using human HPRT mRNA as 
internal control. HPRT primers were: (F: 5’gga tta cat caa agc act gaa tag 3’; R: 5’ggc tta tat 
cca aca ctt cgt g 3’). Data were normalised for transfection efficiency using CT values 
determined in parallel for GFP mRNA.  




Two x106 PBMMSCs were transfected with 5 µg of each of the following plasmids: 
p3EGR1chINS, p3EGR1(A)chINS, p3EGR1(B)chINS, p3EGR1(C)chINS, p3MTchINS and 
pEGFP (as control). Electroporated cells were resuspended in DMEM-2.5 mM glucose medium 
before dispensing into 6-well plates (1.5x105 cells/well) and cultured for 48 h. Glucose-
inducibility: DMEM-2.5 mM glucose was replaced with fresh DMEM medium containing 2.5, 5, 
10 and 20 mM glucose and incubated for 30 min at 37°C, 5% CO2 (3 wells for each glucose 
concentration). Conditioned medium was aspirated from each well for human insulin and human 
proinsulin radioimmunoassays. Insulin-inducibility: DMEM-2.5 mM glucose was replaced with 
fresh DMEM-5 mM glucose medium supplemented with 50, 200, 500 and 5000 pM of cell 
culture grade recombinant insulin (Sigma-Aldrich, USA) and incubated for 60 min in the same 
culture conditions described above (3 wells for each insulin concentration). Conditioned medium 
was aspirated for human C-peptide radioimmunoassay. Dexamethasone-inducibility: DMEM-2.5 
mM glucose was replaced with fresh DMEM-5 mM glucose medium supplemented with 2.5, 10 
and 20 nM dexamethasone sodium phosphate and incubated for 60 min in the same culture 
condition described above (3 wells for each dexamethasone concentration). Conditioned medium 
was aspirated from each well for human insulin radioimmunoassay.  
4.6.3.4. Kinetics of glucose-induced human insulin secretion from plasmid-modified porcine 
BMMSCs  
 The temporal pattern of human insulin secretion was investigated in 1x106  PBMMSCs 
stably integrated with a linearised plasmid construct, either (A) p3EGR1chINS or (B) 
p3EGR1(B)chINS, and co-electroporated with pSEAP. Continuous perifusion (1 ml/min) at 37ºC 
in DMEM was performed 48h after culture in DMEM-3 mM glucose, first with a gradient of 
increasing glucose concentration over 90 min, followed by gradually decreasing glucose 
concentration over 120 min (see section 4.6.1.3 for more details on the perifusion method). The 
gradually increasing gradient of glucose concentration was generated by adding DMEM-30 mM 
glucose at the rate of 1 ml/min into a reservoir of DMEM-2 mM glucose (150 ml) using a 
peristaltic pump. The mixture was vigorously and continuously stirred before reaching a second 
peristaltic pump used to perifuse the cells. The reverse gradient of gradually decreasing glucose 
concentration was generated by adding DMEM-0 mM glucose (1 ml/min) into 100 ml of DMEM 
that had formed at the peak of the aforementioned rising glucose gradient (~20 mM). This 
complete arrangement made it possible to perifuse the cells continuously in a rising or falling 
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glucose gradient in which the glucose concentration either increased or decreased at a constant 
rate of 0.2 mM/min. The perifusate was collected in 5-min fractions throughout each experiment 
and assayed for glucose concentrations (Elite® glucometer), human insulin (ultrasensitive human 
insulin radioimmunoassay kit) and SEAP activity (Clontech™ SEAP kit). Each perifusion 
experiment was performed twice. Appendix 6 shows the experimental set-up. 
4.7. Implantation of plasmid-modified primary adult somatic cells 
4.7.1. Syngeneic implantation of primary murine hepatocytes 
One x106 freshly isolated hepatocytes were electroporated with 5 μg p3MTChINS as 
described in section 4.4.1. About 8 x 105 viable electroporated cells in 0.1 ml Nucleofector 
solution were delivered by direct interstitial injection using a 29G needle into the right lateral 
and right medial lobes of unresected liver, of partially hepatectomised liver or into the mesentery 
of diabetic mice under general anaesthesia. Control diabetic mice were implanted with 
hepatocytes electroporated without plasmid (mock-implanted). The number of hepatocytes 
implanted was limited by the volume of cell suspension that could be injected into the liver or 
mesentery without significant backflow and loss of cells. It was not influenced by the desire to 
avoid hypoglycemia in implanted animals. All mice were of the C57BL/6J strain. 
4.7.2. Autologous implantation of primary porcine hepatocytes 
 Resection of liver wedge was performed by Dr. Wong Jen San, Department of General 
Surgery, Singapore General Hospital. Fourteen diabetic Yorkshire-Landrace pigs (9 male and 5 
female; 17-23 kg) underwent excision of 30% of the left lateral liver lobe (equivalent to <10% of 
total liver mass) under general anaesthesia 10 days post-STZ administration. The left lateral liver 
lobe was mobilised as previously described4.  About 30% of the lobe was resected en masse after 
applying a non-crushing clamp. The main portal vein branch in the resected specimen was 
immediately cannulated and perfused with cold calcium-free Dulbecco’s phosphate buffer. 
Haemostasis was achieved with 5/0 Prolene sutures and diathermy. Surgicel (Johnson & 
Johnson, USA) was applied to the resected surface in situ and the abdominal cavity was washed 
with 5 ml of an antibiotic solution (penicillin 100 mg/ml and ampicillin 100 mg/ml). The 
abdominal wound was closed with continuous 2/0 Ethilon and the skin with 3/0 subcuticular 
Vicryl sutures. All surgical sutures were from Ethicon, USA. Primary hepatocytes prepared from 
excised liver tissue were electroporated ex vivo with p3MTchINS in NC solution as detailed in 
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section 4.4.2 and immediately reimplanted into the liver parenchyma using one of the methods 
below with comparable metabolic outcomes. 
Hepatocyte implantation was performed by Dr. Wong Jen San and Dr. Thng Choon Hua, 
Department of Oncologic Imaging, National Cancer Centre. Open method: The abdominal cavity 
was left open after liver resection while hepatocyte isolation and electroporation were performed. 
Transfected hepatocytes in suspension were injected under direct vision in up to 5 sites of the left 
and right central lobes with a 23G needle (3-4 ml/site). Implantation sites were marked with a 
5/0 Prolene suture. The abdominal incision was then sutured close. Percutaneous method: The 
abdominal incision was closed immediately after liver resection. The suspension of transfected 
hepatocytes was injected percutaneously into 3 sites in the left and right central liver lobes (5–6 
ml/site) using a Spinocan® spinal needle (22G, 3.5 inches long; B. Braun Medical Inc., USA) 
under real-time ultrasonic guidance (Acuson XP10, USA). The animal was placed in a reverse 
Trendelenburg position during this procedure. Gelfoam® suspension (1 ml) (Pharmacia & 
Upjohn, USA) was injected as the needle was withdrawn from the liver parenchyma for 
haemostasis. The number of hepatocytes implanted using either method was 2.0 - 3.3x108 in 15 
ml DMEM. The entire procedure from wedge excision to hepatocyte implantation was 
completed in about 3 h as a single surgical operation.  
4.7.3. Xenogeneic implantation of primary porcine BMMSCs 
Intrahepatic implantation (IH). Two or 5x106 circular plasmid-electroporated PBMMSCs 
or stably linearised plasmid-modified PBMMSCs in 0.2 ml serum-free StemPro™ medium were 
delivered by direct interstitial injection using a 27G needle into the right lateral and right medial 
liver lobes of either non-diabetic or STZ-diabetic NOD-SCID mice. An absorbable haemostatic 
patch of approximately 2 mm2 (Surgicel®, Ethicon, Switzerland) was used to stop bleeding and 
minimise backflow of the injected cell suspension as the needle was withdrawn. Intraperitoneal 
implantation (IP).The same number of modified cells in 0.5 ml serum-free StemPro™ medium 
was injected into the peritoneal cavity of either non-diabetic or STZ-diabetic NOD-SCID mice 
using a 27G needle. Untreated control animals were implanted with PBMMSCs that were 
electroporated without insulin expression plasmid (mock-implanted).   
4.8. Molecular biology techniques 
4.8.1. Plasmid isolation 
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 For large scale plasmid isolation, a starter culture of 2-5 ml LB broth containing selective 
antibiotic was inoculated with a single bacterial colony from a freshly streaked selective plate 
and grown at 37°C for ~6 h with vigorous shaking (~250 rpm). The starter culture was then 
transferred into 500 ml or 2.5 L selective LB broth for plasmid isolation using EndoFree® 
Plasmid Maxi Kit or Giga Kit, respectively (Qiagen, Germany). The culture was further grown 
for 16 h before the bacterial cells were harvested. Plasmid isolation was performed according to 
the manufacturer’s instructions. 
4.8.2. Cellular RNA isolation 
 Total RNA was isolated from cultured cells using RNeasy Fibrous Tissue kit or RNeasy 
Mini kit. Cells were lysed in situ without trypsinisation. Briefly, the culture medium was first 
aspirated completely followed by cell lysis performed to the manufacturer’s instructions. On-
column DNase digestion was performed to eliminate possible DNA contamination.  
4.8.3.  Tissue RNA isolation 
 Tissues (kidney, retina, liver and aorta) harvested during planned autopsies were flash 
frozen and homogenised with mortar and pestle in liquid nitrogen. Total RNA was extracted 
using the guanidine thiocyanate method5. In brief, homogenised tissues were first lysed in a 4 M 
guanidine solution. The cell lysate was then layered on 5.7 M caesium chloride in a silanised, 
autoclaved polyallomer ultracentrifuge tube. RNA was pelleted after ultracentrifugation (150,000 
g, 18°C for 16 h). After removing the supernatant, the RNA pellet was washed with 70% ethanol 
dissolved in RNAse-free water, quantitated by ultraviolet absorbance (NanoDrop® 
Spectrophotometer) and stored at -80°C. All apparatus and solutions were treated with 0.1% v/v 
diethyl pyrocarbonate-water to inhibit RNase activity.  
4.8.4. Polymerase chain reaction (PCR) 
 High fidelity PfuUltra II® fusion hot start DNA polymerase (Stratagene, USA) was used 
to amplify DNA fragments for cloning as well as screening purposes. A typical PCR had the 
following components, unless otherwise stated: 250 ng genomic DNA (gDNA) or 20 ng vector 
DNA, 0.4 µM of each primer, 2 mM dNTPs, 1x PfuUltra II® reaction buffer and 1 U Pfu DNA 
polymerase. PCR was performed on a PTC-200 Peltier Gradient Thermal Cycler (MJ Research, 
Inc., USA). Primers to detect the full-length human insulin expression cassette in stably-




4.8.5. Semi-quantitative PCR 
 Quantitect SYBR® Green PCR master mix (Qiagen, Germany) and a real-time thermal 
cycler (Opticon™, MJ Research Inc., USA) were used to semi-quantitatively amplify genomic 
DNA or cDNA fragments of interest.  
4.8.5.1.Detection of intracellular p3MTchINS 
 Total DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissues 
(Puregene® DNA purification kit; Gentra Systems, USA). A standard curve was constructed 
from semi-quantitative PCR by spiking 50 ng of gDNA isolated from FFPE liver of a virgin pig 
with graded amounts of p3MTChINS DNA (0, 1, 10, 50, 100, 500, 1,000, 5,000 and 10,000 pg). 
Primer sequences amplified the ampicillin resistance gene unique to the plasmid (F: 5’gca act tta 
tcc gcc tcc atc 3’; R: 5’gca aac tat taa ctg gcg aac ta 3’). Plasmid DNA detected in DNA of pig 
liver sections was quantified using the equation derived from the standard curve: log DNA = -
0.2507 Ct + 5.4122 (triplicate assays, r2 = 0.9952).  
4.8.5.2.Determining genomic integration of electroporated transgene 
 gDNA was isolated from (i) unmodified PBMMSCs as negative control, (ii) 
pTopo3EGR1chINS-stably-modified PBMMSC clone 5 as positive control; and (iii) PBMMSCs 
electroporated with the same plasmid in circular form, according to manufacturer’s instructions 
(Qiagen, Germany). To ensure no contamination of gDNA by circular plasmid DNA, plasmid-
electroporated cells were cultured for several cell doublings before isolation of gDNA. Two 
different concentrations of gDNA (5 or 50 ng) prepared from circular plasmid-electroporated 
PBMMSCs (pooled from at least 3 separate electroporations) were used as template. Two pairs 
of PCR primers amplifying 2 different regions of the plasmid were tested, i.e. primers set 1: 
between EGR1 promoter and human (pro)insulin cDNA (165 bp amplicon) (F: 5’ gga tcc ggg 
gag tcg aca g 3’; R: 5’ gaa gtt ctc agg atc ggt cg 3’) and primers set 2: within the neomycin 
resistance gene (117 bp amplicon) (F: 5’ gct cct gcc gag aaa gta tcc 3'; R: 5’ gag tac gtg ctc gct 
cga tgc 3'). Fifty-cycle amplification was performed.  
4.8.6. Real time Reverse Transcription (RT)-PCR 
 Semi-quantitative porcine transcript analyses were performed as described in section 
4.6.1.1. Primer sequences were:  Human insulin (F: 5’ ttt gtg aac caa cac ctg tgc; 3’; R: 5’ ggt 
tca agg gct tta ttc cat ct 3’), Human hypoxanthine phosphoribosyltransferase (F: 5’gga tta cat 
caa agc act gaa tag 3’; R: 5’ggc tta tat cca aca ctt cgt g 3’), S. scrofa insulin (F: 5’ggc ctt cgt 
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gaa cca gca c 3’; R: 5’cca gct cca cgg cac ctg 3’), S. scrofa glucagon (F: 5’gtt tac cag tga cta 
cag c 3’; R: 5’gtc tct caa att cat cgt ga 3’), S. scrofa somatostatin (F: 5’gaa ctg gcc aag tac ttc 
3’; R: 5’gct cca gcc tca ttt cat 3’), S. scrofa pancreatic polypeptide (F: 5’cct gcg tgg ctc tgt tac 
tac 3’; R: 5’ggt cag cat gtt gat gta tct ac 3’), S. scrofa hypoxanthine phosphoribosyltransferase I 
(F: 5’gaa gag cta ctg taa tga cca g 3’; R: 5’gcc agt gtc aat tat atc ttc aac 3’) and ampicillin 
resistance gene (F: 5’gca act tta tcc gcc tcc atc 3’; R: 5’gca aac tat taa ctg gcg aac ta 3’). 
4.8.7. DNA sequencing 
 DNA sequencing was performed using the ABI PRISM Big Dye Terminator version 1.1 
cycle sequencing reaction kit (Applied Biosystem, Life Technologies Corp., USA). Typically, a 
10 µl reaction consisted of 5 µl template DNA (total 200-300 ng), 1 µl of 1.6 µM primer, 2 µl 5x 
buffer and 2 µl master mix. Thirty-cycle PCR reactions (95°C for 30 sec, 50°C for 30 sec and 
60°C for 4 min) were performed. The PCR products were precipitated with 0.1 M EDTA (1 µl), 
3 M sodium acetate, pH 5.2 (1 µl) and absolute ethanol (50 µl) by centrifugation at 16,100 g for 
15 min at 20°C. The pellet was washed with 70% ethanol and vacuum -dried. DNA was 
dissolved in 20 µl buffered formamide before electrophoresis for 100 minutes (ABI automated 
DNA analyser model 3730).  
4.8.8. Transcriptome profiling of porcine tissues 
4.8.8.1. Study design  
We transcriptionally profiled kidney, retina, aorta and liver of normal healthy, treated 
diabetic and untreated diabetic Yorkshire-Landrace pigs (n=2 per group). All animals were 
matched for age, sex and body weight at the start of the experiment. Treated diabetic and 
untreated diabetic pigs were autopsied 34-38 weeks and 36-42 weeks, respectively, after 
autologous hepatocyte implantation. To ensure that the transcriptome profiles were 
representative of the entire organs/tissues of interest, we homogenized (i) a whole kidney; (ii) all 
retinal tissue of one eye; (iii) equal segments from the aortic arch, thoracic and abdominal aorta; 
and (iv) an equal portion from each liver lobe of each pig. Ground tissues were mixed well 
thoroughly before total RNA isolation (section 4.8.3). 
4.8.8.2. Target preparation and hybridisation  
Biotinylated and fragmented cRNA was prepared by the Affymetrix protocol and hybridised to 
Affymetrix GeneChip® Porcine Genome Arrays (each target organ from a single animal was 
profiled in duplicate; there were thus 4 replicate transcriptome datasets for each organ/tissue in 
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each study group). Each array contained probe sets for 20,201 Sus scrofa genes and was scanned 
in a GeneChip® Scanner 3000 (Affymetrix, Inc., Santa Clara, USA).  
4.8.8.3.Data analysis  
 We normalised signal intensities by global scaling to an arbitrary value of 500 using 
Microarray Suite software, version 5.0 (Affymetrix). We next analysed normalised data by target 
organ or tissue type. Genes with absent calls in ≥10 out of 12 datasets (2 arrays x 2 animals x 3 
groups) were excluded. We selected genes that were differentially expressed (i.e. ≥1.5-fold 
difference) in three pairwise comparisons (i.e. normal vs. untreated diabetic, normal vs. treated 
diabetic and treated diabetic vs. untreated diabetic) using FiRe v. 2.2 software6. These genes, 
listed by log2 intensity values, were analysed using Significance Analysis of Microarrays (SAM) 
version 1.21 based on 1,000 permutations7.  Pairwise comparisons allowed us to obtain three 
gene sets, each having a false discovery rate <1%. The inter-relationship of these three gene sets 
was established with Venn diagrams (FiRe v. 2.2 software).  
4.8.9. Transcriptome profiling of human BMMSCs 
4.8.9.1. Study design  
HBMMSCs cultured overnight in DMEM-3 mM glucose (as the low glucose baseline) 
were exposed to DMEM-20 mM glucose (high glucose) for 15 or 30 min, and then returned to 
DMEM-3 mM glucose for 30 or 60 min (5 x 105 cells/plate, 3 plates for each time point, 5 time 
points in total). Cells from each time point were lysed for total cellular RNA isolation (section 
4.8.2) and pooled. 
4.8.9.2.Target preparation and hybridisation 
 Biotinylated and fragmented cRNA was prepared by the Affymetrix protocol and 
hybridised to Affymetrix U133 Plus 2.0 Array GeneChip® (each time point was profiled in 
duplicate; there were thus 10 transcriptome datasets). Each array contained probe sets for 39,000 
human genes and was scanned in a GeneChip® Scanner 3000 (Affymetrix Inc., Santa Clara, 
USA).  
4.8.9.3.Data analysis  
 We normalised signal intensities as described in section 4.8.8.3. We selected genes whose 
expression was upregulated when HBMMSCs were incubated with DMEM-20 mM glucose, and 
downregulated when HBMMSCs were incubated with DMEM-3 mM glucose. Data were 
subjected to the following pairwise comparisons using FiRe v. 2.26.   
230 
 
 (A) baseline vs. 15 min after incubation in DMEM-20 mM glucose;  
 (B) 15 min vs. 30 min after incubation in DMEM-20 mM glucose;  
 (C) 30 min after incubation in DMEM-20 mM glucose vs. 30 min after reversion 
       to DMEM-3 mM glucose; and    
 (D) 30 min vs. 60 min after reversion to DMEM-3 mM glucose.  
 Selected transcripts were validated by semi-quantitative RT-PCR (section 4.6.1.1) using 
cDNAs hybridised to the arrays. Each RT-PCR assay was performed in quadruplicate. Fold 
change was determined as described in section 4.6.3.2. Primer sequences were: EGR1 (F: 5’ gag 
ggt tcc tct tag gtc aga tgg a 3’; R: 5’ ggc agc tga agt caa agg gaa tag 3’); FOS (F: 5’ gag aaa cac 
atc ttc cct aga ggg t 3’; R: 5’ gtc act ggg aac aat aca cac tc 3’).  
4.9. Cell biology techniques 
4.9.1. Microscopy 
4.9.1.1. Light and fluorescence microscopy 
Cultured cells were routinely monitored on an inverted, bright field microscope (model 
CK30-F200, Olympus). Cell number was enumerated using a haemocytometer and a phase 
contrast microscope (model CH30RF200, Olympus). GFP+ cells were examined with an inverted 
fluorescence microscope (Axiovert 25CFC, Carl Zeiss) equipped with a 450-490 nm excitation 
band width filter. Images were acquired with a digital camera attached to the microscope and 
processed with KS400 software (X). For all microscopes, objective lens magnifications were 
10X, 20X and 40X; eyepiece lens magnification was 10X. 
4.9.1.2. Scanning electron microscopy 
Specimens were fixed in 2.5% glutaraldehyde in phosphate-buffered saline for 24 h at 
4°C, and then post-fixed in 1% osmium tetroxide, pH 7.4 for 2 h at room temperature, followed 
by dehydration in a graded ethanol series and drying in a critical point dryer. Preparations were 
coated with gold for viewing (JSM-5660, JEOL, Japan). 
4.9.1.3. Transmission electron microscopy  
Specimens were fixed and post-fixed as for SEM. After dehydration, specimens were 
embedded in epoxy resin (polymerisation at 60°C for 24 h). Ultra-thin sections (90-100 nm) 
were stained with uranyl acetate and lead citrate, and viewed in a microscope (JEM-1220, JEOL, 
Japan) operated at 100 KV. Basement membrane thickness was measured from TEM images of 
20 choroidal capillaries (10 measurements per capillary) and 20 renal glomeruli (10 
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measurements per glomerulus) using a standard grid. The retina and kidney of three animals 
(healthy control, untreated diabetic and treated diabetic pigs) were compared. All measurements 
were made independently by three individuals whose data were pooled for analysis. 
4.9.2.    Histology 
4.9.2.1. Mouse liver 
Fresh liver removed from C57BL/6 mice implanted with p3MTChINS-transfected 
Rosa26 hepatocytes and from control non-diabetic mice implanted with untransfected 
hepatocytes were diced, fixed in 10% formalin for 15 min and stained for β-galactosidase 
activity. Positively stained tissues were further fixed for 12 h and processed to 4 μm paraffin 
sections. After antigen retrieval (microwave heating in citrate buffer, pH 6.0), sections were 
incubated with ready-diluted monoclonal antibody against human insulin (Zymed Laboratories, 
Inc., USA) for 45 min. Bound primary antibody was detected with ChemMate™ Envision™ 
detection kit using the supplier’s protocol (Dako Cytomation, Denmark). Paraffin sections were 
counterstained with haematoxylin.  
The following procedure was used to demonstrate co-localisation of β-galactosidase 
activity and transgenic human insulin expression. Liver was minced, fixed in 0.5% 
glutaraldehyde for 20 min and washed thrice in 2 mM MgCl2, 0.01% (w/v) sodium 
deoxycholate, 0.02% (v/v) Nonidet P-40 and 100 mM sodium phosphate buffer, pH 8.0.  Tissues 
were stained with X-Gal solution for 4 h (β-Gal Staining Set, Roche, Germany), washed thrice in 
phosphate-buffered saline and post-fixed in 10% formalin for 12 h.  Fixed and stained tissues 
were manually processed for sectioning according to a published protocol8 except that xylene 
was replaced by Histoclear™ (National Diagnostics, Inc., USA).  Antigen retrieval on 4 μm 
sections was performed by microwave heating in Target Retrieval Solution pH 9.9 (Dako A/S, 
Denmark).  Antibody detection was as described above. 
4.9.2.2. Pig liver, pancreas and kidney 
Formain-fixed paraffin-embedded liver and pancreas sections (4 µm) were 
immunostained with the following primary antibodies according to manufacturers’ 
recommended protocols: ready-diluted monoclonal mouse anti-human insulin, monoclonal 
mouse anti-rat proliferating cell nuclear antigen (1:50 dilution) and monoclonal rabbit anti-
human Ki-67 (1:100 dilution) (both from Acris Antibodies GmbH, Germany). The latter two 
antibodies also detect the corresponding porcine antigens. Bound primary antibody was detected 
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with ChemMateTM EnvisionTM kit (Dako Cytomation, Denmark). Sections were counterstained 
with haematoxylin. Standard histological evaluations were performed on paraffin sections (4 
µm) of liver and kidney stained with haematoxylin and eosin. Liver sections were also stained 
with periodic acid Schiff (PAS) reagent (Sigma-Aldrich, USA) and counterstained with 
haematoxylin. 
4.10. Techniques involving animals 
4.10.1. General anaesthesia 
C57BL/6J, Rosa26 and NOD-SCID mice were injected with a mixture of Hypnorm 
(fentanyl citrate 0.315 mg/ml and fluanisone 10 mg/ml; Abbyvet Ltd. UK), xylazine (20 mg/ml), 
midazolam (15 mg/ml) and water in 2:1:1:6 volumetric ratios. Doses of the mixture were 100-
200 µl for C57BL/6J and Rosa26 mice, and 80-150 µl for NOD-SCID mice. 
Yorkshire-Landrace pigs were first chemically restrained with ketamine (15 mg/kg), 
intubated and maintained with volatile inhalation of 2-3% isoflurane, with or without 
pentobarbitone (15 mg/kg, IV injection). 
4.10.2. Partial hepatectomy 
Thirty-percent PH was performed on C57BL/6 mice under general anaesthesia by 
resecting the left lateral and left median lobes after tying off with Vicryl 4.0 sutures (Johnson 
and Johnson). 
4.10.3. Induction of diabetes with streptozotocin 
4.10.3.1. C57BL/6J and NOD-SCID mice 
Diabetes was induced by 3 and 4 consecutive daily intraperitoneal injections of STZ 
(100 mg/kg body weight/day dissolved in 100 mM citrate buffer pH4.5; Sigma-Aldrich, USA) in 
NOD-SCID and C57BL/6J, respectively. Non-fasting blood glucose levels were determined two 
days after the last STZ injection using a glucometer and glucose test strips. Mice whose blood 
glucose levels exceeded 14.4 mM (C57BL/6J) and 19.3 mM (NOD-SCID) were considered 
diabetic. 
4.10.3.2. Yorkshire-Landrace pigs 
Pigs were fed ammonium chloride (1.5 g/kg body weight in 500 g moistened chow)9 16 
h before a bolus ear vein injection over 2 min of STZ (150 mg/kg body weight in 0.9% sodium 
chloride solution; Zanosar®, Pfizer) followed immediately by 50 ml of isotonic saline. 
Exogenous insulin injections (Lantus®, Sanofi Aventis; Humulin® R, Lilly) were administered to 
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diabetic pigs only when fasting blood glucose exceeded 11 mM during the 3-day period before 
surgery to reduce the risk of post-operative sepsis. Insulin was not administered to any animal at 
any time after hepatocyte implantation. 
4.10.4. Serial monitoring of metabolic and biochemical indices 
4.10.4.1. C57BL/6J mice 
Heparinised blood (350 μl) was drawn from the retro-orbital plexus on the first day of 
STZ administration, on the day of hepatocyte implantation and thereafter 1, 3, 6, 10, 20 and 30 
days after implantation. After centrifugation at 16,100 g and 4°C for 15 min, plasma samples 
were stored at -20°C until assayed for human insulin and mouse C-peptide. Blood glucose levels 
and body weights were also monitored on the same days. Exogenous insulin was never 
administered. 
4.10.4.2. NOD-SCID mice 
 Serial body weights and blood glucose concentrations were determined during the 
experimental period as follows: day -10 (non-diabetic phase), day -5 (diabetic phase after three 
STZ injections on day -9 to day -7), day 0 (day of cell implantation), day 3 (3rd day post-
implantation), day 7 (1st week post-implantation), day 12 (12th day post-implantation), day 16 
(16th day post-implantation), day 21 (3rd week post-implantation) and day 30 (1 month post-
implantation). Plasma human insulin concentrations were assayed from day 3 onwards using a 
human-specific insulin radioimmunoassay. Intraperitoneal glucose tolerance tests (IPGTTs) were 
performed on days -10, -5, 7 and 21. 
4.10.4.3. Yorkshire-Landrace pigs 
Capillary blood was obtained by ear prick and glucose concentration measured with a 
glucometer (Ascensia ELITE®, Bayer HealthCare, Germany). We drew femoral venous blood 
periodically for measurements of human C-peptide (HCP), porcine C-peptide (PCP) in our 
laboratory, and for the following clinical serum and blood analytes assayed in the Department of 
Pathology, Singapore General Hospital: fructosamine, urea, creatinine, electrolytes (potassium, 
sodium and chloride), total protein and albumin, total bilirubin, alkaline phosphatase, alanine 
aminotransferase (ALT), gamma-glutamyltransferase (GGT), triglycerides, total and HDL 
cholesterol.  
4.10.5. Intraperitoneal glucose tolerance test 
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 This was performed after an overnight fast on all diabetic mice (implanted with 
transfected or untransfected hepatocytes) and on control non-diabetic mice of the same age and 
sex. Glucose solution (75 mg/ml; 1.5 mg/g body weight) was injected intraperitoneally and blood 
glucose was measured at 0, 30, 60, 120 and 180 min (C57BL/6J) or at 0, 10, 20, 30, 45, 60 and 
90 min (NOD-SCID). Glucose tolerance between groups was compared by calculating the AUC 
which was the sum of the trapezoidal area under the blood glucose curve after baseline values 
were subtracted. 
4.10.6. Temporal response of glucose-induced insulin secretion in vivo 
Three days after implantation of syngeneic primary hepatocytes transfected with 
p3MTChINS, an intravenous bolus of glucose solution (75 mg/ml and 1.5 mg/g body weight) 
was administered to diabetic mice via the inferior vena cava. Blood was drawn for plasma insulin 
assay before and at intervals (10, 20 and 30 min) after glucose stimulation. In order to avoid 
possible artefacts caused by hypovolaemia, the blood volume of each mouse was replaced with 
an equal volume of intravenous 0.9% NaCl after each blood sampling. 
4.10.7. Intravenous glucose tolerance test 
We performed IVGTT on 16 h overnight fasted pigs. An internal jugular vein was 
cannulated (7-French; Arrow International, Inc.) under general anaesthesia. To establish the 
baseline, a saline bolus (equal to the volume of glucose solution) was injected over 3 min and 
blood was drawn 10, 20 and 30 min later for blood glucose, plasma HCP and PCP assays. 
IVGTT was initiated by a bolus glucose injection (1 g/kg; 25% w/v solution) over 3 min 
followed by 30 ml saline injection to flush the line. Blood was drawn 1, 3, 5, 10, 20, 30, 45, 60 
and 90 min after the glucose bolus for the same assays. To avoid possible artefacts caused by 
hypovolaemia, 3 ml heparinised saline (equal to the volume of blood withdrawn) was injected 
after each blood sampling. 
4.11. Statistical and survival analysis 
Data were expressed as mean ± s.e.m. The number of animals is denoted by N and the 
total number of data points by n. Groups were compared using Student’s unpaired two-sided t 
test (for data with equal variances) or Mann-Whitney U-test (for data with unequal variances). 
One-way ANOVA with Bonferroni correction was used for multiple group comparisons. All 
statistical tests and the AUC were calculated with GraphPad Prism (GraphPad Software Inc., 
USA). Survival data were presented by the Kaplan-Meier method using SPSS. Cluster analysis 
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of GeneChip® data was performed using algorithms in Genowiz (Ocimum Biosolutions Ltd., 
India). P < 0.05 was considered significant. 
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Appendix 2 Primary murine hepatocytes cultured on different matrices. 
 
p3MTchINS-electroporated primary murine hepatocytes cultured on (A) rat tail collagen I, (B) 
mouse collagen IV, (C) Matrigel®. Original magnification 200X.   
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4.4 ± 0.3  
(2.5-12.4) 
(n=59) 
17.3 ± 0.6 
(4.7->33.3) 
(n=97) 
10.0 ± 0.2 
(3.9-16.4) 
(n=178) 
9.8 ± 0.4 
(2.9-21.3) 
(n=144) 
4.4 ± 0.5 
(2.7-13.1) 
(n=27) 
16.9 ± 1.2 
(3.9->33.3) 
(n=32) 
20.1 ± 0.5 
(10.7->33.3) 
(n=93) 






Nil 0.46 ± 0.05 
(0.30-0.71) 
(n=10) 






0.30 ± 0.03 
(0.15-0.38) 
(n=9) 
-0.10 ± 0.05 
(-0.27)-0.05 
(n=9) 
0.20 ± 0.03 
(0-0.31) 
(n=9) 
0.18 ± 0.02 
(0.14-0.21) 
(n=3) 
0.30 ± 0.02 
(0.26-0.34) 
(n=4) 
-0.06 ± 0.03 
(-0.14)-0.01 
(n=4) 
-0.24 ± 0.15 
(-0.59)-0.02 
(n=4) 





311.9 ± 7.6 
(282-363) 
(n=13) 







538.8 ± 22.7 
(350-766) 
(n=33) 
305.8 ± 9.5 
(276-365) 
(n=8) 
424.6 ± 16.6 
(352-488) 
(n=8) 
632.2 ± 31.9 
(362-885) 
(n=28) 





5.67 ± 0.66 
(2.1-9.1) 
(n=13) 
3.81 ± 0.38 
(2.0-8.0) 
(n=18) 
5.16 ± 0.32 
(2.2-13.4) 
(n=51) 
4.90 ± 0.34 
(2.1-8.0) 
(n=32)  
5.53 ± 1.08 
(2.2-9.7) 
(n=8) 
6.64 ± 0.89 
(4.6-10.0) 
(n=8) 
6.74 ± 0.25 
(4.4-10.3) 
(n=29) 





77.2 ± 8.0 
(52-156) 
(n=14) 
77.3 ± 3.2 
(52-104) 
(n=20)  
77.1 ± 3.1 
(25-121) 
(n=50) 
135.3 ± 4.4 
(91-187) 
(n=34) 
85.9 ± 5.7 
(57-101) 
(n=8) 
87.3 ± 7.9 
(58-126) 
(n=9) 
68.5 ± 3.4 
(25-101) 
(n=30) 





4.11 ± 0.12 
(3.4-4.6) 
(n=12) 
4.26 ± 0.09 
(3.7-4.8) 
(n=18) 
4.06 ± 0.05 
(3.4-4.8) 
(n=48) 
3.91 ± 0.06 
(3.4-5.2) 
(n=33) 
4.19 ± 0.16 
(3.6-4.7) 
(n=8) 
4.17 ± 0.12 
(3.6-4.6) 
(n=9) 
4.06 ± 0.06 
(3.3-5.1) 
(n=32) 





51.3 ± 1.1 
(44-60) 
(n=20) 
53.0 ± 1.1 
(47-69) 
(n=29) 
57.4 ± 0.8 
(42-70) 
(n=52) 
62.4 ± 1.2 
(51-83) 
(n=35) 
59.3 ± 2.6 
(49-73) 
(n=8) 
53.9 ± 1.5 
(44-60) 
(n=9) 
58.7 ± 1.3 
(45-70) 
(n=30) 





14.9 ± 0.4 
(11-18) 
(n=21) 
14.9 ± 0.3 
(11-18) 
(n=30) 
14.6 ± 0.3 
(11-18) 
(n=52) 
13.9 ± 0.5 
(10-18) 
(n=35) 
16.8 ± 1.1 
(10-21) 
(n=8) 
16.3 ± 0.7 
(12-19) 
(n=9) 
14.9 ± 0.3 
(12-17) 
(n=30) 





2.10 ± 0.25 
(1.0-6.0) 
(n=21) 
2.69 ± 0.27 
(1.0-7.0) 
(n=30) 






1.63 ± 0.18 
(1.0-2.0) 
(n=8) 
3.0 ± 0.65 
(1.0-7.0) 
(n=8) 
5.97 ± 0.96 
(1.0-20.0) 
(n=32) 






179.9 ± 9.3 
(131-275) 
(n=21) 
174.3 ± 10.0 
(81-269) 
(n=30) 
146.7 ± 6.3 
(61-263) 
(n=54) 
158.4 ± 8.4 
(61-259) 
(n=35) 
156.3 ± 10.0 
(126-209) 
(n=8) 
123.6 ± 13.9 
(63-180) 
(n=9) 
124.7 ± 10.7 
(61-268) 
(n=32) 





36.9 ± 2.0 
(27-59) 
(n=21) 
39.0 ± 1.8 
(24-57) 
(n=30) 
49.4 ± 2.5 
(25-135) 
(n=54) 
41.0 ± 3.1 
(15-96) 
(n=35) 
36.9 ± 3.3 
(25-48) 
(n=8) 
40.2 ± 3.5 
(31-65) 
(n=9) 
68.9 ± 3.3 
(43-147) 
(n=31) 





22.2 ± 2.0 
(15-45) 
(n=21) 
25.8 ± 2.6 
(13-57) 
(n=30) 
28.4 ± 1.9 
(14-67) 
(n=54) 
24.7 ± 0.7 
(19-35) 
(n=35) 
19.6 ± 0.7 
(17-22) 
(n=8) 
18.8 ± 1.0 
(14-23) 
(n=9) 
24.6 ± 1.2 
(17-39) 
(n=32) 





0.36 ± 0.05 
(0.15-0.88) 
(n=19) 
0.94 ± 0.09 
(0.39-1.87) 
(n=29) 
0.40 ± 0.03 
(0.17-1.29) 
(n=52) 
0.31 ± 0.01 
(0.14-0.38) 
(n=35) 
0.29 ± 0.08 
(0.12-0.83) 
(n=8) 
0.81 ± 0.15 
(0.33-1.61) 
(n=9) 
1.03 ± 0.11 
(0.17-2.26) 
(n=29) 










1.83 ± 0.06 
(0.86-2.36) 
(n=30) 
1.62 ± 0.04 
(1.11-2.38) 
(n=54) 
1.51 ± 0.04 
(1.14-2.03) 
(n=35) 
1.71 ± 0.08 
(1.35-2.01) 
(n=8) 
2.23 ± 0.25 
(1.70-3.78) 
(n=8) 
2.22 ± 0.18 
(1.37-5.41) 
(n=32) 





0.92 ± 0.03 
(0.64-1.22) 
(n=20) 
1.02 ± 0.03 
(0.53-1.27) 
(n=29) 
0.91 ± 0.02 
(0.51-1.17) 
(n=52) 
0.91 ± 0.03 
(0.61-1.18) 
(n=35) 
0.91 ± 0.06 
(0.71-1.21) 
(n=8) 
1.34 ± 0.15 
(0.58-1.72) 
(n=9) 
1.14 ± 0.09 
(0.55-2.16) 
(n=30)  















1201 ± 112 
(1139-1256) 
(n=3) 
986 ± 31 
(913-1055) 
(n=4) 
2164 ± 251 
(1677-2300) 
(n=4) 
1714 ± 48 
(1490-1936) 
(n=4) 







6.26 ± 2.56 
(0-14.66) 
(n=5) 












9.46 ± 3.08 
(3.88-18.26) 
(n=4) 
6.29 ± 1.12 
(3.79-9.10) 
(n=4) 
5.17 ± 0.61 
(3.74-8.55) 
(n=4) 

























12.48 ± 1.87 
(8.52-16.20) 
(n=4) 
13.02 ± 1.59 
(8.55-16.81) 
(n=4) 



























Appendix 6 Experimental set-up in kinetic perifusion studies. 
 
 
 
 
 
 
 
 
 
